4209 trials were due to report results; 1722 (40·9%; 95% CI 39·4–42·2) did so within the 1-year deadline. 2686 (63·8%; 62·4–65·3) trials had results submitted at any time. Compliance has not improved since July, 2018.

Thus nearly 60% of trials are not reported within the deadline, they also looked at the relative compliance of the different sectors

Industry sponsors and large (experienced) sponsors were most likely to report trial data, whereas universities were the least likely. The sponsor with the lowest compliance was the US government.

To aid monitoring they have produced FDAAA trials Tracker which allows anyone to check compliance.

It will take place on Thursday 30th April 2020 at The Fielder Centre, Hatfield, Hertfordshire, UK

Registration is now open.

Full details of the scientific programme and registration details are on the website https://www.maggichurchouseevents.co.uk/bmcs/hatfield_symposium-31.htm

Always a very popular meeting so registration early is recommended.

Twitter hashtag #HatfieldMedChem20

• A high-throughput, but “lower content” phenotypic approach that is suited to screening ELF’s entire compound collection, and
• A more complex “high content” screening approach using microscopy or flow cytometry to probe phenotype on a smaller subset of the compound collection

While low content assays can be live measurements or have fixed end points and involve well-averaged readouts, high content assays can be much more complex, based on live or fixed cells, multiple cell types and usually have more than one parameter as a readout. The complexity of the latter workflow makes it better suited to being performed on a smaller representative subset of the large collection.

Phenotypic screening historically has been the basis for the discovery of many drugs. Compounds are screened in cellular or animal disease models to identify compounds that cause a desirable change in phenotype. Only after the compounds have been discovered are efforts made to determine the biological targets of the compounds - a process known as target deconvolution.

Proposals for phenotypic screening approaches follow the normal review and selection process. A dedicated application form is available here.

The submission deadline for the next review and selection round is February 7, 2020.

The EFMC created the “EFMC Prize for a Young Medicinal Chemist in Industry/Academia” as we felt it was important to acknowledge and recognise outstanding young medicinal chemists (≤ 12 years after PhD) working in European industry and academia. The 2020 Prizes will be given at the XXVI EFMC "International Symposium on Medicinal Chemistry" (EFMC-ISMC 2020) to be held in Basel, Switzerland on September 6-10, 2020. Both prizes consist of a diploma, an invitation to give an oral communication at the EFMC-ISMC, and a cash prize of € 1,000.

To find out more on the regulations and the application procedure visit the EFMC website: https://www.efmc.info/prizes, closing date Jan 31 2020.

Of the 61 approvals in 2019, 45 were small molecule drugs and 16 were biologics. The structures of the small molecules are shown below

Looking at the calculated physiochemical properties of the small molecules one thing is quite interesting, around 50% are predicted to be ionised at physiological pH.

As shown in the plot below (Blue = small molecules, Green = Biologics) the largest group of drugs were Antineoplastic agents, the next largest groups being anti-virals and immunosuppressants.

Biosimilars

Four "biosimilars" were also approved. Kromeya and idacio both of which contain adalimumab (Humira) a TNF-alpha inhibitor as the active ingredient. Adalimumab was the first fully human monoclonal antibody approved by the FDA in 2002.

Grasustek contains the active substance pegfilgrastim (Neulasta) a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. Zirabev contains the active substance bevacizumab (Avastin) that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).

These four drugs join a number of other biosimilars approved in Europe, with the UK in particular keen to move to biosimilars. Biosimilars are expected to save the EU up to $44 billion in health care costs by 2020 LINK.

Most important, the EU is realizing the benefits of biosimilars without sacrificing safety or quality. Of the biosimilars approved since 2006, none have been withdrawn or suspended for safety or efficacy reasons. Further, regulators have not identified any differences in the nature, severity or frequency of adverse effects between biosimilars and biologics.

The pages are

Fragment-Based Screening
Building a Fragment Collection
Available Fragment Collections
Profiles of Fragment Collections
Fragment-Based Screening Published Hits

The published fragments contains details of fragments that have been reported as hits in the literature, this database now has over 1500 entries culled from over 310 publications directed at nearly 220 different molecular targets using 26 different detection technologies.

It could be argued that published fragment hits perhaps gives us an insight into the best fragments to include in library design.

Calculated physicochemical properties for the individual components (I guess some are not so small).

As usual any monies saved on cards will be donated to the MS Society

Lipophilicity is possibly the most important physicochemical property of a potential drug, it plays a role in solubility, absorption, membrane penetration, plasma protein binding, distribution, CNS penetration and partitioning into other tissues or organs such as the liver and has an impact on the routes of clearance. It is important in ligand recognition, not only to the target protein but also CYP450 interactions, HERG binding, and PXR mediated enzyme induction.

The contributions of various functional groups to LogD has been explored "LogD contributions of substituents commonly used in medicinal chemistry" DOI, this study used matched molecular pairs analysis of experimental LogD values from several thousand compounds collected using the shake-flask method at pH = 7.4. They reported the average deltaLogD difference for particular molecular pairs. I've compared these experimental results with calculated LogD.

In addition, I've expanded the Absorption and Bioavailability page to include more on bioavailability with links to physicochemical properties. The Distribution and Plasma Protein Binding section has a couple of extra examples demonstrating the impact plasma protein binding has on other pharmacokinetic properties. I've added a few details of in vitro assays to the Transporters page, and expanded the in silico brain penetration models section.

The section on Aldehyde oxidase has been greatly expanded and now includes a section on prediction and mitigation, and added useful references.

The results underline the increase in the use of fragment based screening across the industry with 85% of the respondents now reporting that they actively use fragment screening. The technologies used to detect binding have also diversified with X-ray, NMR and SPR dominating. This mirrors my findings from published fragment hits. The choice of detection technology may be due to the additional structural information that X-Ray and NMR can offer.

I was delighted to see this comment,

For the first time we asked about use of literature to identify fragments, and nearly a third of respondents said they incorporate previously published fragments into their work. As the amount of publicly available information continues to increase it will be interesting to see whether this number grows.

I'll be updating the published fragment hits at the end of the year.

In this release there is data on

• 27,069 targets
• 13,579 diseases
• 8.91 million pieces of evidence
• 6.33 million associations between targets and diseases

The 20 Years of the Rule of Five Meeting brought together researchers from a number of different areas of drug discovery and provided both a historical overview of the use of Lipinski’s rules, as well as looking to the future and how these rules might evolve in the changing drug compound landscape. The meeting had a capacity attendance of over 100, with Sygnature kindly providing the venue. The audience was a nice mix of industry “veterans”, students and those new to the industry. The meeting format was a morning session giving a historical viewpoint followed by a panel discussion, and the afternoon was dedicated by a more forward looking session again followed by a panel discussion.

The full report is here in PDF format Full Report, many thanks to the presenters for permission to use the images.

More details and the available slide decks are here, Twitter hashtag - #RuleofFive2019.

What we need: Additional chemical matter for screening. The Diamond screening platform is high-throughput and we would ideally be able to take full advantage of this.

Full details are on the Open Source Antibiotics website

This publication suggests this area is going to become more important "An activity-guided map of electrophile-cysteine interactions in primary human immune cells" https://www.biorxiv.org/content/10.1101/808113v1.

Here, we present a global map of cysteines in primary human T cells that are susceptible to covalent modification by electrophilic small molecules. More than 3000 covalently liganded cysteines were found on functionally and structurally diverse proteins, including many that play fundamental roles in immunology.

Pivot Park Screening Centre has successfully completed the first ultra-High Throughput Screening in IMI’s ESCulab project, and as such restarting the operations of the European Lead Factory. The screening on the European Compound Collection of ~500.000 compounds using a biochemical 1536-wells assay was finished within 4 days. Currently triaging of the UK owned program is ongoing within the Consortium, applying further biochemical and biophysical follow-up assays as well as the resynthesis of promising hits.

The programme is currently accepting proposals http://www.europeanleadfactory.eu/drug-target-assays.

First call for proposals to the Psychiatry Consortium. Read more about the kind of projects the Psychiatry Consortium is looking to fund on the website https://md.catapult.org.uk/syndicates/psychiatry-consortium/?.

Register here

This publication looks very useful History of rare diseases and their genetic causes - a data driven approach.

This dataset provides information about monogenic, rare diseases with a known genetic cause supplemented with manually extracted provenance of both the disease and the discovery of the underlying genetic cause of the disease.

More details of how the dataset was constructed.

We collected 4166 rare monogenic diseases according to their OMIM identifier, linked them to 3163 causative genes which are annotated with Ensembl identifiers and HGNC symbols. The PubMed identifier of the scientific publication, which for the first time describes the rare disease, and the publication which found the gene causing this disease were added using information from OMIM, Wikipedia, Google Scholar, Whonamedit, and PubMed. The data is available as a spreadsheet and as RDF in a semantic model modified from DisGeNET.

A very interesting read.

27,024 targets 10,474 diseases 3.33 million pieces of evidence 7.78 million associations between targets and diseases

In addition, a number of Target Enabling Packages (TEP) provided by Structural Genomics Consortium have been included, there are more details here. Several new chemical probes have also been included.

An event (with free registration) to foster the In silico Toxicology Community in the UK and beyond. Scientific contributions are as welcome as those on ongoing work, regulatory aspects, industry perspectives, databases, relevant software, journals etc. in the field. This event is meant to stimulate interactions and discussions, hence speakers are asked to present both about in silico toxicology approaches that are already useful to be applied at the current stage, as well as aspects that don't work that well right now, and where future developments are hence needed.

Venue 26 November 2019, Unilever Lecture Theatre, Department of Chemistry, University of Cambridge (CB2 1EW)

Full details and link for registration here In Silico Toxicology' Network Meeting 2019.

The Drug Discovery Resources pages are intended to act as a resource for scientists undertaking drug discovery, they were initially based on a course I give but have been expanded to give much more detail and to cover subjects not covered in the course.

Over the first six months there were nearly 35,000 users with users on average viewing 2-3 pages. The visitors come from 152 different countries with the US (33%), UK (14%) , India (8%), Germany (3.2%) and Canada (3.1%) topping the list.

The most viewed pages over this period were

• Lipophilicity
• Calculating Physicochemical Properties
• Distribution and Plasma Protein Binding
• Bioisosteres
• Molecular Interactions
• Kinase Inhibitors
• Acid Bioisosteres
• Aromatic Bioisosteres
• Solvation and desolvation
• Aspartic Acid Proteases
• CYP Interactions
• Fragment based screening
• HERG

Looking at the operating systems 56% are Windows users, 20% Mac users, 10% iOS and 10% Android, Chrome dominates the browser stats (65%) with Safari second (17%) and Firefox third (10%).

CO-ADD is a non-for-profit initiative led by academics at The University of Queensland. Our goal is to screen compound for antimicrobial activity for academic research groups and generate a public knowledge database for the development of novel agents for the treatment of microbial infections. The knowledge base contains chemical structures and antimicrobial activity data from CO-ADD’s screening, made publicly available by the academic research groups, with more data to be released over time.

The database is available here.

Results demonstrate that there are very strong HB acceptors (e.g.,DMSO) with nearly isotropic interactions, and weak ones (e.g.,thioacetone) with a sharp directional profile. Similarly, groups can have comparable directional propensity, but be very distant in the strength spectrum (e.g., thioacetone and pyridine).

This work also includes a fabulous sheet in the supplementary information giving details of interaction energies for various groups.

I've updated the molecular interactions page.

The GHIT Fund announces an investment opportunity for the Target Research Platform (TRP) in Partnership with the Wellcome Trust. The TRP investments are intentionally broad in potential scope and focus on new technologies and novel approaches.

TRP investments are intentionally broad in potential scope and focus on new technologies and novel approaches. Proposals must be within the project scope and investment eligibility below in order to be considered. The TRP is currently focused on technologies and approaches that address unmet or priority needs within malaria, tuberculosis, HIV/AIDS and Neglected Tropical Diseases listed in the GHIT Intent to Apply form.

MRC/AstraZeneca Centre for Lead Discovery

The MRC/AstraZeneca Centre for Lead Discovery (CLD) aims to support academic researchers in discovering potential starting points for small molecule therapeutic approaches with a clear line-of-sight to therapeutic use. The MRC/AZ Centre for Lead Discovery will form a unique cornerstone for academic and industrial drug discovery projects by supplying high throughput screening (HTS) infrastructure (NiCoLA-B).

Canada-UK Artificial Intelligence Initiative

The call aims to support innovative and cutting-edge interdisciplinary AI research that encourages the exploration of new interdisciplinary research methodologies, approaches and tools that cuts across at least two of the following research domains:

• social sciences and humanities;
• health and biomedical sciences; and
• natural sciences and engineering (including computational and/or mathematical sciences).

There is also a more comprehensive listing of grant funding here.

You can read it here Where Drugs Come From it is well worth spending a little reading, digesting and then sending the link to others.

canSAR is an integrated knowledge-base that brings together multidisciplinary data across biology, chemistry, pharmacology, structural biology, cellular networks and clinical annotations, and applies machine learning approaches to provide drug-discovery useful predictions. canSAR’s goal is to enable cancer translational research and drug discovery through providing this knowledge to researchers from across different disciplines. It provides a single information portal to answer complex multi-disciplinary questions including - among many others: what is known about a protein, in which cancers is it expressed or mutated and what chemical tools and cell line models can be used to experimentally probe its activity? What is known about a drug, its cellular sensitivity profile and what proteins is it known to bind that may explain unusual bioactivity?

This update includes

Target safety information

As a follow-up to the safety data in Open Targets Platform release 19.04, now has more targets with known safety effects and safety risk information, including TBXA2R and JAK2.

TEPs and chemical probes

In this release, they've included the latest Target Enabling Packages (TEPs) for GALT, GALK1 and MLLT1. Also added more chemical probes, small-molecule modulators of a protein’s function that can be used in cell-based or animal studies.

Target-disease associations

A new release always means new evidence available for novel target-disease associations.

It is aimed at early career (up to 5 years’ experience) medicinal chemists. Registration for this event will be at no additional cost to the main meeting.

The workshop will consist of a team-based exercise around a virtual medicinal chemistry programme and will offer participants:

• Training in advanced medicinal chemistry
• Testing out leadership/decision making skills
• Networking between potential future leaders of different organisations
• Introductions of possible future collaborators from pharma, CRO, charity and SME sectors
• Opportunity for informal interaction with experienced medicinal chemists workshop facilitators who will be open to questions around their own experiences
• Attendance at the full 20th SCI/RSC Medicinal Chemistry Symposium including lectures on a full range of drug targets, key enabling processes and technologies

Feedback from previous events has been excellent for this unique learning experience.

Also note there are student bursaries to help fund attendance at this event, email conferences@soci.org for more information.

2nd RSC-BMCS / RSC-CICAG Artificial Intelligence in Chemistry

Artificial Intelligence is presently experiencing a renaissance in development of new methods and practical applications to ongoing challenges in Chemistry. Following the success of the inaugural “Artificial Intelligence in Chemistry” meeting in 2018 a second meeting has been organised at Fitzwilliam College, Cambridge (2nd to 3rd September 2019). The lineup is now finalised and looks like a great selection of speakers. There is still time to submit posters (closing date 5th July).

Registration is open and there are discounts for RSC members.

The Twitter hashtag - #AIChem19 is already being actively used.

20th SCI/RSC Medicinal Chemistry Symposium

This is Europe’s premier biennial Medicinal Chemistry event, focussing on first disclosures and new strategies in Medicinal Chemistry. It takes place a Churchill College, Cambridge UK, 8 September - 11 September 2019. There is a fantastic lineup of speakers and looks to be one of the highlights of the MedChem calendar. Early career scientists can also take part in a Medicinal chemistry workshop on the Sunday afternoon, a great way for people to learn medicinal chemistry and meet other scientists in a fun and informal setting.

You can register here both RSC and SCI members get a reduced rate, and despite the slightly confusing page on the SCI website you don't have to be a member to attend, just select "Event Member FREE from the dropdown menu and you can register for the event without membership.

Twenty Years of the Rule of Five

It has been over twenty years since Lipinski published his work determining the properties of drug molecules associated with good solubility and permeability. Since then, there have been a number of additions and expansions to these “rules”. There has also been keen interest in the application of these guidelines in the drug discovery process and how these apply to new emerging chemical structures such as macrocycles.

This meeting aims to have a look at the impact the Ro5 has had on drug discovery and as well as looking to the future and how we use these rules in the changing drug compound landscape as drug discovery moves into novel areas of chemistry.

There is a very exciting group of speakers and the timetable has been designed to allow a panel discussion after each session. Given the topic and the speakers I'm sure these will be entertaining sessions.

You can register here and there are discounts for RSC members

Twitter hashtag - #RuleofFive2019

The European Lead Factory was launched in 2013 and set up a joint collection of half a million compounds and a state-of-the-art high throughput screening centre. By the time the project ended last year, they had delivered results to researchers in universities, small biotechs and large companies across Europe, helping them to identify potential new drug candidates and breathing new life into a range of disease areas. In many cases, the seeds sown by the European Lead Factory resulted in new patents, partnering deals, and two start-ups. Now, a new IMI project, ESCulab will build on the work of the European Lead Factory. This means that researchers with drug targets can apply to screen the project’s compound collection for hits and get help developing any compounds further if they like. Jon de Vlieger, coordinator of the ESCulab consortium at Lygature, said: ‘It’s truly exciting to continue the onboarding of new and innovative proposals for screening and provide high quality starting points for drug discovery to academics and SMEs throughout Europe. In an effort to broaden our scope we are not only looking for target-based approaches, but now also enable phenotypic screens.’

You can apply here. If you don't have an assay in a format suitable for ultra high-throughput screening it is worth noting that the Wellcome Trust have small awards designed to help with the technology change required for HTS.

I can't help but think that a better metric might be the number of patients treated. Whilst I don't have access to worldwide prescriptions the NHS in the UK does provide some information as part of the Prescription cost analysis for 2018. Whilst the number of prescriptions does correspond exactly with the number of patients treated I suspect it gives a very good indication.

Looking at the categories of drugs it is interesting to note that cancer does not figure in the top 20 categories. As you might expect lipid-lowering drugs, gastric ulcer treatment, treatments for cardiovascular disease, anti-depressants and analgesics are the most prescribed.

Looking at the top most prescribed drugs, small molecule drugs dominate for all indications.

Also of note is the number of prescriptions for drugs that are readily available over the counter.

BUT….

Am J Psychiatry. 2019 May 1;176(5):376-387. DOI

The study results do not support previous depression candidate gene findings, in which large genetic effects are frequently reported in samples orders of magnitude smaller than those examined here. Instead, the results suggest that early hypotheses about depression candidate genes were incorrect and that the large number of associations reported in the depression candidate gene literature are likely to be false positives.

How many other early gene disease association studies need to be checked?

The Following Pages have been Updated

Macrocycles
Predicting Metabolism
Covalent Inhibitors

PROteolysis TArgeting Chimeras (PROTACs), Lysosome Targeting Chimeras (LYTACs), and ENDosome TArgeting Chimeras (ENDTACs)

It has been over twenty years since Lipinski published his work determining the properties of drug molecules associated with good solubility and permeability. Since then, there have been a number of additions and expansions to these “rules”. There has also been keen interest in the application of these guidelines in the drug discovery process and how these apply to new emerging chemical structures such as macrocycles.

This symposium will bring together researchers from a number of different areas of drug discovery and will provide a historical overview of the use of Lipinski’s rules, as well as looking to the future and how we use these rules in the changing drug compound landscape.

Full details and registration are here https://www.maggichurchouseevents.co.uk/bmcs/twenty-years-Ro5.htm.

BI-9740 is a very potent and highly selective inhibitor of the enzymatic activity of Cathepsin C. It blocks human CatC in vitro with an IC50 of 1.8 nM and shows > 1500x selectivity versus the related proteases Cathepsin B, F, H, K, L and S. BI-9740 displays no activity against 34 unrelated proteases from different classes up to a concentration of 10 µM.

Chemical probes are absolutely essential for target validation and it is great to see so many high quality tools being made available.

Full details here https://www.europeanleadfactory.eu/news-events/european-lead-factory-europe’s-largest-collaborative-drug-discovery-platform-continues.

Over the next five years, the European Lead Factory will initiate 185 new drug discovery projects by screening medically relevant drug targets from European researchers, small and medium-sized enterprises and pharmaceutical industry against the ELF library of 550,000 unique chemical compounds.

The Universities that have failed to publish a single trial result are highlighted in red in the table below.

The contrast between the UK universities and the rest of Europe could not be starker,

UK universities in the survey performed significantly better than those in the rest of Europe. The University of Oxford and King’s College London had both published 93% of the trial results due on the register, and University College London had posted 81%.

According to the report every single medical university in the UK is currently working hard to upload missing clinical trial results onto the EU registry, and in many cases onto other registries such as ISRCTN and the US registry Clinicaltrials.gov as well. This demonstrates that where there is a will, there is a way.

If we remove the UK Universities from the analysis the level of reporting falls to a pitiful 7%.

Lack of transparency in clinical trials harms patients. The timely posting of summary results is an ethical and scientific obligation.

Twitter #AIChem19

Artificial Intelligence is presently experiencing a renaissance in development of new methods and practical applications to ongoing challenges in Chemistry. Following the success of the inaugural “Artificial Intelligence in Chemistry” meeting in 2018, we are pleased to announce that the Biological & Medicinal Chemistry Sector (BMCS) and Chemical Information & Computer Applications Group (CICAG) of the Royal Society of Chemistry are once again organising a conference to present the current efforts in applying these new methods. The meeting will be held over two days and will combine aspects of artificial intelligence and deep machine learning methods to applications in chemistry.

Speakers

Deep learning applied to ligand-based de novo design: a real-life lead optimization case study, Quentin Perron, IKTOS, USA
A Turing test for molecular generators, Jacob Bush, GlaxoSmithKline, UK
Presentation title to be confirmed, Keynote: Regina Barzilay, Massachusetts Institute of Technology, USA
Artificial intelligence for predicting molecular Electrostatic Potentials (ESPs): a step towards developing ESP-guided knowledge-based scoring functions, Prakash Rathi, Astex Pharmaceuticals, UK
Molecular transformer for chemical reaction prediction and uncertainty estimation, Alpha Lee, University of Cambridge, UK
Drug discovery disrupted - quantum physics meets machine learning, Noor Shaker, GTN, UK
Presentation title to be confirmed, Christian Tyrchan, AstraZeneca,
Presentation title to be confirmed, Anthony Nicholls, OpenEye Scientific Software, USA
Deep generative models for 3D compound design from fragment screens, Fergus Imrie, University of Oxford, UK
DeeplyTough: learning to structurally compare protein binding sites, Joshua Meyers, BenevolentAI, UK
Presentation title to be confirmed, Maciej Haranczyk, IMDEA, Spain
Deep learning for drug discovery, Keynote:  David Koes, University of Pittsburgh, USA
Presentation title to be confirmed, Olexandr Isayev, University of North Carolina at Chapel Hill, USA
Dreaming functional molecules with generative ML models, Christoph Kreisbeck, Kebotix, USA
Presentation title to be confirmed, Keynote:  Adrian Roitberg, University of Florida, USA

Applications for poster presentations are welcomed, the closing date for submission is 5th July. A number of RSC-BMCS and RSC-CICAG student bursaries are available up to a value of £250, to support registration, travel and accommodation costs for PhD and post-doctoral applicants studying at European academic institutions. The closing date for bursary applications is 15th July.

Full details are on the conference website

I suspect many will have noticed the recent announcement of the Early Results in Drug Discovery Partnership with AI Biotech Company. These are the first results of the Atomwise AIMS awards:

The researchers have been using Atomwise’s AI-powered in silico screening technology to develop therapeutic treatments for, among others, certain types of strokes, hand-foot-and-mouth disease, and an infection that causes reproductive failure in pigs.

The AIMS award program is a great opportunity for university research scientists to easily access AI-assisted structure-based virtual screening technology:

• Customized small molecule virtual screen using AtomNet™ technology
• 72 small molecules predicted to bind to a specific target protein – QC verified by mass spectrophotometry, resuspended and diluted to a convenient concentration, aliquoted into microtiter plates, and delivered at no cost to the researcher
• Support from Atomwise’s medicinal chemists and structural biologists
• Opportunity to receive up to $30K USD to subsidize assay work

If you have a target protein with an X-ray crystal, Cryo-EM, or NMR structure, or with close sequence homology to a protein with available structures, and an assay in place to evaluate 72 potential hits, then you should consider applying.

Full details are on the AIMs awards page and the closing date is 29 April 2019.

Open Source Antibiotics (https://github.com/opensourceantibiotics) is intended to be a platform for a collaborative effort towards antibiotic discovery.

The first projects have been initiated

Mur Ligase (https://github.com/opensourceantibiotics/murligase) and the background to these exciting targets can be found on the wiki page.

https://github.com/opensourceantibiotics/murligase/wiki

This also provides details of the first two fragment screens.

MurD https://github.com/opensourceantibiotics/murligase/wiki/MurD-fragment-screen

and

MurE https://github.com/opensourceantibiotics/murligase/wiki/MurE-fragment-screen

What we want now is for people to join in and suggest the next round of fragments that should be screened. Ideally these should be commercially available but if people want to design, make and submit their own fragments we would be happy to screen them.

If you feel appropriate, we would appreciate any publicity on this exciting new project

Registration is on the 20th SCI / RSC Medicinal Chemistry Symposium website

A recent publication highlights a new technology "Lysosome Targeting Chimeras (LYTACs) for the Degradation of Secreted and Membrane Proteins" DOI that further extends the protein degradation options.

Targeted protein degradation is a powerful strategy to address the canonically undruggable proteome. However, current technologies are limited to targets with cytosolically-accessible and ligandable domains. Here, we designed and synthesized conjugates capable of binding both a cell surface lysosome targeting receptor and the extracellular domain of a target protein…. LYTACs represent a modular strategy for directing secreted and membrane proteins for degradation in the context of both basic research and therapy.

Registration for the 20th Cambridge MedChem Meeting is now open !!

https://www.soci.org/events/20th-scirsc-medicinal-chemistry-symposium.

Really is a fabulous lineup of speakers. Also includes Malcolm Campbell Memorial Prize presentation

We have all the programmes from the 13th to 19th meetings, and I've managed to get details of the first meeting shown in this PDF. If you could share scanned copies of programme from the 2nd to 12th meetings it would be really great.

Also if you have particular memories of meetings you would be willing to share feel free to send an email.

In particular, s drug targets become more challenging medicinal chemists are looking at alternatives to small molecule competitive inhibitors, the section on covalent inhibitors have been expanded and a new page on PROTACs has been added. PROTACs are bifunctional molecules that bind to the target protein and an E3 ligase, the simultaneous PROTAC binding of two proteins brings the target protein in close enough proximity for polyubiquitination by the E2 enzyme associated to the E3 ligase, which flags the target protein for degradation through the proteasome. This offers a powerful alternative to competitive inhibition.

The Probes & Drugs portal has been added to the chemical probes page, this is a public resource joining together focused libraries of bioactive compounds (probes, drugs, specific inhibitor sets etc.) with commercially available screening libraries.

The page describing commercial fragment screening libraries has been updated to include a couple of new additions and flagging some that seem to be unavailable, if I've missed any feel free to let me know.

The section on hERG has been updated with links to new references and details of hERGcentral.

hERGCentral: A Large Database to Store, Retrieve, and Analyze Compound-Human Ether-à-go-go Related Gene Channel Interactions to Facilitate Cardiotoxicity Assessment in Drug Development. The hERGCentral database hergcentral.org is based on experimental data obtained from a primary screen by electrophysiology against more than 300,000 structurally diverse compounds screened at 1 and 10uM.

Unfortunately the database appears to be no longer available. Whilst the supplementary information for the original publication does not contain the structures of the tested compounds it does reference the PubChem substance ID. I used these identifiers to download the structures of the >300,000 records and combined them with the experimental data provided in the Excel tables in the supplementary information. The complete dataset can be downloaded from the hERG page.

Small molecules can potentially bind to a variety of bimolecular targets and whilst counter-screening against a wide variety of targets is feasible it can be rather expensive and probably only realistic for when a compound has been identified as of particular interest. For this reason there is considerable interest in building computational models to predict potential interactions the page on predicting bioactivities has been expanded.

The section on bioisosteres also have a few new examples.

SMILES format

or in

sdf file format

Bear in mind this is single point data and there will be a fair amount of scatter.

I've added this information to the page on hERG.

The school is designed for graduate and post-doctoral chemists with 1-5 years’ experience in the field of drug research. Drug discovery is an interdisciplinary subject so delegates from biological or computational backgrounds will benefit from attendance at the school. In addition, final year PhD students from pharmaceutical or organic chemistry contemplating a career in drug discovery are also encouraged to attend.

The course includes the following topics:

• Target Validation
• Computational Chemistry
• Biological Mechanisms
• Pharmacokinetics and Drug Metabolism
• Screening of New Compounds
• Patents
• Molecular Biology in Medicinal Chemistry
• Exploiting a Chemical Lead
• Combinatorial Chemistry and Molecular Diversity
• Case Histories of Drug Discovery
• Toxicology in Drug Discovery
• Pharmaceutical Considerations in Drug Development
• Structure-guided Drug Design
• Physical Properties and Quantitative Structure-Activity Relationships
• Hints and Tips in Medicinal Chemistry

Full details here http://www.rsc.org/events/detail/33379/medicinal-chemistry-residential-school-2019.

The promises of precision medicine are to dramatically change patient care via individually tailored therapies and, as a result, to prevent disease, improve survival, and extend healthspan.

However, nearly two decades after the first predictions of dramatic success, we find no impact of the human genome project on the population’s life expectancy or any other public health measure, notwithstanding the vast resources that have been directed at genomics. Exaggerated expectations of how large an impact on disease would be found for genes have been paralleled by unrealistic timelines for success, yet the promotion of precision medicine continues unabated.

In light of the limitations of the precision medicine narrative, it is urgent that the biomedical research community reconsider its ongoing obsession with the human genome and reassess its research priorities including funding to more closely align with the health needs of our nation. We do not lack for pressing public health problems. We must counter the toll of obesity, inactivity, and diabetes; we need to address the mental health problems that lead to distress and violence; we cannot stand by while a terrible opiate epidemic ravages our country; we have to prepare conscientiously for the next influenza pandemic; we have a responsibility to prevent the ongoing contamination of our air, food, and water. Topics such as these have taken a back seat to the investment of the NIH and of many research universities in a human genome–driven research agenda that has done little to solve these problems, but has offered us promises and more promises.

The human genome project was undoubtedly a magnificent achievement, but has the investment in genomics delivered?

There is an extended discussion on In the Pipeline https://blogs.sciencemag.org/pipeline/archives/2019/01/31/precision-medicine-real-soon-now.

The world is facing multiple health challenges. These range from outbreaks of vaccine-preventable diseases like measles and diphtheria, increasing reports of drug-resistant pathogens, growing rates of obesity and physical inactivity to the health impacts of environmental pollution and climate change and multiple humanitarian crises.

Here are 10 of the many issues that will demand attention from WHO and health partners in 2019.

• Air pollution and climate change
• Noncommunicable diseases (diabetes, cancer and heart disease)
• Global influenza pandemic
• Fragile and vulnerable settings (combination of drought, famine, conflict, and population displacement)
• Antimicrobial resistance
• Ebola and other high-threat pathogens
• Weak primary health care
• Vaccine hesitancy (the reluctance or refusal to vaccinate despite the availability of vaccine)
• Dengue
• HIV

1. Compounds addressing the key priorities of the malaria eradication agenda

Novel families of molecules in the hit-to-lead or lead optimization stages are sought without G6PD deficiency liabilities that either:

Kill or reactivate hypnozoites for use as part of a P. vivax radical cure; or have activity against sexual stage V gametocytes and evidence of transmission blocking in SMFA.

2. Compounds having activity against asexual liver and/or blood stages

Novel chemical series with EC50<500nM and which have one or more of the following key features:

A known, novel mechanism of action; An inability to select resistant mutants in vitro; Activity at more than one life-cycle stage; A long half-life (ideally >4h in rodents) and confirmed in vivo efficacy. For advanced series, we are seeking novel compounds with, ideally, a predicted human half-life >100h and a predicted oral single human dose <500mg or an i.m. dose that can be administered in <1mL and sufficient for up to 3 months’ protection in humans.

3. Novel approaches for screening

To help identify new phenotypic and/ or target based hits, as well as confirm activity of MMV compounds on all human malaria asexual blood stages, new screening proposals are sought amongst the three categories below:

Validated Plasmodium target-based assays, ideally with evidence of target essentiality beyond asexual blood stages. Biological validation should be supported by a biological target based screening assay suited for identification of novel chemical series. Novel whole cell phenotypic screening paradigms to potentially identify new relevant chemistry. Asexual blood stage assays for vivax and ovale malaria.

Compounds for Target Identification

MMV also welcomes requests for support to investigate the mechanism of action of compounds:

Call for African proposals

Finally, MMV welcomes proposals from endemic region African scientists focused in the following priority areas:

1. Compounds with confirmed activity on any antimalarial life-cycle stage. Novel families of molecules with confirmed activity (EC50 < 10uM) and a medicinal chemistry plan that tackles any known or anticipated liability. Priority will be given to proposals that maximize use of local natural products.

2. Assay development and screening

The tutorials will be given a series of outstanding experts Christian Lemmen (BioSolveIT), Akos Tarcsay (ChemAxon), Giovanna Tedesco (Cresset), Dan Ormsby (Dotmatics) Greg Landrum (Knime ) and Matt Segall (Optibrium), you will be able to install the software packages on you own laptops together with a license to allow you to use it for a limited period after the event.

Registration opened just before Christmas and apparently there were a number of people sign up over the festive period. Remember there are a limited number of places and it is first come first served.

Registration and full details are here.

Also a free one-day symposium Streamlining Drug Discovery" in Frankfurt
The very successful symposia series "Streamlining Drug Discovery" comes to Frankfurt on 14 February 2019. Jointly BioSolveIT, Optibrium, Lhasa and Elsevier invite you for this free one-day event highlighting new approaches and technologies being applied to the search for future therapeutics. For further details please visit the symposium website https://www.biosolveit.de/symposium/2019-02-14/

Discovery and development of 210 new molecular entities (NMEs; new drugs) approved by the US Food and Drug Administration 2010–2016 was facilitated by 3D structural information generated by structural biologists worldwide and distributed on an open-access basis by the PDB. The molecular targets for 94% of these NMEs are known. The PDB archive contains 5,914 structures containing one of the known targets and/or a new drug, providing structural coverage for 88% of the recently approved NMEs across all therapeutic areas. More than half of the 5,914 structures were published and made available by the PDB at no charge, with no restrictions on usage >10 years before drug approval. Citation analyses revealed that these 5,914 PDB structures significantly affected the very large body of publicly funded research reported in publications on the NME targets that motivated biopharmaceutical company investment in discovery and development programs that produced the NMEs.

The Drug Discovery Resources website continues to increase in popularity with over 147,000 page views, an increase of 8% over the figure for 2017. The pages were visited by over 72,500 viewers and around a third of the visitors come back on multiple occasions suggesting they find it useful. The visitors come from 172 different countries with the US (32%), UK (13%) and India (8%) topping the list.

The most viewed pages in 2018 were

• Lipophilicity
• Distribution and Plasma Protein Binding
• Bioisosteres
• Calculating Physicochemical Properties
• Molecular Interactions
• Kinase Inhibitors
• Aspartic Acid Protease Inhibitors
• Solvation and desolvation
• Hit Identification
• CYP Interactions
• Acid Bioisosteres
• Fragment based screening
• HERG

There have been a number of significant updates to the Drug Discovery Resources this year, in particular, a new section on Macrocycles which has proved very popular. The Target Validation section has been updated several times, as has the Molecular Interactions page and I'm grateful for readers who have pointed out relevant recent publications.

Interestingly the Books and Grant funding research have seasonal peaks in viewing.

Looking at the operating systems 56% are Windows users, 20% Mac users, 10% iOS and 10% Android, Chrome dominates the browser stats (64%) with Safari second (17%) and Firefox third (10%).

Centre for Therapeutic Target Validation is a pre competitive public-private venture that aims to provide evidence on the biological validity of therapeutic targets and provide an initial assessment of the likely effectiveness of pharmacological intervention on these targets, using genome-scale experiments and analysis. The platform currently contains 28,931 targets, 3,049,882 associations for 10,053 diseases.

There is an open access portal to the platform here https://www.targetvalidation.org. All data is also available for download https://www.targetvalidation.org/downloads/data.

As in previous years all monies saved for not sending greetings cards will be given to the Multiple Sclerosis Society.

To foster innovation, we openly share selected molecules with the scientific community to unlock their full potential - all for free, no hidden costs.

The latest addition is a potent Chymase inhibitor, Chymase is a chymotrypsin-like serine protease that is stored in a latent form in the secretory granules of mast cells. Upon stimulation, it is released in its active form into the local tissue, contributing to the activation of TGF-ß, matrix metalloproteases and cytokines.

BI-1942 is a highly potent inhibitor of human chymase (IC50 = 0.4 nM) that can be used to test biological hypotheses involving this target in vitro. With BI-1829 we also offer a structurally close analog that is more than 1000 fold less active (IC50 = 850 nM) and can thus be used as negative control for in vitro studies.

Macrocycles lie outside the usual "drug space" delineated by the Rule-of-5 and macrocycles can adopt different conformation in various media, hiding polar atoms or forming intramolecular hydrogen bonds, thus retaining good cell permeability and ADME properties

I recently got an email from ChemBridge highlighting a new 11,000 member Macrocyclic Library for screening. The general characteristics of compounds in the ChemBridge Macrocycle Library include:

• Molecular weight range up to 800
• Primary ring size ranging from 11 to 27 atoms
• Heterocyclic primary rings
• Scaffolds with and without peptidic backbone elements as part of the macrocyclic ring
• Scaffolds with and without fused rings as part of the primary macrocyclic ring

This latest correspondence in Nature highlights some of the issues, "Industry is more alarmed about reproducibility than academia" DOI.

This paragraph I find particularly troubling.

By contrast, academic scientists may be reluctant to devote extra time and effort to confirming research results in case they fail. That would put paid to publication in high-impact journals, damage career opportunities and curtail further funding. Evidence of questionable practices such as selective publishing and cherry-picking of data indicates that rigour is not always a high priority.

Through an in-depth programme of lectures, case studies and hands-on tutorial sessions, this five-day course strengthens excellence in medicinal chemistry by advancing understanding of the factors governing modern drug discovery. Full details are here.

Make sure that you register for this course as soon as possible to take full advantage of early bird savings. Registration includes attendance at all sessions, refreshments and lunch on each full day – plus a conference dinner with wine on Thursday 6 June.

This is a recording of the Neglected and Tropical Diseases Session at the 19th Cambridge MedChem Meeting, 11-13 September 2017. The speakers are Kelly Chibale (Univ of Capetown), Christoph Boss (Actelion), Rob Young (GlaxoSmithKline), Jonathan Large (LifeArc) and Charles Mowbray (DNDI).

So I was delighted to hear that IUPHAR/BPS Guide to pharmacology database have been funded by MMV to add details of antimalarials to their database.

This link http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=970 gives details of antimalarial targets, including gene name, synonyms and Uniprot ID.

This link http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=999 gives details of antimalarial ligands, including mode of action and properties. For example artemisinin.

I'd urge you have a look and I'm sure they would be happy to hear any suggestions.

• CYP interactions now includes details of published crystal structures and more information on known inhibitors
• I've added page on CYP1A2 from ChEMBL data and updated the CYP2D6 and CYP3A4 pages
• Updated the page on Aldehyde Oxidase
• Added new examples on the bioisosteres page
• Updated the Published Fragments section, including adding the overlay of all examples of Kinase fragment hits from the PDB.
• Added new examples to the Chemical Probes page
• Included more examples of halogen bonding to the Molecular Interactions page

Abstract deadline: Friday 9th November 2018

The organising committee wishes to solicit late-breaking, high impact medicinal chemistry talks to finalise the scientific programme. Potential contributions should be communicated to the secretariat at conferences@soci.org by Friday 9th November 2018. A number of conference places will be reserved for poster presenters and contributions are invited from the whole field of medicinal chemistry. Those presenting a poster may also elect to advertise their poster via oral presentation of a single slide 'flash' poster. Detailed procedures and submission deadlines for poster abstracts will be provided in the second announcement.

More details

Until recently work in this area suffered from the lack of high quality, selective inhibitors, the best studied being the immunosuppressants Cyclosporin and Sanglifehrin A.

At the recent Macrocycles 2018 meeting Vicky Steadman described the identification and optimisation of potent and orally available selective Cyclophilin inhibitors, more details have just been published J Med Chem paper DOI.

Let's hope with potent, cell penetrant and orally available tools in hand we can sort out the biology and bring forward a new class of therapeutic agents.

The ReFRAME collection of 12,000 compounds is a best-in-class drug repurposing library containing nearly all small molecules that have reached clinical development or undergone significant preclinical profiling. The purpose of such a screening collection is to enable rapid testing of compounds with demonstrated safety profiles in new indications, such as neglected or rare diseases, where there is less commercial motivation for expensive research and development.

To date, 12,000 compounds (80% of compounds identified from data mining) have been purchased or synthesized and subsequently plated for screening. In addition, an open-access data portal (https://reframedb.org) has been developed to share ReFRAME screen hits to encourage additional follow-up and maximize the impact of the ReFRAME screening collection.

The website can be searched by structure or text string.

For Example searching for Malaria highlights a number of known therapeutic agents.

https://reframedb.org/#/search?query=malaria&type=string

This looks like it will be an invaluable resource.

Open Targets Genetics is a new portal developed by Open Targets, an innovative partnership that brings together expertise from six complementary institutions to systematically identify and prioritise targets from which safe and effective medicines can be developed. The Portal offers three unique features to help you discover new associations between genes, variants, and traits, Gene2Variant analysis pipeline, Fine mapping/ credible set analysis, UK Biobank + GWAS Catalog integration.

More details https://genetics.opentargets.org/docs/open-targets-genetics-infographic.pdf

An analysis of physicochemical properties on the hit-to-clinical pairs shows an average increase in molecular weight (ΔMW = +85) but no change in lipophilicity (ΔclogP = −0.2), although exceptions are noted. The majority (>50%) of clinical candidates were found to be structurally very different from their starting point and were more complex.

I thought it might be interesting to look at the calculated properties of the 66 clinical candidates. Interestingly many have molecular weights > 500 and only around 30% contain an ionisable group. All structures contain an aromatic ring and 48 molecules contain 3 or more aromatic rings.

In case anyone was wondering the high molecular weight compounds are not peptides or macrocycles.

In this release there is now data on:

• 21,149 targets
• 10,101 diseases
• 6.5 million pieces of evidence
• 2.9 million associations between targets and diseases

The Open Targets Platform is a comprehensive and robust data integration for access to and visualisation of potential drug targets associated with disease. It brings together multiple data types and aims to assist users to identify and prioritise targets for further investigation. A drug target can be a protein, protein complex or RNA molecule and it’s displayed by its gene name from the Human Gene Nomenclature Committee, HGNC. We integrate all the evidence to the target using Ensembl stable IDs and describe relationships between diseases by mapping them to Experimental Factor Ontology (EFO) terms. The Platform supports workflows starting from a target or disease, and shows the available evidence for target – disease associations. Target and Disease profile pages showing specific information for both target (e.g baseline expression) and disease (e.g. Disease Classification) are also available

Click on the link and you will get an alphabetical listing of all categories with appropriate links.

It may take a day or so for the new menu bar to appear on all pages.

Real-Time Oncology Review Pilot Program is a project to try and reduce the time needed to gain approval.

There are important caveats though.

Submissions to be considered for the RTOR pilot should meet the following criteria:
Drugs likely to demonstrate substantial improvements over available therapy, which may include drugs previously granted Breakthrough Therapy Designation for the same or other indications. Drugs meeting other criteria for other expedited programs (e.g. fast track, priority review) may also be considered. Straight forward study designs, as determined by the review division and the OCE. Studies conducted exclusively outside the United States and adjuvant, neoadjuvant, and prevention studies will be excluded. Endpoints that can be easily interpreted (for example, overall survival in a randomized trial). Supplements with CMC formulation changes and supplements with pharmacology/toxicology data will be excluded. Submissions with greater complexity, including those with companion diagnostics, may also be excluded for the purposes of the pilot program.

The real time review means the FDA can continuously review data as it is produced and give early feedback.

RTOR allows the FDA to review much of the data earlier, before the applicant formally submits the complete application. First, the applicant will present topline data for the FDA to determine whether RTOR would be appropriate for the supplement. If the agency determines RTOR is an appropriate review pathway, the applicant can start sending pre-submission data to the agency, under the original NDA/BLA, 2-4 weeks after all patient data has been entered and locked by the applicant in their database

This sort of process may be ideal for some indications where the trials give clear end points, survival in oncology, clearance of parasite in Malaria or other infectious diseases. Clinical trials for Psychiatric disease, marginal improvements over existing therapy or slowly progressing neurological diseases will probably not be suitable.

opnMe.com, the new open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives and enable new disease biology in areas of high unmet medical need by sharing well-characterized, best-in-class, pre-clinical tool compounds.

BI-5521 is a potent and selective ATP-competitive small molecule inhibitor of glycogen synthase kinase 3 (GSK-3), GSK-3β (IC50) 1.1 nM, with demonstrated in vivo activity. Rat pharmacokinetics are available, together with an inactive related compound.

Another useful tool for Target Validation.

Full details of the meeting and registration is available online here http://www.maggichurchouseevents.co.uk/bmcs/macrocycles_2018-online%20registration.htm.

The Polypharmacology Browser PPB2: Target Prediction Combining Nearest Neighbors with Machine Learning DOI

To build PPB2 we collected a bioactivity dataset of all compounds having at least IC50 < 10 uM on a single protein target in ChEMBL22 considering only high confidence data points as annotated in ChEMBL and only targets for which at least 10 compounds were documented

You can try it out here PPB2., depending on the model chosen the results are calculated in a couple of minutes, but don't post your proprietary molecules. Typical results are shown below, clicking on the green "Show NN" button shows the most similar structures.

You can download the full details of the meeting here PDF.

A number of outstanding talks have already been confirmed.

More details here

Secure the funding you need to progress your projects towards commercialisation. Use our dedicated grant application team to ensure your submissions stand the best chance of success. Our experienced commercial and scientific teams have connections across industry, academia, finance, government, and research networks – we can help take your projects further towards commercial viability.

I've also compiled a page on Grant funded Research

"We want to take advantage of the surprising, left-field ideas that pose the question 'what if?' and support them in a new way that complements our existing funding structures."

Sounds like the aim is to support more high-risk research.

We don’t expect all projects to succeed, but we think the possibilities are incredibly exciting. And in taking some risks and backing at scale, we think we can deliver transformational developments that will improve people’s lives around the world

Wellcome have also recently announced the Open Research fund

Our new Open Research Fund supports innovative approaches that enable data, code or other research outputs to be discovered, accessed and reused

I've also compiled a page on Grant funded Research

So completing this set, I looked at 101 papers, all published in the same month in the same journal. Of these, 63 contained photographic images (the others had only line graphs and/or tables). Of those, 8 have potential duplications. That is 12.7%

With all the advances in AI and image recognition I'm slightly disappointed that there is not a programme that can do this automatically for Elisabeth.

The PDB also contains 25626 chemical components - 24007 as free ligands in 106374 PDB file and you can search via a web interface or download the structures in sdf file format. However browsing through the downloaded file it was apparently that macrocycles were not well represented. A discussion with the extraordinarily helpful Rachel Kramer Green at PDB revealed the issue. Basically any ligand containing more that two amino-acids is treated as a protein not a ligand, there are other rules to deal with modified amino-acids etc. but the bottom line is that the only way to get a comprehensive view of macrocycles in the PDB is to download the entire PDB and programmatically by parsing the entire data set.

First we need to decide what size ring constitutes a macrocycle. asking the "internet" failed to produce a definitive answer.

You can read the results and download the script here.

There is also a page that discusses macrocycles in drug discovery.

There is also an upcoming meeting on Macrocycles, 3rd RSC BMCS Medicinal Chemistry Symposium on Macrocycles. Monday-Tuesday, 8th-9th October 2018, GlaxoSmithKline, Stevenage, UK. Full details are here http://www.maggichurchouseevents.co.uk/bmcs/Macrocycles-2018.htm. #BMCS_Macrocycles

The objective of this symposium is to promote scientific interaction between scientists with a shared interest in the field of Macrocycles. This area is responsible for a growing number of therapeutic approaches and development candidates, all of which go ‘beyond the rule-of–five’. As a researcher in this field, come along to hear about the latest advances and also to share in some of the secrets of discovering therapeutic agents which go beyond Lipinski’s rules.

Development of a high-throughput assay provide access to the various drug discovery initiatives that are available to the academic community, i.e. MRC DPFS, Bayer G4Targets, Wellcome Trust translational fund, the European Lead Factory, AZ innovation portal etc.

There is also an upcoming meeting on Macrocycles, 3rd RSC BMCS Medicinal Chemistry Symposium on Macrocycles. Monday-Tuesday, 8th-9th October 2018, GlaxoSmithKline, Stevenage, UK. Full details are here http://www.maggichurchouseevents.co.uk/bmcs/Macrocycles-2018.htm. #BMCS_Macrocycles

The objective of this symposium is to promote scientific interaction between scientists with a shared interest in the field of Macrocycles. This area is responsible for a growing number of therapeutic approaches and development candidates, all of which go ‘beyond the rule-of–five’. As a researcher in this field, come along to hear about the latest advances and also to share in some of the secrets of discovering therapeutic agents which go beyond Lipinski’s rules.

https://a16z.com/2018/04/30/building-therapeutics-startups/

Halogens are present in around 25% of drugs, calculated using data from Guide to Pharmacology Database and often used as bioisosteric replacements for H, Methyl, OH and NH₂.

Bonds to halogen are significantly weaker than hydrogen bonds but there are many examples in the PDB of carbonyls interacting with halogens with bonds to I, and Br predominating. It is perhaps worth noting that halogens have been introduced into ligands to aid X-ray analysis, but they may also influence binding. Based on the observed bond angles the interaction is between the halogen and pi-cloud of the carbonyl rather than the lone pair with a clear clustering of X--O=C-N dihedral angles of 90° associated with interactions that involve primarily the pi-system of the carbonyl.

Two new probes for BRD9 and BRD7/9 have been added.

I've added them to the Chemical Probes page.

Twitter hashtag - #RSC_AIChem

09.00 Registration, refreshments, and exhibition
10.00 Presentation title to be confirmed Marwin Segler, Benevolent AI, UK
10.30 Presentation title to be confirmed Nadine Schneider, Novartis, Switzerland
11.00 Refreshments, exhibition and posters
11.30 Keynote: What I learned about machine learning - revisited Bob Sheridan, Merck, USA
12.30 Lunch, posters and exhibition
14.00 Molecular de novo design through deep learning Ola Engkvist, AstraZeneca, Sweden
14.30 Scaling de novo design, from single target to disease portfolio Wilhem van Hoorn, Exscientia, UK
15.00 Refreshments, posters and exhibition
15.30 Investigating clusters in solvent data using K-means Ella Gale, University of Bristol, UK
16.00 Deep learning and chemical data Colin Batchelor, Royal Society of Chemistry, UK
16.30 Automation, analytics and AI Darren Green, Molecular Design UK, RD Platform Technology & Science, GlaxoSmithKline, UK
17.00 Drinks reception
18.00 Close

Register here.

Friday, 15th June 2018, Royal Society of Chemistry at Burlington House, London, UK
Poster closing date is 13th April
Bursary closing date is 3rd May

Applications for oral and poster presentations are welcome. Posters will be displayed throughout the meeting and applicants should indicate whether they wish to be considered for a flash oral presentation when submitting an abstract (two minutes, single slide).The closing dates of 28th February (oral) and 8th August (poster).

PhD Student and Post-Doc Conference Bursaries

Did you know that most BMCS sponsored meetings have a number of bursaries available for PhD and post-doctoral students? Normally up to a value of £250, these awards help to cover registration and travel costs. Preference will be given to members of the RSC (and meeting co-sponsors if applicable), especially those who are selected to give posters.

Macrocycles 2018 meeting #BMCS_Macrocycles

Monday-Tuesday, 8th-9th October 2018, GlaxoSmithKline, Stevenage, UK

The objective of this symposium is to promote scientific interaction between scientists with a shared interest in the field of Macrocycles. This area is responsible for a growing number of therapeutic approaches and development candidates, all of which go ‘beyond the rule-of–five’. As a researcher in this field, come along to hear about the latest advances and also to share in some of the secrets of discovering therapeutic agents which go beyond Lipinski’s rules.

Full details and application forms are here http://www.maggichurchouseevents.co.uk/bmcs/Macrocycles-2018.htm.

More details here….

Join the discussion https://www.reddit.com/r/OpenSourceMycetoma/

or Twitter https://twitter.com/MycetOS

Files here https://github.com/OpenSourceMycetoma

Monday-Tuesday, 8th-9th October 2018, GlaxoSmithKline, Stevenage, UK

The objective of this symposium is to promote scientific interaction between scientists with a shared interest in the field of Macrocycles. This area is responsible for a growing number of therapeutic approaches and development candidates, all of which go ‘beyond the rule-of–five’. As a researcher in this field, come along to hear about the latest advances and also to share in some of the secrets of discovering therapeutic agents which go beyond Lipinski’s rules.

Applications for oral and poster presentations are welcome. Posters will be displayed throughout the meeting and applicants should indicate whether they wish to be considered for a flash oral presentation when submitting an abstract (two minutes, single slide).The closing dates of 28th February (oral) and 8th August (poster).

Full details and application forms are here http://www.maggichurchouseevents.co.uk/bmcs/Macrocycles-2018.htm.

This briefing summarises a new peer-reviewed study estimating the economic returns generated by public and charitable investment in UK medical research.

Bottom line , Every £1 invested in medical research delivers a return equivalent to around 25p every year, for ever.

Studies have focused on cancer, cardiovascular, musculoskeletal disease and mental health research

1. Compounds addressing the key priorities of the malaria eradication agenda

Novel families of molecules in the hit-to-lead or lead optimization stages are sought without G6PD deficiency liabilities that either:

• Kill or reactivate hypnozoites for use as part of a P. vivax radical cure; or
• Have activity against sexual stage V gametocytes and evidence of transmission blocking in SMFA.

2. Compounds with activity against asexual liver and/or blood stages

Novel chemical series with EC50<500nM and which have one or more of the following key features:

• A known, novel mechanism of action;
• An inability to select resistant mutants in vitro;
• Activity at more than one life-cycle stage;
• A long half-life (ideally >4h in rodents) and confirmed in vivo efficacy.
• For advanced series, we are seeking novel compounds with, ideally, a predicted human half-life >100h and a predicted oral single human dose <500mg or an i.m. dose that can be administered in <1mL and sufficient for up to 3 months’ protection in humans.

3. Novel approaches for screening

• To help identify new phenotypic and/ or target based hits, as well as confirm activity of MMV compounds on all human malaria asexual blood stages, new screening proposals are sought .

There are many important therapeutic targets within neuroscience but our biological understanding is currently inadequate to justify the investment in drug discovery, a selection of well characterised probes may provide the tools to support the necessary basic biological research.

A recent publication describes a related approach looking for multi target ligands, a systematic analysis of currently available X-ray structures for compounds forming complexes with different targets DOI, by using X-ray structures they aim to avoid molecules that might interfere with the assay, some of these ligands were described in the medicinal chemistry literature, making it possible to consider additional target annotations and search for analogues. This work identified 133 unique analogue-series-based scaffolds were isolated that can serve as templates for the design of new compounds with multitarget activity.

I've added this to the Privileged Structures page of the Drug Discovery Resources.

The most viewed pages in 2017 were

• Distribution and Plasma Protein Binding
• Lipophilicity
• Calculating Physicochemical Properties
• Molecular Interactions
• Bioisosteres
• Molecular Interactions
• Solvation and desolvation
• Formulation
• Kinase Inhibitors
• Acid Bioisosteres
• Fragment based screening
• Aspartic Acid Protease Inhibitors
• HERG
• CYP Interactions

There have been a number of significant updates to the Drug Discovery Resources this year, in particular Target Validation has been expanded and the section on Chemical Probes given a separate page, highlighting invaluable resources like Probe Miner. Another new addition to the site has been the page on Covalent Inhibitors I got a significant amount of feedback on this page and it was updated several times.

I posted a poll on the website asking how many molecules are usually selected from a virtual screening run?

Some people also emailed me with further information. For companies with large internal physical screening collections, and the ability to cherry pick samples, it effectively costs the same to fill a high density plate (>1000 compounds) as it does to select a handful of compounds. On the other hand if the scientist has to purchase compounds then the logistics and cost become a significant obstacle.

There have been a couple of publications this year describing problems arising from analysis of high-throughput screening data, I've updated the Analysis of high-throughput screening data page to try and highlight some of the issues and strategies.

One of the highlights of the year for me was the 19th RSC / SCI Medicinal Chemistry Symposium (#19thCamMedChem) which took place 10th-13th September 2017 at Churchill College, Cambridge, UK. In particular a session on Neglected and Tropical Diseases, to increase the exposure of the brilliant science undertaken in this important therapeutic area the conference organisers arranged for this to be a live webinar. The session was also recorded and is now available online.

https://youtu.be/XLOCFrjrMEY

This is a recording of the Neglected and Tropical Diseases Session at the 19th Cambridge MedChem Meeting, 11-13 September 2017. The speakers are Kelly Chibale (Univ of Capetown), Christoph Boss (Actelion), Rob Young (GlaxoSmithKline), Jonathan Large (LifeArc) and Charles Mowbray (DNDI). To date this has been watched nearly 250 times.

Please feel free to share. #19thCamMedChem.

The European Lead Factory (ELF) is a collaborative public-private partnership aiming to deliver novel lead molecules for drug discovery programs. When the consortium was formed around 5 years ago there was a lot of scepticism about whether a group of 30 partners rating from large Pharma companies to small academic groups could ever agree on a legal framework that would allow the ELF to function. In a addition, in an industry where confidentiality was critical to maintaining intellectual property the idea that a group of large Pharma companies would share their sample collections often regarded as the "Crown Jewels" seemed impossible. However I was at the European Lead factory Stakeholder Meeting (24-25 April 2017) and it is clear that is has been a success and I've written a summary here.

Interestingly the Books and Grant funding research have seasonal peaks in viewing.

The website was also updated this year to use https rather than http, this involved editing a fair number of of hardcoded URLs. Whilst I don't require any secure transactions it does seem that https offers a level of trust that is beneficial. It seems likely that other web browsers will follow Google's lead and have a popup message when accessing any page using http, I suspect this could rapidly become irritating so I've decided to make the move. You will still able to access using http but I'll be setting up redirects later this week. Hopefully the visitors will not really notice any difference.

Looking at the operating systems 52% are Windows users, 21% Mac users, 10% iOS and 9% Android, Chrome dominates the browser stats (62%) with Safari second (20%) and Firefox third (12%).

Clare College view of bridge from Old Court

As in previous years all monies saved for not sending greetings cards will be given to the Multiple Sclerosis Society

BoBER (Base of Bioisosterically Exchangeable Replacements) is a freely available method which implements an interface to a database of bioisosteric and scaffold hopping replacements. The web-server enables fast and user-friendly searches for bioisosteric replacements which were obtained by mining the whole Protein Data Bank. BoBER enables medicinal chemists to quickly search and get new and unique ideas about possible bioisosteric or scaffold hoping replacements that could be used to improve specific hit or lead drug-like compounds.

You can submit whole molecule structures which are divided into fragments and then bioisosteric replacements for each fragment can then be identified.

There is a section on bioisosters in the Drug Discovery Resources.

Open Access DOI

Several PD-L1 inhibitors are in development, including Atezolizumab.

A recent post gives an opportunity for everyone to participate, you can read a description of the background here Poll to decide which compounds to synthesise next as 'Pfizer phenol' analogues and the actual poll is here.

Following on from @JoshMaxwell's introductory post #554, we're keen to continue exploring this chemistry which now appears to be working well, and applying it to make further analogues of the phenol compound OSM-S-412, OpenSourceMalaria/Series4#3.

You should of course feel free to suggest additional modifications, it would be particularly useful if you could include a brief comment as to why you think your suggestion might be interesting.

The Drug Design Data Resource (D3R) ran Grand Challenge 2 (GC2) from September 2016 through February 2017. This challenge was based on a dataset of structures and affinities for the nuclear receptor farnesoid X receptor (FXR), contributed by F. Hoffmann-La Roche. The dataset contained 102 IC50 values, spanning six orders of magnitude, and 36 high-resolution co-crystal structures with representatives of four major ligand classes. Strong global participation was evident, with 49 participants submitting 262 prediction submission packages in total. Procedurally, GC2 mimicked Grand Challenge 2015 (GC2015), with a Stage 1 sub-challenge testing ligand pose prediction methods and ranking and scoring methods, and a Stage 2 sub-challenge testing only ligand ranking and scoring methods after the release of all blinded co-crystal structures. Two smaller curated sets of 18 and 15 ligands were developed to test alchemical free energy methods. This overview summarises all aspects of GC2, including the dataset details, challenge procedures, and participant results. We also consider implications for progress in the field, while highlighting methodological areas that merit continued development. Similar to GC2015, the outcome of GC2 underscores the pressing need for methods development in pose prediction, particularly for ligand scaffolds not currently represented in the Protein Data Bank (http://www.pdb.org), and in affinity ranking and scoring of bound ligands.

Conclusions:

• Successful prediction of ligand–protein poses depends on the entire workflow, including factors extrinsic to the core docking algorithm, such as the conformation of the protein selected.
• The accuracy of pose predictions tends to be improved by the use of available structural data, via ligand overlays and/or selection of receptor structures solved with similar ligands.
• The accuracy of the poses used in structure-based affinity rankings does not clearly correlate with ranking accuracy.
• Explicit solvent free energy methods did not, overall, pro-vide greater accuracy than faster, less detailed scoring methods

Given that many of the inhibitors target the ATP binding site it is perhaps not surprising that many molecules inhibit multiple kinases, unfortunately this information is not in a readily searchable format. A recent publication "The target landscape of clinical kinase drugs" DOI describes an approach to provide better understanding

To this end, we used a chemical proteomic approach (kinobeads) and quantitative mass spectrometry to characterize the target space of 243 clinical KIs that are approved drugs or have been tested in humans…..The number of targets for a given drug differed substantially. Whereas some compounds showed exquisite selectivity, others targeted more than 100 kinases simultaneously, making it difficult to attribute their biological effects to any particular mode of action.

All drug profiles can be interactively explored in ProteomicsDB and a purpose-built shinyApp.

The Chemical Probes Portal is designed to change the way scientists find and use small-molecule reagents called chemical probes in biomedical research and drug discovery. The Portal is backed by reviews and commentary from recognised chemical probe experts. Our knowledge-dissemination model, focused on providing accessible expert advice, promises to increase research reproducibility, maximise investment outcomes and accelerate the discovery science that informs the next generation of therapeutic

Recently Boehringer Ingelheim have decided to provide access to a number of chemical probes.

To foster innovation, Boehringer Ingelheim (BI) is openly sharing selected molecules with the scientific community to unlock their full potential. There are two types of Boehringer Ingelheim molecules that you can access on this portal: some for ordering, some for collaboration.

These molecules cover a range of interesting molecular targets.

Looking at the selective Aurora B kinase inhibitor BI 831266, it is clear that BI is making available high quality molecules, they provide the structure, in vitro activity, together with both in vitro and in vivo DMPK data in multiple species. They also suggest a related compound as a negative control in which the N-Me serves to block the critical hinge binding.

There is also a co-crystal structure and some counter-screening data, together with key references from the literature. Any data generated can be published without approval from BI.

This looks to be a very exciting initiative and it will be interesting to see if other companies follow suit.

They have also created a search engine BI Miner to search multiple data sources simultaneously (PubMed Central, Medline, Patents, Drug labels, Expression Data, NIH Grants, Clinical Trials), this open access.

The device is based on the standard equilibrium dialysis method to measure the fraction of low molecular weight compound bound to proteins. It is constructed from a standard polypropylene 96-well plate, dialysis tubing, and low viscosity epoxy resin. The device can be readily prepared for a small fraction of the cost of a commercial, multi-chamber, micro-dialysis device.

The results obtained agree favourably with literature values.

We reasoned that the antibody receptor and ubiquitin ligase TRIM21 could be used as a tool to drive the degradation of endogenous proteins by using a 3-step strategy: first, the introduction of exogenous TRIM21; second, the introduction of an antibody against the protein of interest; and third, TRIM21-mediated ubiquitination followed by degradation of the antibody-bound protein of interest.

There is more information on the MRC website

I've added it to the Target Validation page.

These databases cover a huge area of biological science, including:-

• Nucleic acid sequence, structure, and regulation
• Protein sequence and structure, motifs, and domains
• Metabolic and signalling pathways, enzymes
• Viruses, bacteria, protozoa and fungi
• Human genome, model organisms, comparative genomics
• Genomic variation, diseases, and drugs
• Plant databases

I'm delighted to report that over 200 people have now watched the video online, looks like it was a valuable resource.

One of the nice things about my job is I get the chance to take part in some truly inspiring events. Last month I had the honour of chairing a session on Neglected and Tropical Diseases at the 19th Cambridge MedChem Meeting. In an effort of extend the exposure of the brilliant science undertaken in this important therapeutic area the conference organisers arranged for this to be a live webinar. The session was also recorded and is now available online.

https://youtu.be/XLOCFrjrMEY

This is a recording of the Neglected and Tropical Diseases Session at the 19th Cambridge MedChem Meeting, 11-13 September 2017. The speakers are Kelly Chibale (Univ of Capetown), Christoph Boss (Actelion), Rob Young (GlaxoSmithKline), Jonathan Large (LifeArc) and Charles Mowbray (DNDI).

Please feel free to share. #19thCamMedChem.

The Organising Committee are inviting abstract submissions for both oral and poster presentation. Please download an abstract template from the event website and return it the secretariat. Closing dates for submissions are:

24th November 2017 for oral abstracts
23rd February 2018 for poster abstract

Remember this is an absolutely critical step, almost everything else can be fixed.

The results of a virtual screening run are effectively a rank ordering of the virtual screening deck ordered by whatever scoring function(s) that have been used. The task then becomes selection of molecules for experimental determination of activity.

I posed this question on the website and the results are shown below. Whilst this obviously a limited snapshot it is interesting that there is a wide variety of responses.

I've included the results on the page on Selecting Compounds from a Virtual Screening Run.

• Denmark, Spain and the United Kingdom eliminated measles;
• The Republic of Moldova, Sweden and the former Yugoslav Republic of Macedonia eliminated rubella;
• Croatia, Greece, Iceland, Lithuania, Montenegro and Uzbekistan eliminated both measles and rubella.
• Spain and United Kingdom achieved elimination status for rubella as of 2015

This is another great success for the vaccination program with Measles no longer endemic in 79% of the WHO European Region

Full details here http://www.euro.who.int/en/media-centre/sections/press-releases/2017/measles-no-longer-endemic-in-79-of-the-who-european-region

Multidisciplinary Project Award supports collaborations between cancer researchers and scientists from engineering/physical science disciplines.

Applications should ideally include:

• a minimum of two PIs working in distinct scientific disciplines
• at least one PI working in cancer research at any career stage
• at least one PI from an engineering/physical science discipline at any career stage

Applications will be accepted from UK universities, research institutions, Cancer Research UK core-funded Institutes, medical schools and hospitals. The award is not required to be co-located and can be held across institutions in the UK, supporting roles from international and commercial organisations may also be included.

The Medici Effect, With a New Preface and Discussion Guide: What Elephants and Epidemics Can Teach Us About Innovation

The book is the basis for "The Medici Effect," a term coined by Johansson and used throughout various industries to describe innovation that happens when disciplines and ideas intersect.

This might go some way towards correcting the bias against interdisciplinary research

I've captured a screenshot of the plots but I'd urge to go and have a look at the interactive plot on the website http://visual.ons.gov.uk/causes-of-death-over-100-years/.

What is very apparent is the impact the introduction of antibiotics had in the late 1940's, and the introduction of mass vaccinations, deaths due to infections have been virtually eliminated.

In men heart disease remains the major killer whilst in women it is breast cancer. Sadly among the young it looks like mental health issues are a major concern.

This Award was founded in 2002 in memory of the chemists Nigel Capps, Richard Green and Alex Zomaya to recognise outstanding contributions to medicinal or computational medicinal chemistry.

• Run biennially
• The winner receives £2000, a certificate and a medal
• The winner is invited to give the 'Capps Green Zomaya Memorial Lecture' at the East of England
• Medicinal Chemistry Symposium in April 2018
• The winner will be chosen by an independent panel of senior chemists, selected by the Committee of the RSC Biological and Medicinal Chemistry Sector (BMCS) and the Capps Green Zomaya Trust.

More details are here http://www.rsc.org/ScienceAndTechnology/Awards/CappsGreenZoyama/

Whilst virtual screening is certainly less expensive than high-throughput screening it is not free, even an in house academic cluster has an overhead (probably equating to > $10,000 per virtual screen). So with that investment how much would you invest in actual compounds?

New for 2017 - Live Webcast Session on Neglected Tropical Diseases
Tuesday, 12th September Afternoon (13-30pm start).
Session Chair: Chris Swain, Consultant, UK

Introduction to the Neglected Tropical Diseases (NTD) session
Kelly Chibale, University of Capetown, South Africa
PI4K inhibitors that target multiple life cycle stages of the human malaria parasite
Kelly Chibale, University of Capetown, South Africa
Discovery and characterization of ACT-451840: an antimalarial drug with a novel mechanism of action
Christoph Boss, Actelion, Switzerland

Refreshments and short film clips

Rapid discovery of non-covalent inhibitors of DprE1, a novel and exciting target to treat Mycobacterium tuberculosis: impact of medicinal chemistry on an open source collaboration
Rob Young, GlaxoSmithKline, UK
Potent, selective and orally efficacious inhibitors of Plasmodium falciparum Protein Kinase G (PfPKG)
Jon Large, LifeArc, UK
First disclosure of a new oral development candidate for the treatment of visceral and cutaneous leishmaniasis
Charlie Mowbray, DNDi (Drugs for Neglected Diseases initiative), Switzerland
Closing remarks for NTD session
Charlie Mowbray, DNDi, Switzerland

The meeting is now fully booked but we hope that scientists around the world will be able to watch the presentations live using this link

LiveStream.

Please feel free to share this link.

The data from screening campaigns invariably contains errors

• It is often a single point assay
• Quality and diversity of Sample Collection is variable
• Compounds may interfere with the detection system
• False positives due to aggregation
• High density plates can result in cross contamination, edge effects

There is a very simple mantra you should adopt when analysing screening data "Trust but verify".

• Check compounds that were found active against the selected target are re-tested using the same assay conditions used during the HTS.
• Does a resynthesised (not repurchased) show the same activity
• Dose response curve generation: an IC50 or EC50 value is then generated, does it have a reasonable slope? Uneffected by incubation time.
• Are related analogues available, check for genuine Structure-Activity Relationships

There is a strategy for the analysis of HTS data in the Drug Discovery Resources.

If you can't make it, the books are available elsewhere. The ideal coffee table book.

If you want to edit your bookmarks here is the new link https://www.cambridgemedchemconsulting.com

Point of View: Correcting the bias against interdisciplinary research DOI

When making decisions about funding and jobs the scientific community should recognise that most of the tools used to evaluate scientific excellence are biased in favour of established disciplines and against interdisciplinary research.

Scientists who leave the safe haven of their home discipline to explore the uncharted territory that lies outside and between established disciplines are often punished rather than rewarded for following their scientific curiosity

Perhaps all funding bodies should read this book

The Medici Effect, With a New Preface and Discussion Guide: What Elephants and Epidemics Can Teach Us About Innovation

The book is the basis for "The Medici Effect," a term coined by Johansson and used throughout various industries to describe innovation that happens when disciplines and ideas intersect.

Closing date is 27 Sept 2017

https://www.mrc.ac.uk/funding/browse/mrc-az-cld/mrc-astrazeneca-centre-for-lead-discovery/.

Further information on the collaboration with AstraZeneca

This is accompanied by a more detailed publication DOI giving a state-of-the-art overview.

Malaria is caused in humans by five species of single-celled eukaryotic Plasmodium parasites (mainly Plasmodium falciparum and Plasmodium vivax) that are transmitted by the bite of Anopheles spp. mosquitoes. Malaria remains one of the most serious infectious diseases; it threatens nearly half of the world's population and led to hundreds of thousands of deaths in 2015, predominantly among children in Africa. Malaria is managed through a combination of vector control approaches (such as insecticide spraying and the use of insecticide-treated bed nets) and drugs for both treatment and prevention. The widespread use of artemisinin-based combination therapies has contributed to substantial declines in the number of malaria-related deaths; however, the emergence of drug resistance threatens to reverse this progress. Advances in our understanding of the underlying molecular basis of pathogenesis have fuelled the development of new diagnostics, drugs and insecticides. Several new combination therapies are in clinical development that have efficacy against drug-resistant parasites and the potential to be used in single-dose regimens to improve compliance. This ambitious programme to eliminate malaria also includes new approaches that could yield malaria vaccines or novel vector control strategies. However, despite these achievements, a well-coordinated global effort on multiple fronts is needed if malaria elimination is to be achieved.

Malaria has been the subject of intensive research efforts and the image below shown the Medicines for Malaria Venture supported projects

Bioisosteres are chemical substituents or groups with similar steric or electrostatic properties which produce broadly similar biological properties to another chemical compound.

Bioisosteres won't always give improved properties, and sometimes we find that a transformation that improves metabolic stability in one series might have the reverse effect in another. However they provide useful (literature precedented) starting points for structural transformations that allow exploration of structure activity relationships. Sometimes they yield similar activity but offer alternative structural vectors for exploration, sometimes they simply improve solubility.

I've now updated the bioisosteres section of the Drug Discovery Resources including new examples people have kindly sent to me.

Closing date for abstract submission is 15th September 2017

The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry will be hosting its 11th postgraduate symposium for PhD students and postdoctoral workers researching in biological or medicinal chemistry and related areas. The event will be held in the Department of Chemistry at the University of Cambridge on Friday 8th December 2017. Researchers working in these areas are invited to participate. Registration will start at 9:00 am with talks beginning at 10:00 am. The day will consist of 11 oral presentations (8 student and 3 keynote) plus a Flash Poster section. Each 20 minute student talk will be followed by 10 minutes for questions.

This is a fantastic meeting for anyone interested in medicinal chemistry and drug discovery, this event is FREE but all attendees should register as soon as possible and no later than the 1st December 2017.

Fragment Based Screening

Added a little on strategies for following the initial leads and also updated the details on drugs in the clinic discovered using fragment-based approaches.

One of the key aims is to make the work instantly accessible but at the moment persuading search engines to index SMILES/InChI is proving a challenge. As a temporary fix I'm posting all the details here with a link to the original online spreadsheet.

Index of Open Source molecules from https://docs.google.com/spreadsheets/d/1Rvy6OiM291d1GNcyT6eSwC3lSuJ1jaR7AJa8hgGsc/edit#gid=510297618 9 July 2017

Worth reading, InChI in the wild: an assessment of InChIKey searching in Google DOI

OSM Number,Internal ID,PubChem CID,MMV ID,SMILES,InChI,IChI Key


OSM-A-1,,1233035,,O=C(/C(S/1)=C/C2=C(C)N(C(C)=C2)C3=CC=C(S(=O)(N)=O)C=C3)NC1=N\C4=CC=CC=C4,"InChI=1S/C22H20N4O3S2/c1-14-12-16(15(2)26(14)18-8-10-19(11-9-18)31(23,28)29)13-20-21(27)25-22(30-20)24-17-6-4-3-5-7-17/h3-13H,1-2H3,(H2,23,28,29)(H,24,25,27)/b20-13-",ODRSSOQWOHNABY-MOSHPQCFSA-N
OSM-A-10,,,,O=C([H])C1=C(C)N(C(C)=C1)C2=CC(OC)=CC=C2,"InChI=1S/C14H15NO2/c1-10-7-12(9-16)11(2)15(10)13-5-4-6-14(8-13)17-3/h4-9H,1-3H3",XTPVHYRCFNPCRL-UHFFFAOYSA-N
OSM-A-11,,,,IC1=CC=C(N2C(C)=CC=C2C)C=C1,"InChI=1S/C12H12IN/c1-9-3-4-10(2)14(9)12-7-5-11(13)6-8-12/h3-8H,1-2H3",CLGKGHWNVMDYQB-UHFFFAOYSA-N
OSM-A-12,,,,IC1=CC=C(N2C(C)=CC(C([H])=O)=C2C)C=C1,"InChI=1S/C13H12INO/c1-9-7-11(8-16)10(2)15(9)13-5-3-12(14)4-6-13/h3-8H,1-2H3",SSNYMKCLPCTDEB-UHFFFAOYSA-N
OSM-A-2,,,,O=C(/C(S/1)=C/C2=C(C)N(C(C)=C2)C3=CC=C(C#N)C=C3)NC1=N\C4=CC=CC=C4,"InChI=1S/C23H18N4OS/c1-15-12-18(16(2)27(15)20-10-8-17(14-24)9-11-20)13-21-22(28)26-23(29-21)25-19-6-4-3-5-7-19/h3-13H,1-2H3,(H,25,26,28)/b21-13-",LXPLFPVISCVJSC-BKUYFWCQSA-N
OSM-A-3,,,,O=C(/C(S/1)=C/C2=C(C)N(C(C)=C2)C3=CC(OC)=CC=C3)NC1=N\C4=CC=CC=C4,"InChI=1S/C23H21N3O2S/c1-15-12-17(16(2)26(15)19-10-7-11-20(14-19)28-3)13-21-22(27)25-23(29-21)24-18-8-5-4-6-9-18/h4-14H,1-3H3,(H,24,25,27)/b21-13-",QRGVMORNNJFJKZ-BKUYFWCQSA-N
OSM-A-4,,,,O=C(/C(S/1)=C/C2=C(C)N(C(C)=C2)C3=CC=C(I)C=C3)NC1=N\C4=CC=CC=C4,"InChI=1S/C22H18IN3OS/c1-14-12-16(15(2)26(14)19-10-8-17(23)9-11-19)13-20-21(27)25-22(28-20)24-18-6-4-3-5-7-18/h3-13H,1-2H3,(H,24,25,27)/b20-13-",LZWDTKNFRNEIKZ-MOSHPQCFSA-N
OSM-A-5,,,,CC1=CC=C(C)N1C2=CC=C(S(=O)(N)=O)C=C2,"InChI=1S/C12H14N2O2S/c1-9-3-4-10(2)14(9)11-5-7-12(8-6-11)17(13,15)16/h3-8H,1-2H3,(H2,13,15,16)",STHWURXTZRCILS-UHFFFAOYSA-N
OSM-A-6,,,,O=C([H])C1=C(C)N(C(C)=C1)C2=CC=C(S(N)=O)C=C2,"InChI=1S/C13H14N2O2S/c1-9-7-11(8-16)10(2)15(9)12-3-5-13(6-4-12)18(14)17/h3-8H,14H2,1-2H3",JYZXFZAZSQBBQH-UHFFFAOYSA-N
OSM-A-7,,,,CC1=CC=C(C)N1C2=CC=C(C#N)C=C2,"InChI=1S/C13H12N2/c1-10-3-4-11(2)15(10)13-7-5-12(9-14)6-8-13/h3-8H,1-2H3",FNDFKQYZEDOHRC-UHFFFAOYSA-N
OSM-A-8,,,,O=C([H])C1=C(C)N(C(C)=C1)C2=CC=C(C#N)C=C2,"InChI=1S/C14H12N2O/c1-10-7-13(9-17)11(2)16(10)14-5-3-12(8-15)4-6-14/h3-7,9H,1-2H3",AZYQCNIOZJETFM-UHFFFAOYSA-N
OSM-A-9,,,,CC1=CC=C(C)N1C2=CC(OC)=CC=C2,"InChI=1S/C13H15NO/c1-10-7-8-11(2)14(10)12-5-4-6-13(9-12)15-3/h4-9H,1-3H3",GVGRVGMGPYDHOB-UHFFFAOYSA-N
OSM-E-1,PT-1-10 ,57519183,,FC1=CC=C(N2C(C)=CC(S(N(C)CC(N)=O)(=O)=O)=C2C)C=C1,"InChI=1S/C15H18FN3O3S/c1-10-8-14(23(21,22)18(3)9-15(17)20)11(2)19(10)13-6-4-12(16)5-7-13/h4-8H,9H2,1-3H3,(H2,17,20)",KRDORFFFZGUMFF-UHFFFAOYSA-N
OSM-E-10,PT-1-6; PT-1-7; PT-1-8; PT-1-9,,,FC1=CC=C(N2C(C)=CC(S(N(C)CC(OC)=O)(=O)=O)=C2C)C=C1,"InChI=1S/C16H19FN2O4S/c1-11-9-15(24(21,22)18(3)10-16(20)23-4)12(2)19(11)14-7-5-13(17)6-8-14/h5-9H,10H2,1-4H3",LIADENKDGVSTCO-UHFFFAOYSA-N
OSM-E-11,PT-1-11,,,FC1=CC=C(N2C(C)=CC(S(N([H])CC(OC)=O)(=O)=O)=C2C)C=C1,"InChI=1S/C15H17FN2O4S/c1-10-8-14(23(20,21)17-9-15(19)22-3)11(2)18(10)13-6-4-12(16)5-7-13/h4-8,17H,9H2,1-3H3",MAMSLIRHTVGOCI-UHFFFAOYSA-N
OSM-E-12,PT-1-4,,,FC1=CC=C(N2C(C)=CC(S([O-])(=O)=O)=C2C)C=C1.[H][N+]3=CC=CC=C3,"InChI=1S/C12H12FNO3S.C5H5N/c1-8-7-12(18(15,16)17)9(2)14(8)11-5-3-10(13)4-6-11;1-2-4-6-5-3-1/h3-7H,1-2H3,(H,15,16,17);1-5H",GVWFBFKDWILLTG-UHFFFAOYSA-N
OSM-E-13,PT-1-3,,,FC1=CC=C(N2C(C)=C(S(N(CC(OC)=O)C)(=O)=O)C(S(N(C)CC(OC)=O)(=O)=O)=C2C)C=C1,"InChI=1S/C20H26FN3O8S2/c1-13-19(33(27,28)22(3)11-17(25)31-5)20(34(29,30)23(4)12-18(26)32-6)14(2)24(13)16-9-7-15(21)8-10-16/h7-10H,11-12H2,1-6H3",HLULFYCSKNZRBP-UHFFFAOYSA-N
OSM-E-14,PT-1-13,10877131,,O=C(OC)COCC#C,"InChI=1S/C6H8O3/c1-3-4-9-5-6(7)8-2/h1H,4-5H2,2H3",AIQJXQPQNMKDGJ-UHFFFAOYSA-N
OSM-E-2,PT-1-12,,,FC1=CC=C(N2C(C)=CC(S(NCC(N)=O)(=O)=O)=C2C)C=C1,"InChI=1S/C14H16FN3O3S/c1-9-7-13(22(20,21)17-8-14(16)19)10(2)18(9)12-5-3-11(15)4-6-12/h3-7,17H,8H2,1-2H3,(H2,16,19)",RMHRPTFDPMUFGU-UHFFFAOYSA-N
OSM-E-3,PT-1-5,,,FC1=CC=C(N2C(C)=C(S(N(CC(N)=O)C)(=O)=O)C(S(N(C)CC(N)=O)(=O)=O)=C2C)C=C1,"InChI=1S/C18H24FN5O6S2/c1-11-17(31(27,28)22(3)9-15(20)25)18(32(29,30)23(4)10-16(21)26)12(2)24(11)14-7-5-13(19)6-8-14/h5-8H,9-10H2,1-4H3,(H2,20,25)(H2,21,26)",TZMPVBDMPWKREJ-UHFFFAOYSA-N
OSM-E-4,PT-1-14-C1,,,FC1=CC=C(N2N=NC(COC(CBr)=O)=C2)C=C1,"InChI=1S/C11H9BrFN3O2/c12-5-11(17)18-7-9-6-16(15-14-9)10-3-1-8(13)2-4-10/h1-4,6H,5,7H2",UNGOTBWYUGGCJU-UHFFFAOYSA-N
OSM-E-5,PT-1-14-C2,,,FC1=CC=C(N2N=NC(COCC(OCC)=O)=C2)C=C1,"InChI=1S/C13H14FN3O3/c1-2-20-13(18)9-19-8-11-7-17(16-15-11)12-5-3-10(14)4-6-12/h3-7H,2,8-9H2,1H3",OAQNGCWJHOFYIG-UHFFFAOYSA-N
OSM-E-6,PT-1-14-C3,,,FC1=CC=C(N2N=NC(COCC(OC)=O)=C2)C=C1,"InChI=1S/C12H12FN3O3/c1-18-12(17)8-19-7-10-6-16(15-14-10)11-4-2-9(13)3-5-11/h2-6H,7-8H2,1H3",MXCBYXCXBDMCMO-UHFFFAOYSA-N
OSM-E-7,PT-1-14-C4,,,FC1=CC=C(N2N=NC(COCC(OCC3=CN(C4=CC=C(F)C=C4)N=N3)=O)=C2)C=C1,"InChI=1S/C20H16F2N6O3/c21-14-1-5-18(6-2-14)27-9-16(23-25-27)11-30-13-20(29)31-12-17-10-28(26-24-17)19-7-3-15(22)4-8-19/h1-10H,11-13H2",CWJPLXSSRWVEAF-UHFFFAOYSA-N
OSM-E-8,PT-1-15,,,FC1=CC=C(N2N=NC(COCC(N)=O)=C2)C=C1,"InChI=1S/C11H11FN4O2/c12-8-1-3-10(4-2-8)16-5-9(14-15-16)6-18-7-11(13)17/h1-5H,6-7H2,(H2,13,17)",XMSVYANCVZPQJL-UHFFFAOYSA-N
OSM-E-9,PT-1-9; PMY54,,,FC1=CC=C(N2C(C)=CC(S(Cl)(=O)=O)=C2C)C=C1,"InChI=1S/C12H11ClFNO2S/c1-8-7-12(18(13,16)17)9(2)15(8)11-5-3-10(14)4-6-11/h3-7H,1-2H3",MZWDVJVLEJEILM-UHFFFAOYSA-N
OSM-L-1,SBBH-1-9,,,CC(N1C2=CC(F)=CC=C2)=CC(/C=C(C(N/3C4=CC=CC=C4)=O)\SC3=N/C5=CC=CC=C5)=C1C,"InChI=1S/C28H22FN3OS/c1-19-16-21(20(2)31(19)25-15-9-10-22(29)18-25)17-26-27(33)32(24-13-7-4-8-14-24)28(34-26)30-23-11-5-3-6-12-23/h3-18H,1-2H3/b26-17-,30-28-",URZLHIHAUACTCO-DUPRQXJUSA-N
OSM-L-2,SBHK-516,,,O=C(OCC#N)C1=C(C)N(N=C1)C2=CC=CC=C2,"InChI=1S/C13H11N3O2/c1-10-12(13(17)18-8-7-14)9-15-16(10)11-5-3-2-4-6-11/h2-6,9H,8H2,1H3",LVOFSOINGBOZCK-UHFFFAOYSA-N
OSM-S-1,PMY1; AEW1; PT1; MD22,3145454,,FC1=CC=C(N2C(C)=CC=C2C)C=C1,"InChI=1S/C12H12FN/c1-9-3-4-10(2)14(9)12-7-5-11(13)6-8-12/h3-8H,1-2H3",AIWFQKZWZOYVMK-UHFFFAOYSA-N
OSM-S-10,PMY14-3-A; AEW80,1228983,MMV689017,FC1=CC=C(N2C(C)=CC(/C=C3S/C(NC\3=O)=N\C4=CC=CC=C4)=C2C)C=C1,"InChI=1S/C22H18FN3OS/c1-14-12-16(15(2)26(14)19-10-8-17(23)9-11-19)13-20-21(27)25-22(28-20)24-18-6-4-3-5-7-18/h3-13H,1-2H3,(H,24,25,27)/b20-13-",IMCPBTMVWRMBHR-MOSHPQCFSA-N
OSM-S-100,AEW73; MD18,71450943,,FC1=CC=C(N2C(C)=CC(C(OC(C)C(O)=O)=O)=C2C)C=C1,"InChI=1S/C16H16FNO4/c1-9-8-14(16(21)22-11(3)15(19)20)10(2)18(9)13-6-4-12(17)5-7-13/h4-8,11H,1-3H3,(H,19,20)",CLQCMRDHQCCPEN-UHFFFAOYSA-N
OSM-S-101,PMY59,71459966,,FC1=CC=C(N2C(C)=CC(C3=NC(C(O)=O)=CO3)=C2C)C=C1,"InChI=1S/C16H13FN2O3/c1-9-7-13(15-18-14(8-22-15)16(20)21)10(2)19(9)12-5-3-11(17)4-6-12/h3-8H,1-2H3,(H,20,21)",PZPDUGQJGPKVEM-UHFFFAOYSA-N
OSM-S-102,MNR53,71461679,,FC1=CC=C(N2C(C)=CC(C(CCC(NC)=O)=O)=C2C)C=C1,"InChI=1S/C17H19FN2O2/c1-11-10-15(16(21)8-9-17(22)19-3)12(2)20(11)14-6-4-13(18)5-7-14/h4-7,10H,8-9H2,1-3H3,(H,19,22)",NTSUYUWERKMXIY-UHFFFAOYSA-N
OSM-S-103,MNR54,71452751,,CC(N1C2=CC=C(F)C=C2)=C(C(CCC(N)=O)=O)C=C1C,"InChI=1S/C16H17FN2O2/c1-10-9-14(15(20)7-8-16(18)21)11(2)19(10)13-5-3-12(17)4-6-13/h3-6,9H,7-8H2,1-2H3,(H2,18,21)",IUFWRPRMBNNROV-UHFFFAOYSA-N
OSM-S-104,MNR55,71450944,,FC1=CC=C(N2N=CC(C3=NC(C(O)=O)=CO3)=C2C)C=C1,"InChI=1S/C14H10FN3O3/c1-8-11(13-17-12(7-21-13)14(19)20)6-16-18(8)10-4-2-9(15)3-5-10/h2-7H,1H3,(H,19,20)",WPAXFMQFJQZBFD-UHFFFAOYSA-N
OSM-S-105,MNR56,57519185,,FC1=CC=C(N2N=CC(C3=NC(C(N)=O)=CO3)=C2C)C=C1,"InChI=1S/C14H11FN4O2/c1-8-11(14-18-12(7-21-14)13(16)20)6-17-19(8)10-4-2-9(15)3-5-10/h2-7H,1H3,(H2,16,20)",JODCOGVLCRBBMU-UHFFFAOYSA-N
OSM-S-106,,44528665,,NC1=C2C(C=C(C3=CC(S(N)(=O)=O)=CC=C3)S2)=NC=N1,"InChI=1S/C12H10N4O2S2/c13-12-11-9(15-6-16-12)5-10(19-11)7-2-1-3-8(4-7)20(14,17)18/h1-6H,(H2,13,15,16)(H2,14,17,18)",MQMXDJVOZKMSNT-UHFFFAOYSA-N
OSM-S-107,,,,FC(C=C1)=CC=C1CN(CC2)CCN2C3=C4C(C=CS4)=NC=N3,"InChI=1S/C17H17FN4S/c18-14-3-1-13(2-4-14)11-21-6-8-22(9-7-21)17-16-15(5-10-23-16)19-12-20-17/h1-5,10,12H,6-9,11H2",HYCIFMXWGMZZSB-UHFFFAOYSA-N
OSM-S-108,AEW34,,,O=C(/C(S/1)=C/C2=C(C)NC(C)=C2)NC1=N\C3=CC=CC=C3,"InChI=1S/C16H15N3OS/c1-10-8-12(11(2)17-10)9-14-15(20)19-16(21-14)18-13-6-4-3-5-7-13/h3-9,17H,1-2H3,(H,18,19,20)/b14-9-",RARJKBCELXYZBB-ZROIWOOFSA-N
OSM-S-109,MNR82,,,O=C(/C(S/1)=C/C2=C(C)N(C3=CC=C([N+]([O-])=O)C=C3)C(C)=C2)NC1=N\C4=CC=CC=C4,"InChI=1S/C22H18N4O3S/c1-14-12-16(15(2)25(14)18-8-10-19(11-9-18)26(28)29)13-20-21(27)24-22(30-20)23-17-6-4-3-5-7-17/h3-13H,1-2H3,(H,23,24,27)/b20-13-",CHHZBZWZMLCOEW-MOSHPQCFSA-N
OSM-S-11,PMY15; PMY18; AEW3; MNR97,894104,,FC1=CC=C(N2C(C)=C(CO)C=C2C)C=C1,"InChI=1S/C13H14FNO/c1-9-7-11(8-16)10(2)15(9)13-5-3-12(14)4-6-13/h3-7,16H,8H2,1-2H3",RXDPKDMALDFFCU-UHFFFAOYSA-N
OSM-S-110,MNR83,,,O=C(/C(S/1)=C/C2=C(C)N(C3=CC=C([N+]([O-])=O)C=C3)C(C)=C2)NC1=N\C4=CC(O)=CC=C4,"InChI=1S/C22H18N4O4S/c1-13-10-15(14(2)25(13)17-6-8-18(9-7-17)26(29)30)11-20-21(28)24-22(31-20)23-16-4-3-5-19(27)12-16/h3-12,27H,1-2H3,(H,23,24,28)/b20-11-",NAHYEQMJTBIJRP-JAIQZWGSSA-N
OSM-S-111,MNR84,,,O=C(/C(S/1)=C/C2=C(C)N(C3=CC=C(OC)C=C3)C(C)=C2)NC1=N\C4=CC=CC=C4,"InChI=1S/C23H21N3O2S/c1-15-13-17(16(2)26(15)19-9-11-20(28-3)12-10-19)14-21-22(27)25-23(29-21)24-18-7-5-4-6-8-18/h4-14H,1-3H3,(H,24,25,27)/b21-14-",KXIVXNPEYYNDHE-STZFKDTASA-N
OSM-S-112,MNR85,,,O=C(/C(S/1)=C/C2=C(C)N(C3=CC=C(OC)C=C3)C(C)=C2)NC1=N\C4=CC(O)=CC=C4,"InChI=1S/C23H21N3O3S/c1-14-11-16(15(2)26(14)18-7-9-20(29-3)10-8-18)12-21-22(28)25-23(30-21)24-17-5-4-6-19(27)13-17/h4-13,27H,1-3H3,(H,24,25,28)/b21-12-",RTYHWQWUZGEAOW-MTJSOVHGSA-N
OSM-S-113,MNR92,,,O=C(/C(S/1)=C/C2=C(C)N(C3=CC=CC=N3)C(C)=C2)NC1=N\C4=CC=C(O)C=C4,"InChI=1S/C21H18N4O2S/c1-13-11-15(14(2)25(13)19-5-3-4-10-22-19)12-18-20(27)24-21(28-18)23-16-6-8-17(26)9-7-16/h3-12,26H,1-2H3,(H,23,24,27)/b18-12-",QZBWTSAVUQHJPY-PDGQHHTCSA-N
OSM-S-114,MNR94,,,O=C(/C(S/1)=C/C2=C(C)N(C3=CC=CC=C3)C(C)=C2)NC1=N\C4=CC(O)=CC=C4,"InChI=1S/C22H19N3O2S/c1-14-11-16(15(2)25(14)18-8-4-3-5-9-18)12-20-21(27)24-22(28-20)23-17-7-6-10-19(26)13-17/h3-13,26H,1-2H3,(H,23,24,27)/b20-12-",ASANPQFHMMSZFH-NDENLUEZSA-N
OSM-S-115,MNR95,,,O=C(/C(S/1)=C/C2=C(C)N(C3=CC=CC=C3)C(C)=C2)NC1=N\C4=CC=C(O)C=C4,"InChI=1S/C22H19N3O2S/c1-14-12-16(15(2)25(14)18-6-4-3-5-7-18)13-20-21(27)24-22(28-20)23-17-8-10-19(26)11-9-17/h3-13,26H,1-2H3,(H,23,24,27)/b20-13-",OIEJMTDGFAFKDZ-MOSHPQCFSA-N
OSM-S-116,AEW77,6915212,,CC(N1C2=CC=C(F)C=C2)=C(C(OC(C)C(N)=O)=O)C=C1C,"InChI=1S/C16H17FN2O3/c1-9-8-14(16(21)22-11(3)15(18)20)10(2)19(9)13-6-4-12(17)5-7-13/h4-8,11H,1-3H3,(H2,18,20)",JKLVGXNSTVWIID-UHFFFAOYSA-N
OSM-S-117 (DUPLICATE OF OSM-S-64),,,,,,
OSM-S-118,,,,C12=NC=NC(C3=CC=CC=C3)=C1SC=C2,InChI=1S/C12H8N2S/c1-2-4-9(5-3-1)11-12-10(6-7-15-12)13-8-14-11/h1-8H,ROUKINVYJAEUCD-UHFFFAOYSA-N
OSM-S-119,,,,BrC1=C(Br)C2=NC=NC(C3=CC=CC=C3)=C2S1,InChI=1S/C12H6Br2N2S/c13-8-10-11(17-12(8)14)9(15-6-16-10)7-4-2-1-3-5-7/h1-6H,MHSGERTZTNZZKP-UHFFFAOYSA-N
OSM-S-12,PMY20,292955,,CC(N1C2=CC=CC=C2)=CC(C(O)=O)=C1C,"InChI=1S/C13H13NO2/c1-9-8-12(13(15)16)10(2)14(9)11-6-4-3-5-7-11/h3-8H,1-2H3,(H,15,16)",CIRVCSCFJALBOH-UHFFFAOYSA-N
OSM-S-120,,,,BrC1=CC2=NC=NC(C3=CC=CC=C3)=C2S1,InChI=1S/C12H7BrN2S/c13-10-6-9-12(16-10)11(15-7-14-9)8-4-2-1-3-5-8/h1-7H,TUFQXFIDQNLCGQ-UHFFFAOYSA-N
OSM-S-121,,,,ClC1=C2C(C=C(Br)S2)=NC=N1,InChI=1S/C6H2BrClN2S/c7-4-1-3-5(11-4)6(8)10-2-9-3/h1-2H,RJKAKJGOZXERRE-UHFFFAOYSA-N
OSM-S-122,,,,C12=NC=NC(C3=CC=CC=C3)=C1SC(C4=CC=CC=C4)=C2,InChI=1S/C18H12N2S/c1-3-7-13(8-4-1)16-11-15-18(21-16)17(20-12-19-15)14-9-5-2-6-10-14/h1-12H,QDXZKUSOZDDGPU-UHFFFAOYSA-N
OSM-S-123,,,,NC1=C2C(C=C(C3=CC=CC=C3)S2)=NC=N1,"InChI=1S/C12H9N3S/c13-12-11-9(14-7-15-12)6-10(16-11)8-4-2-1-3-5-8/h1-7H,(H2,13,14,15)",WQVHTLKGGYMXIO-UHFFFAOYSA-N
OSM-S-124,,,,COC(C=C1)=CC=C1C2=CC3=NC=NC(N4CCOCC4)=C3S2,"InChI=1S/C17H17N3O2S/c1-21-13-4-2-12(3-5-13)15-10-14-16(23-15)17(19-11-18-14)20-6-8-22-9-7-20/h2-5,10-11H,6-9H2,1H3",LPCKDTSEWUTBJN-UHFFFAOYSA-N
OSM-S-125,,,,BrC1=CC2=NC=NC(N3CCOCC3)=C2S1,"InChI=1S/C10H10BrN3OS/c11-8-5-7-9(16-8)10(13-6-12-7)14-1-3-15-4-2-14/h5-6H,1-4H2",WUXPEHRGQLOSNM-UHFFFAOYSA-N
OSM-S-126,,,,C12=NC=NC(N3CCOCC3)=C1SC(C4=CC=CC=C4)=C2,"InChI=1S/C16H15N3OS/c1-2-4-12(5-3-1)14-10-13-15(21-14)16(18-11-17-13)19-6-8-20-9-7-19/h1-5,10-11H,6-9H2",LBOQIBFHJGJRTG-UHFFFAOYSA-N
OSM-S-127,,,,NS(C1=CC(C2=CC3=NC=NC(N4CCOCC4)=C3S2)=CC=C1)(=O)=O,"InChI=1S/C16H16N4O3S2/c17-25(21,22)12-3-1-2-11(8-12)14-9-13-15(24-14)16(19-10-18-13)20-4-6-23-7-5-20/h1-3,8-10H,4-7H2,(H2,17,21,22)",MDGVTZLJAVLGJP-UHFFFAOYSA-N
OSM-S-128,,,,NC1=C2C(C=C(C3=CC=C(C(C)(C)C)C=C3)S2)=NC=N1,"InChI=1S/C16H17N3S/c1-16(2,3)11-6-4-10(5-7-11)13-8-12-14(20-13)15(17)19-9-18-12/h4-9H,1-3H3,(H2,17,18,19)",KLCMSKCOVXKOMY-UHFFFAOYSA-N
OSM-S-129,,,,NC1=C2C(C=C(C3=CC=C(S(N)(=O)=O)C=C3)S2)=NC=N1,"InChI=1S/C12H10N4O2S2/c13-12-11-9(15-6-16-12)5-10(19-11)7-1-3-8(4-2-7)20(14,17)18/h1-6H,(H2,13,15,16)(H2,14,17,18)",NPCFGALHIPAZAV-UHFFFAOYSA-N
OSM-S-13,PMY21,757547,,CC1=CC=C(N2C(C)=C(C(O)=O)C=C2C)C=C1,"InChI=1S/C14H15NO2/c1-9-4-6-12(7-5-9)15-10(2)8-13(11(15)3)14(16)17/h4-8H,1-3H3,(H,16,17)",YNFCEUIZSXIFCE-UHFFFAOYSA-N
OSM-S-130,,,,NC1=C2C(C=C(C3=CC=C(C(N(C)C)=O)C=C3)S2)=NC=N1,"InChI=1S/C15H14N4OS/c1-19(2)15(20)10-5-3-9(4-6-10)12-7-11-13(21-12)14(16)18-8-17-11/h3-8H,1-2H3,(H2,16,17,18)",XJSSUNQWKKUSSC-UHFFFAOYSA-N
OSM-S-131,,,,NC1=C2C(C=C(C3=CC=C(OC)C=C3)S2)=NC=N1,"InChI=1S/C13H11N3OS/c1-17-9-4-2-8(3-5-9)11-6-10-12(18-11)13(14)16-7-15-10/h2-7H,1H3,(H2,14,15,16)",DRUQZXVTFOTIEO-UHFFFAOYSA-N
OSM-S-132,,,,NC1=C2C(C=C(C3=CC=C(C(N4CCOCC4)=O)C=C3)S2)=NC=N1,"InChI=1S/C17H16N4O2S/c18-16-15-13(19-10-20-16)9-14(24-15)11-1-3-12(4-2-11)17(22)21-5-7-23-8-6-21/h1-4,9-10H,5-8H2,(H2,18,19,20)",KOSDTDDFEYEHDU-UHFFFAOYSA-N
OSM-S-133,,,,NC1=C2C(C=C(C3=CC=CC(C(N(C)C)=O)=C3)S2)=NC=N1,"InChI=1S/C15H14N4OS/c1-19(2)15(20)10-5-3-4-9(6-10)12-7-11-13(21-12)14(16)18-8-17-11/h3-8H,1-2H3,(H2,16,17,18)",UZIAJWZVDQPKFB-UHFFFAOYSA-N
OSM-S-134,,,,NC1=C2C(C=C(C3=CC=C(C(N4CCN(C)CC4)=O)C=C3)S2)=NC=N1,"InChI=1S/C18H19N5OS/c1-22-6-8-23(9-7-22)18(24)13-4-2-12(3-5-13)15-10-14-16(25-15)17(19)21-11-20-14/h2-5,10-11H,6-9H2,1H3,(H2,19,20,21)",OUPUOWHKLRDGOE-UHFFFAOYSA-N
OSM-S-135,,,,NC1=C2C(C=C(C3=CC=CC(C(N)=O)=C3)S2)=NC=N1,"InChI=1S/C13H10N4OS/c14-12-11-9(16-6-17-12)5-10(19-11)7-2-1-3-8(4-7)13(15)18/h1-6H,(H2,15,18)(H2,14,16,17)",YWVZUIYPEKTRTJ-UHFFFAOYSA-N
OSM-S-136,,,,BrC1=CC2=NC=NC(N3CCN(CC4=CC=C(F)C=C4)CC3)=C2S1,"InChI=1S/C17H16BrFN4S/c18-15-9-14-16(24-15)17(21-11-20-14)23-7-5-22(6-8-23)10-12-1-3-13(19)4-2-12/h1-4,9,11H,5-8,10H2",DQEWYYDIDSUSJB-UHFFFAOYSA-N
OSM-S-137,,,,FC(C=C1)=CC=C1CN(CC2)CCN2C3=C4C(C=C(C5=CC=CC(S(N)(=O)=O)=C5)S4)=NC=N3,"InChI=1S/C23H22FN5O2S2/c24-18-6-4-16(5-7-18)14-28-8-10-29(11-9-28)23-22-20(26-15-27-23)13-21(32-22)17-2-1-3-19(12-17)33(25,30)31/h1-7,12-13,15H,8-11,14H2,(H2,25,30,31)",OWXZZWFFXSEZNL-UHFFFAOYSA-N
OSM-S-138,MNR121,,,CC1=CC(/C=C(S/2)/C(NC2=N\C3=CC=CC=C3)=O)=C(C)N1C4=CC=C(N)C=C4,"InChI=1S/C22H20N4OS/c1-14-12-16(15(2)26(14)19-10-8-17(23)9-11-19)13-20-21(27)25-22(28-20)24-18-6-4-3-5-7-18/h3-13H,23H2,1-2H3,(H,24,25,27)/b20-13-",HRLJSVOIZGABSH-MOSHPQCFSA-N
OSM-S-139,,,,BrC1=CC2=NC=NC(N)=C2S1,"InChI=1S/C6H4BrN3S/c7-4-1-3-5(11-4)6(8)10-2-9-3/h1-2H,(H2,8,9,10)",VKZWSZNMIMJBJX-UHFFFAOYSA-N
OSM-S-14,PMY22,18179364,,CC(N1C2=CC=C(C(F)(F)F)C=C2)=CC(C(O)=O)=C1C,"InChI=1S/C14H12F3NO2/c1-8-7-12(13(19)20)9(2)18(8)11-5-3-10(4-6-11)14(15,16)17/h3-7H,1-2H3,(H,19,20)",LVAKCYJWXASSHB-UHFFFAOYSA-N
OSM-S-140,,,,BrC1=CC2=NC=NC(NN)=C2S1,"InChI=1S/C6H5BrN4S/c7-4-1-3-5(12-4)6(11-8)10-2-9-3/h1-2H,8H2,(H,9,10,11)",KWCMTNUZOMHMJQ-UHFFFAOYSA-N
OSM-S-141,,,,CN(C)C1=C2C(C=CS2)=NC=N1,"InChI=1S/C8H9N3S/c1-11(2)8-7-6(3-4-12-7)9-5-10-8/h3-5H,1-2H3",AXPZJYARDJLZHH-UHFFFAOYSA-N
OSM-S-142,,,,NC1=C2C(C=C(C3=CC(C(N4CCN(C)CC4)=O)=CC=C3)S2)=NC=N1,"InChI=1S/C18H19N5OS/c1-22-5-7-23(8-6-22)18(24)13-4-2-3-12(9-13)15-10-14-16(25-15)17(19)21-11-20-14/h2-4,9-11H,5-8H2,1H3,(H2,19,20,21)",USHWEAINWXCOHP-UHFFFAOYSA-N
OSM-S-143,,,,ClC1=C2C(C=C(C3=CC(S(N)(=O)=O)=CC=C3)S2)=NC=N1,"InChI=1S/C12H8ClN3O2S2/c13-12-11-9(15-6-16-12)5-10(19-11)7-2-1-3-8(4-7)20(14,17)18/h1-6H,(H2,14,17,18)",WDYQLTAMDQFUGG-UHFFFAOYSA-N
OSM-S-144,,,,NS(C1=CC=CC(C2=CC3=NC=NC(OCCN(C)C)=C3S2)=C1)(=O)=O,"InChI=1S/C16H18N4O3S2/c1-20(2)6-7-23-16-15-13(18-10-19-16)9-14(24-15)11-4-3-5-12(8-11)25(17,21)22/h3-5,8-10H,6-7H2,1-2H3,(H2,17,21,22)",WBVWEEAUMTUSGX-UHFFFAOYSA-N
OSM-S-145,,,,NS(C1=CC=CC(C2=CC3=NC=NC(N(C)C)=C3S2)=C1)(=O)=O,"InChI=1S/C14H14N4O2S2/c1-18(2)14-13-11(16-8-17-14)7-12(21-13)9-4-3-5-10(6-9)22(15,19)20/h3-8H,1-2H3,(H2,15,19,20)",CGTVWFYTOADSRO-UHFFFAOYSA-N
OSM-S-146,,,,CC(C(C)(C)O1)(C)OB1C2=CC(S(NC(OC(C)(C)C)=O)(=O)=O)=CC=C2,"InChI=1S/C17H26BNO6S/c1-15(2,3)23-14(20)19-26(21,22)13-10-8-9-12(11-13)18-24-16(4,5)17(6,7)25-18/h8-11H,1-7H3,(H,19,20)",MSQKEIBBVCULRN-UHFFFAOYSA-N
OSM-S-147,,,,O=C(OC)C1=NC=CN=C1,"InChI=1S/C6H6N2O2/c1-10-6(9)5-4-7-2-3-8-5/h2-4H,1H3",TWIIRMSFZNYMQE-UHFFFAOYSA-N
OSM-S-148,,,,O=C(OC)C1=NC=C[N+]([O-])=C1,"InChI=1S/C6H6N2O3/c1-11-6(9)5-4-8(10)3-2-7-5/h2-4H,1H3",ZTAQCRRTNOJVIU-UHFFFAOYSA-N
OSM-S-149,,,,O=C(OC)C1=NC(Cl)=CN=C1,"InChI=1S/C6H5ClN2O2/c1-11-6(10)4-2-8-3-5(7)9-4/h2-3H,1H3",MVVYUJFEXRODQA-UHFFFAOYSA-N
OSM-S-15,PMY26,464,,O=C(C1=CC=CC=C1)NCC(O)=O,"InChI=1S/C9H9NO3/c11-8(12)6-10-9(13)7-4-2-1-3-5-7/h1-5H,6H2,(H,10,13)(H,11,12)",QIAFMBKCNZACKA-UHFFFAOYSA-N
OSM-S-150,,,,OC(C1=NC(Cl)=CN=C1)=O,"InChI=1S/C5H3ClN2O2/c6-4-2-7-1-3(8-4)5(9)10/h1-2H,(H,9,10)",KGGYMBKTQCLOTE-UHFFFAOYSA-N
OSM-S-151,,,,CC(C(C)(C)O1)(C)OB1C2=CC(S(N)(=O)=O)=CC=C2,"InChI=1S/C12H18BNO4S/c1-11(2)12(3,4)18-13(17-11)9-6-5-7-10(8-9)19(14,15)16/h5-8H,1-4H3,(H2,14,15,16)",OHKKUZJVWWPUNY-UHFFFAOYSA-N
OSM-S-152,,,,CC(C(C)(C)O1)(C)OB1C2=CC(S(NC)(=O)=O)=CC=C2,"InChI=1S/C13H20BNO4S/c1-12(2)13(3,4)19-14(18-12)10-7-6-8-11(9-10)20(16,17)15-5/h6-9,15H,1-5H3",YIIPTCFKYOTDME-UHFFFAOYSA-N
OSM-S-153,,,,CC(C(C)(C)O1)(C)OB1C2=CC(S(N(C)C)(=O)=O)=CC=C2,"InChI=1S/C14H22BNO4S/c1-13(2)14(3,4)20-15(19-13)11-8-7-9-12(10-11)21(17,18)16(5)6/h7-10H,1-6H3",YFEWVSRTWWHXFP-UHFFFAOYSA-N
OSM-S-154,,,,BrC1=CC(S(NC)(=O)=O)=CC=C1,"InChI=1S/C7H8BrNO2S/c1-9-12(10,11)7-4-2-3-6(8)5-7/h2-5,9H,1H3",UVSNSICXRVZAJR-UHFFFAOYSA-N
OSM-S-155,,,,BrC1=CC(S(N(C)C)(=O)=O)=CC=C1,"InChI=1S/C8H10BrNO2S/c1-10(2)13(11,12)8-5-3-4-7(9)6-8/h3-6H,1-2H3",RHBJVOGENJVLGT-UHFFFAOYSA-N
OSM-S-156,,,,CCOC(CCSCC(OCC)=O)=O,"InChI=1S/C9H16O4S/c1-3-12-8(10)5-6-14-7-9(11)13-4-2/h3-7H2,1-2H3",VKVGPGWOHFRXIG-UHFFFAOYSA-N
OSM-S-157,,,,O=C(OCC)C1SCCC1,"InChI=1S/C7H12O2S/c1-2-9-7(8)6-4-3-5-10-6/h6H,2-5H2,1H3",VHDROBMEJHQSNW-UHFFFAOYSA-N
OSM-S-158,,,,O=C(OC)C1=C(NC(C(F)(F)F)=O)C=CS1,"InChI=1S/C8H6F3NO3S/c1-15-6(13)5-4(2-3-16-5)12-7(14)8(9,10)11/h2-3H,1H3,(H,12,14)",CJNCTQZMIQZVQQ-UHFFFAOYSA-N
OSM-S-159,,,,IC1=CC2=NC=NC(N3CCOCC3)=C2S1,"InChI=1S/C10H10IN3OS/c11-8-5-7-9(16-8)10(13-6-12-7)14-1-3-15-4-2-14/h5-6H,1-4H2",UZWIPNXYAJRTAG-UHFFFAOYSA-N
OSM-S-16,PMY27,54704,,O=C(NC1=C(C)N(C)N(C2=CC=CC=C2)C1=O)CNC(C3=CC=CC=C3)=O,"InChI=1S/C20H20N4O3/c1-14-18(20(27)24(23(14)2)16-11-7-4-8-12-16)22-17(25)13-21-19(26)15-9-5-3-6-10-15/h3-12H,13H2,1-2H3,(H,21,26)(H,22,25)",URWSDMBJVGVIQC-UHFFFAOYSA-N
OSM-S-167,,,,BrC1=CC2=NC=NC(NC)=C2S1,"InChI=1S/C7H6BrN3S/c1-9-7-6-4(10-3-11-7)2-5(8)12-6/h2-3H,1H3,(H,9,10,11)",ICKALLHQGIOSOG-UHFFFAOYSA-N
OSM-S-168,,,,CNC1=C2C(C=CS2)=NC=N1,"InChI=1S/C7H7N3S/c1-8-7-6-5(2-3-11-6)9-4-10-7/h2-4H,1H3,(H,8,9,10)",AZPMALJVBUIZFS-UHFFFAOYSA-N
OSM-S-169,,,,CN(C)C1=C2C(C=C(Br)S2)=NC=N1,"InChI=1S/C8H8BrN3S/c1-12(2)8-7-5(10-4-11-8)3-6(9)13-7/h3-4H,1-2H3",QWNQRCLDQDDVBK-UHFFFAOYSA-N
OSM-S-17,PMY29; AEW63; AEW72; AEW64,57515636,,O=C(NC1=C(C)N(C)N(C2=CC=CC=C2)C1=O)CNC(OC(C)(C)C)=O,"InChI=1S/C18H24N4O4/c1-12-15(20-14(23)11-19-17(25)26-18(2,3)4)16(24)22(21(12)5)13-9-7-6-8-10-13/h6-10H,11H2,1-5H3,(H,19,25)(H,20,23)",MUHIYEGCMCBELD-UHFFFAOYSA-N
OSM-S-170,,,,BrC1=CC2=NC=NC(OCCN(C)C)=C2S1,"InChI=1S/C10H12BrN3OS/c1-14(2)3-4-15-10-9-7(12-6-13-10)5-8(11)16-9/h5-6H,3-4H2,1-2H3",SVRSGHTXGBHHFG-UHFFFAOYSA-N
OSM-S-171,,,,O=C1C2=C(C=CS2)NC=N1,"InChI=1S/C6H4N2OS/c9-6-5-4(1-2-10-5)7-3-8-6/h1-3H,(H,7,8,9)",PZMKGWRBZNOIPQ-UHFFFAOYSA-N
OSM-S-172,,,,COC1=C2C(C=CS2)=NC=N1,"InChI=1S/C7H6N2OS/c1-10-7-6-5(2-3-11-6)8-4-9-7/h2-4H,1H3",YDKUAOWCMDNAEX-UHFFFAOYSA-N
OSM-S-173,,,,O=S(C1=CC=C(Br)C=C1)(N(C)C)=O,"InChI=1S/C8H10BrNO2S/c1-10(2)13(11,12)8-5-3-7(9)4-6-8/h3-6H,1-2H3",NQAUNPZZVCXYEJ-UHFFFAOYSA-N
OSM-S-174,,,,CN(CC1)CCN1C2=C3C(C=CS3)=NC=N2,"InChI=1S/C11H14N4S/c1-14-3-5-15(6-4-14)11-10-9(2-7-16-10)12-8-13-11/h2,7-8H,3-6H2,1H3",UFWRIHSVBLJCSP-UHFFFAOYSA-N
OSM-S-175,AEW 300-1,,MMV670944,O=C(NC1=CC=NC(C(F)(F)F)=C1)C2=CN=CC3=NN=C(C4=CC=C(OC(F)F)C=C4)N32,"InChI=1S/C18H11F3N6O2/c19-14-7-11(5-6-23-14)24-17(28)13-8-22-9-15-25-26-16(27(13)15)10-1-3-12(4-2-10)29-18(20)21/h1-9,18H,(H,23,24,28)",UEOZBGRWGZEYED-UHFFFAOYSA-N
OSM-S-176,INHERITED,,MMV668958,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NCC4=CC(Cl)=CC=C4)=O)N32,"InChI=1S/C20H14ClF2N5O2/c21-14-3-1-2-12(8-14)9-25-19(29)16-10-24-11-17-26-27-18(28(16)17)13-4-6-15(7-5-13)30-20(22)23/h1-8,10-11,20H,9H2,(H,25,29)",YTUMNGGXAMTEHR-UHFFFAOYSA-N
OSM-S-177,EGT 111-1,,MMV669000,O=C(N1CC(C=CC=C2)=C2C1)C3=CN=CC4=NN=C(C5=CC=C(OC(F)F)C=C5)N43,"InChI=1S/C21H15F2N5O2/c22-21(23)30-16-7-5-13(6-8-16)19-26-25-18-10-24-9-17(28(18)19)20(29)27-11-14-3-1-2-4-15(14)12-27/h1-10,21H,11-12H2",ZTZAUSYERGBZNZ-UHFFFAOYSA-N
OSM-S-178,INHERITED,,MMV669001,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NCC4=CC=C(Cl)C=C4)=O)N32,"InChI=1S/C20H14ClF2N5O2/c21-14-5-1-12(2-6-14)9-25-19(29)16-10-24-11-17-26-27-18(28(16)17)13-3-7-15(8-4-13)30-20(22)23/h1-8,10-11,20H,9H2,(H,25,29)",FLHAMBHOAHIIDC-UHFFFAOYSA-N
OSM-S-179,INHERITED,,MMV669003,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NCC4CCOCC4)=O)N32,"InChI=1S/C19H19F2N5O3/c20-19(21)29-14-3-1-13(2-4-14)17-25-24-16-11-22-10-15(26(16)17)18(27)23-9-12-5-7-28-8-6-12/h1-4,10-12,19H,5-9H2,(H,23,27)",RKFIFNSJUCTPBT-UHFFFAOYSA-N
OSM-S-18,PMY28; PMY30; AEW64,3073741,,NCC(NC1=C(C)N(C)N(C2=CC=CC=C2)C1=O)=O,"InChI=1S/C13H16N4O2/c1-9-12(15-11(18)8-14)13(19)17(16(9)2)10-6-4-3-5-7-10/h3-7H,8,14H2,1-2H3,(H,15,18)",CAOVTXITBPMFQE-UHFFFAOYSA-N
OSM-S-180,INHERITED,,MMV669010,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(N4CCN(C5=NC=CC=C5)CC4)=O)N32,"InChI=1S/C23H22F2N8O2/c24-23(25)35-17-6-4-16(5-7-17)21-30-29-20-14-26-13-18(33(20)21)22(34)28-15-31-9-11-32(12-10-31)19-3-1-2-8-27-19/h1-8,13-14,23H,9-12,15H2,(H,28,34)",JSWJRHIWIVDMEN-UHFFFAOYSA-N
OSM-S-181,INHERITED,,MMV669011,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NCCN4CCOCC4)=O)N32,"InChI=1S/C19H20F2N6O3/c20-19(21)30-14-3-1-13(2-4-14)17-25-24-16-12-22-11-15(27(16)17)18(28)23-5-6-26-7-9-29-10-8-26/h1-4,11-12,19H,5-10H2,(H,23,28)",LYBWZYLEKBKOOG-UHFFFAOYSA-N
OSM-S-182,INHERITED,,MMV669022,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(N4CCCC4)=O)N32,"InChI=1S/C17H15F2N5O2/c18-17(19)26-12-5-3-11(4-6-12)15-22-21-14-10-20-9-13(24(14)15)16(25)23-7-1-2-8-23/h3-6,9-10,17H,1-2,7-8H2",HDIHMYGJUUDJKO-UHFFFAOYSA-N
OSM-S-183,INHERITED,,MMV669104,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(N4CCCC4C5=CC=CC=C5)=O)N32,"InChI=1S/C23H19F2N5O2/c24-23(25)32-17-10-8-16(9-11-17)21-28-27-20-14-26-13-19(30(20)21)22(31)29-12-4-7-18(29)15-5-2-1-3-6-15/h1-3,5-6,8-11,13-14,18,23H,4,7,12H2",VLZTZFFNDKJWSH-UHFFFAOYSA-N
OSM-S-184,INHERITED,,MMV669023,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(N4CCN(S(C)(=O)=O)CC4)=O)N32,"InChI=1S/C18H18F2N6O4S/c1-31(28,29)25-8-6-24(7-9-25)17(27)14-10-21-11-15-22-23-16(26(14)15)12-2-4-13(5-3-12)30-18(19)20/h2-5,10-11,18H,6-9H2,1H3",NZXJIDBDCVXJFP-UHFFFAOYSA-N
OSM-S-185,INHERITED,,MMV669020,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(N4CCOCC4)=O)N32,"InChI=1S/C17H15F2N5O3/c18-17(19)27-12-3-1-11(2-4-12)15-22-21-14-10-20-9-13(24(14)15)16(25)23-5-7-26-8-6-23/h1-4,9-10,17H,5-8H2",LFRCBCKOIXZMLV-UHFFFAOYSA-N
OSM-S-186,INHERITED,,MMV669024,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(N[C@H](C)C4=CC=CC=C4)=O)N32,"InChI=1S/C21H17F2N5O2/c1-13(14-5-3-2-4-6-14)25-20(29)17-11-24-12-18-26-27-19(28(17)18)15-7-9-16(10-8-15)30-21(22)23/h2-13,21H,1H3,(H,25,29)/t13-/m1/s1",MLKRVCDSVIMHCB-CYBMUJFWSA-N
OSM-S-187,,,,N#CC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCCC4=CC=CC=C4)N32,"InChI=1S/C20H15N5O/c21-12-16-6-8-17(9-7-16)20-24-23-18-13-22-14-19(25(18)20)26-11-10-15-4-2-1-3-5-15/h1-9,13-14H,10-11H2",ZUPHNBXHMXOSSS-UHFFFAOYSA-N
OSM-S-188,JU 9-1,,,N#CC(C=C1)=CC=C1C2=NN=C3C=NC=C(SCCC4=CC=CC=C4)N32,"InChI=1S/C20H15N5S/c21-12-16-6-8-17(9-7-16)20-24-23-18-13-22-14-19(25(18)20)26-11-10-15-4-2-1-3-5-15/h1-9,13-14H,10-11H2",UNOPMJXTFSQGHI-UHFFFAOYSA-N
OSM-S-189,JU 10-1,,MMV639725,N#CC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCCC4=CC=CC=C4Cl)N32,"InChI=1S/C20H14ClN5O/c21-17-4-2-1-3-15(17)9-10-27-19-13-23-12-18-24-25-20(26(18)19)16-7-5-14(11-22)6-8-16/h1-8,12-13H,9-10H2",DQNFHRXLTAOFIL-UHFFFAOYSA-N
OSM-S-19,PMY31; AEW59,57515637,,CC(N1C2=CC=C(F)C=C2)=CC(C(NCC(N)=O)=O)=C1C,"InChI=1S/C15H16FN3O2/c1-9-7-13(15(21)18-8-14(17)20)10(2)19(9)12-5-3-11(16)4-6-12/h3-7H,8H2,1-2H3,(H2,17,20)(H,18,21)",NNGDJLZNBQLHHL-UHFFFAOYSA-N
OSM-S-190,JU 11-1,,,N#CC(C=C1)=CC=C1C2=NN=C3C=NC=C(NCCC4=CC(Cl)=CC=C4)N32,"InChI=1S/C20H15ClN6/c21-17-3-1-2-14(10-17)8-9-24-18-12-23-13-19-25-26-20(27(18)19)16-6-4-15(11-22)5-7-16/h1-7,10,12-13,24H,8-9H2",XDIXATSCLPARDX-UHFFFAOYSA-N
OSM-S-191,JU 12-1,,,ClC(C=C1)=CC=C1C2=NN=C3C=NC=C(NCCC4=CC(Cl)=CC=C4)N32,"InChI=1S/C19H15Cl2N5/c20-15-6-4-14(5-7-15)19-25-24-18-12-22-11-17(26(18)19)23-9-8-13-2-1-3-16(21)10-13/h1-7,10-12,23H,8-9H2",ADHKXMMCJCKELF-UHFFFAOYSA-N
OSM-S-192,PMY5; PMY9; AEW78,16770273,,OCC(NC1=C(C)N(C)N(C2=CC=CC=C2)C1=O)=O,"InChI=1S/C13H15N3O3/c1-9-12(14-11(18)8-17)13(19)16(15(9)2)10-6-4-3-5-7-10/h3-7,17H,8H2,1-2H3,(H,14,18)",PVJDMAYRZQJDCY-UHFFFAOYSA-N
OSM-S-193,PMY7; AEW75,4460493,,O=C1COC(C)(C)O1,"InChI=1S/C5H8O3/c1-5(2)7-3-4(6)8-5/h3H2,1-2H3",JKUCOZWILDFXMF-UHFFFAOYSA-N
OSM-S-194,,,,C12=CC=CC=C1C3=C(C4(CCN(CC5=CC=CC=C5)CC4)OCC3)N2,"InChI=1S/C22H24N2O/c1-2-6-17(7-3-1)16-24-13-11-22(12-14-24)21-19(10-15-25-22)18-8-4-5-9-20(18)23-21/h1-9,23H,10-16H2",ZZRXZXUKZZBHSK-UHFFFAOYSA-N
OSM-S-195,,,,ClC1=C2C(C3(CCN(CC4=CC=CC=C4)CC3)OCC2)=CC=C1,"InChI=1S/C20H22ClNO/c21-19-8-4-7-18-17(19)9-14-23-20(18)10-12-22(13-11-20)15-16-5-2-1-3-6-16/h1-8H,9-15H2",MMFIRWPCCHXYHI-UHFFFAOYSA-N
OSM-S-196,,,,COC1=C(OC)C=C(C2(CCN(CC3=CC=CC=C3)CC2)OCC4)C4=C1,"InChI=1S/C22H27NO3/c1-24-20-14-18-8-13-26-22(19(18)15-21(20)25-2)9-11-23(12-10-22)16-17-6-4-3-5-7-17/h3-7,14-15H,8-13,16H2,1-2H3",ADXUPDCQQACVPU-UHFFFAOYSA-N
OSM-S-197,,,,C12=CC=CC=C1C3=C(C4(CCNCC4)OCC3)[N]2,"InChI=1S/C15H17N2O/c1-2-4-13-11(3-1)12-5-10-18-15(14(12)17-13)6-8-16-9-7-15/h1-4,16H,5-10H2",SYDQFEZUKSJIHJ-UHFFFAOYSA-N
OSM-S-198,,,,C1(C2(CCN(CC3=CC=CC=C3)CC2)OCC4)=C4C=CS1,"InChI=1S/C18H21NOS/c1-2-4-15(5-3-1)14-19-10-8-18(9-11-19)17-16(6-12-20-18)7-13-21-17/h1-5,7,13H,6,8-12,14H2",ZZQIGFUYNABBCP-UHFFFAOYSA-N
OSM-S-199,,,,C1(C(C=CC=C2)=C2[N]3)=C3C4(CCN(CC5=CC=C(OCCO6)C6=C5)CC4)OCC1,"InChI=1S/C24H25N2O3/c1-2-4-20-18(3-1)19-7-12-29-24(23(19)25-20)8-10-26(11-9-24)16-17-5-6-21-22(15-17)28-14-13-27-21/h1-6,15H,7-14,16H2",MQGOARLENPUGRJ-UHFFFAOYSA-N
OSM-S-2,PMY2; AEW2,951687,,CC1=CC(C=O)=C(C)N1C1=CC=C(F)C=C1,"InChI=1S/C13H12FNO/c1-9-7-11(8-16)10(2)15(9)13-5-3-12(14)4-6-13/h3-8H,1-2H3",COLPZCHNJIVKMV-UHFFFAOYSA-N
OSM-S-20,PMY32,57506927,,FC1=CC=C(N2C(C)=CC(C(Cl)=O)=C2C)C=C1,"InChI=1S/C13H11ClFNO/c1-8-7-12(13(14)17)9(2)16(8)11-5-3-10(15)4-6-11/h3-7H,1-2H3",PFYKYZUJWZEKFH-UHFFFAOYSA-N
OSM-S-200,,,,C12=CC=CC=C1C3=C(C4(CCN(CC5=CC=CC=C5)CC4)OCC3)S2,"InChI=1S/C22H23NOS/c1-2-6-17(7-3-1)16-23-13-11-22(12-14-23)21-19(10-15-24-22)18-8-4-5-9-20(18)25-21/h1-9H,10-16H2",BXTAXLWLFOLFKL-UHFFFAOYSA-N
OSM-S-201,TM 9-2,,MMV675718,O=C(NC1=C(C)C(Cl)=CC=C1)C2=CN=CC(N23)=NN=C3C4=CC=C(OC(F)F)C=C4,"InChI=1S/C20H14ClF2N5O2/c1-11-14(21)3-2-4-15(11)25-19(29)16-9-24-10-17-26-27-18(28(16)17)12-5-7-13(8-6-12)30-20(22)23/h2-10,20H,1H3,(H,25,29)",IVENWLQUYSRINV-UHFFFAOYSA-N
OSM-S-202,TM 14,,MMV669542,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NC4=CC=CC(Cl)=C4)=O)N32,"InChI=1S/C19H12ClF2N5O2/c20-12-2-1-3-13(8-12)24-18(28)15-9-23-10-16-25-26-17(27(15)16)11-4-6-14(7-5-11)29-19(21)22/h1-10,19H,(H,24,28)",AJGOFYWOTIIYLR-UHFFFAOYSA-N
OSM-S-203,TM 13,,,ClC1=CC(NC(C(N23)=CN=CC2=NN=C3C4=CC=C(C#N)C=C4)=O)=CC=C1,"InChI=1S/C19H11ClN6O/c20-14-2-1-3-15(8-14)23-19(27)16-10-22-11-17-24-25-18(26(16)17)13-6-4-12(9-21)5-7-13/h1-8,10-11H,(H,23,27)",YYVVJIHSHHKYPC-UHFFFAOYSA-N
OSM-S-204,TM 19-2,,MMV675946,O=C(NC1=C(F)C(Cl)=CC=C1)C2=CN=CC(N23)=NN=C3C4=CC=C(OC(F)F)C=C4,"InChI=1S/C19H11ClF3N5O2/c20-12-2-1-3-13(16(12)21)25-18(29)14-8-24-9-15-26-27-17(28(14)15)10-4-6-11(7-5-10)30-19(22)23/h1-9,19H,(H,25,29)",WBRLFZGDBUVKSB-UHFFFAOYSA-N
OSM-S-205,TM 18-1,,,ClC1=C(F)C(NC(C(N23)=CN=CC2=NN=C3C4=CC=C(C#N)C=C4)=O)=CC=C1,"InChI=1S/C19H10ClFN6O/c20-13-2-1-3-14(17(13)21)24-19(28)15-9-23-10-16-25-26-18(27(15)16)12-6-4-11(8-22)5-7-12/h1-7,9-10H,(H,24,28)",IDMCTWULSGGMQZ-UHFFFAOYSA-N
OSM-S-206,AEW 120,,MMV675719,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NC4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)=O)N32,InChI=1S/C21H11F8N5O2/c22-19(23)36-14-3-1-10(2-4-14)17-33-32-16-9-30-8-,GCJUFPUQPKTUOT-UHFFFAOYSA-N
OSM-S-207,AEW 134-1,,,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(N4CC(C(F)=CC=C5)=C5C4)=O)N32,"InChI=1S/C21H14F3N5O2/c22-16-3-1-2-13-10-28(11-15(13)16)20(30)17-8-25-9-18-26-27-19(29(17)18)12-4-6-14(7-5-12)31-21(23)24/h1-9,21H,10-11H2",WLABWHOTAUUXHJ-UHFFFAOYSA-N
OSM-S-208,AEW 145-1,,,FC(C=C1)=C(F)C=C1C(OC)COC2=CN=CC3=NN=C(C4=CC=C(C#N)C=C4)N32,"InChI=1S/C21H15F2N5O2/c1-29-18(15-6-7-16(22)17(23)8-15)12-30-20-11-25-10-19-26-27-21(28(19)20)14-4-2-13(9-24)3-5-14/h2-8,10-11,18H,12H2,1H3",PERKBMZWWUEZNJ-UHFFFAOYSA-N
OSM-S-209,,,,C1(CCOC23CCN(CC4=CC=CC=C4)CC3)=C2C=CS1,"InChI=1S/C18H21NOS/c1-2-4-15(5-3-1)14-19-10-8-18(9-11-19)16-7-13-21-17(16)6-12-20-18/h1-5,7,13H,6,8-12,14H2",WRPOPKKINJVHKF-UHFFFAOYSA-N
OSM-S-21,PMY34; AEW65,57515638,,FC1=CC=C(N2C(C)=CC(C(NCC(NC3=C(C)N(C)N(C4=CC=CC=C4)C3=O)=O)=O)=C2C)C=C1,"InChI=1S/C26H26FN5O3/c1-16-14-22(17(2)31(16)20-12-10-19(27)11-13-20)25(34)28-15-23(33)29-24-18(3)30(4)32(26(24)35)21-8-6-5-7-9-21/h5-14H,15H2,1-4H3,(H,28,34)(H,29,33)",RRYQCWKAZAVYJI-UHFFFAOYSA-N
OSM-S-210,,,,C1(CCOC23CCN(CC4=CC(OCCO5)=C5C=C4)CC3)=C2C=CS1,"InChI=1S/C20H23NO3S/c1-2-17-18(23-11-10-22-17)13-15(1)14-21-7-5-20(6-8-21)16-4-12-25-19(16)3-9-24-20/h1-2,4,12-13H,3,5-11,14H2",NCRPMBWORFWNGT-UHFFFAOYSA-N
OSM-S-211,,,,C1(CCOC23CCN(CC4=CC(OCO5)=C5C=C4)CC3)=C2C=CS1,"InChI=1S/C19H21NO3S/c1-2-16-17(22-13-21-16)11-14(1)12-20-7-5-19(6-8-20)15-4-10-24-18(15)3-9-23-19/h1-2,4,10-11H,3,5-9,12-13H2",ACOYQJHGMQYDJB-UHFFFAOYSA-N
OSM-S-212,,,,ClC(C=C1)=CC=C1CN(CC2)CCC32C4=C(SC=C4)CCO3,"InChI=1S/C18H20ClNOS/c19-15-3-1-14(2-4-15)13-20-9-7-18(8-10-20)16-6-12-22-17(16)5-11-21-18/h1-4,6,12H,5,7-11,13H2",IKDZLARXTXDYSV-UHFFFAOYSA-N
OSM-S-213,,,,O=C(C1=CC=C(Br)C=C1)N(CC2)CCC32C4=C(SC=C4)CCO3,"InChI=1S/C18H18BrNO2S/c19-14-3-1-13(2-4-14)17(21)20-9-7-18(8-10-20)15-6-12-23-16(15)5-11-22-18/h1-4,6,12H,5,7-11H2",NZVHUZGXLTUEBD-UHFFFAOYSA-N
OSM-S-214,,,,CC1=C(C=C(C)N1C2=CC=C(F)C=C2)CN(CC3)CCC43C5=C(SC=C5)CCO4,"InChI=1S/C24H27FN2OS/c1-17-15-19(18(2)27(17)21-5-3-20(25)4-6-21)16-26-11-9-24(10-12-26)22-8-14-29-23(22)7-13-28-24/h3-6,8,14-15H,7,9-13,16H2,1-2H3",JOUHIYBEDRSIMN-UHFFFAOYSA-N
OSM-S-215,,,,C1(CCOC23CCN(C4CCCCC4)CC3)=C2C=CS1,"InChI=1S/C17H25NOS/c1-2-4-14(5-3-1)18-10-8-17(9-11-18)15-7-13-20-16(15)6-12-19-17/h7,13-14H,1-6,8-12H2",XLYPXGDSQIIAGC-UHFFFAOYSA-N
OSM-S-216,,,,O=C(C1=CC=CC=C1)N(CC2)CCC32C4=C(SC=C4)CCO3,"InChI=1S/C18H19NO2S/c20-17(14-4-2-1-3-5-14)19-10-8-18(9-11-19)15-7-13-22-16(15)6-12-21-18/h1-5,7,13H,6,8-12H2",IKDZLARXTXDYSV-UHFFFAOYSA-N
OSM-S-217,,,,O=C(OCCCl)N(CC1)CCC21C3=C(SC=C3)CCO2,"InChI=1S/C14H18ClNO3S/c15-5-9-18-13(17)16-6-3-14(4-7-16)11-2-10-20-12(11)1-8-19-14/h2,10H,1,3-9H2",RXXGDCXYAFFODV-UHFFFAOYSA-N
OSM-S-218,AEW 313-1,,MMV669844/MMV897709,FC(C=C1)=C(F)C=C1C(OC)COC2=CN=CC3=NN=C(C4=CC=C(C#N)C=C4)N32,"InChI=1S/C21H15F2N5O2/c1-29-18(15-6-7-16(22)17(23)8-15)12-30-20-11-25-10-19-26-27-21(28(19)20)14-4-2-13(9-24)3-5-14/h2-8,10-11,18H,12H2,1H3/t18-/m0/s1",
OSM-S-219,JU 3; AEW 97,,,ClC1=CN=CC2=NN=C(C3=CC=C(C#N)C=C3)N21,"InChI=1S/C12H6ClN5/c13-10-6-15-7-11-16-17-12(18(10)11)9-3-1-8(5-14)2-4-9/h1-4,6-7H",IXZMOLDGRAEJRY-UHFFFAOYSA-N
OSM-S-22,PMY42,52440675,,FC1=CC=C(N2C(C)=CC(C(N)=O)=C2C)C=C1,"InChI=1S/C13H13FN2O/c1-8-7-12(13(15)17)9(2)16(8)11-5-3-10(14)4-6-11/h3-7H,1-2H3,(H2,15,17)",PVWNZUQYNDFAEV-UHFFFAOYSA-N
OSM-S-220,JU 8; CCS 2-1,,,ClC1=CN=CC2=NN=C(C3=CC=C(Cl)C=C3)N21,InChI=1S/C11H6Cl2N4/c12-8-3-1-7(2-4-8)11-16-15-10-6-14-5-9(13)17(10)11/h1-6H,VCWFDFYRPOTNNX-UHFFFAOYSA-N
OSM-S-222,AEW 103,,,COC(C(O)C1=CC(F)=C(F)C=C1)=O,"InChI=1S/C9H8F2O3/c1-14-9(13)8(12)5-2-3-6(10)7(11)4-5/h2-4,8,12H,1H3",FSNBVAIULMGGMB-UHFFFAOYSA-N
OSM-S-226,AEW 94-1,,,C[Si](C)(OC(C1=CC(F)=C(F)C=C1)C#N)C,"InChI=1S/C11H13F2NOSi/c1-16(2,3)15-11(7-14)8-4-5-9(12)10(13)6-8/h4-6,11H,1-3H3",ZAXNXBJYTHDLNG-UHFFFAOYSA-N
OSM-S-227,TM 3,,,CC1=C(Cl)C=CC=C1NC(C2=NC(Cl)=CN=C2)=O,"InChI=1S/C12H9Cl2N3O/c1-7-8(13)3-2-4-9(7)17-12(18)10-5-15-6-11(14)16-10/h2-6H,1H3,(H,17,18)",XUNQSXQSMQZCMD-UHFFFAOYSA-N
OSM-S-228,TM 20-1,,,ClC1=C(F)C(NC(C2=NC(Cl)=CN=C2)=O)=CC=C1,"InChI=1S/C11H6Cl2FN3O/c12-6-2-1-3-7(10(6)14)17-11(18)8-4-15-5-9(13)16-8/h1-5H,(H,17,18)",JMFWWNDHJIICEU-UHFFFAOYSA-N
OSM-S-229,TM 21-1,,,CC1=C(NC(C2=NC(Cl)=CN=C2)=O)C=C(Cl)C=C1,"InChI=1S/C12H9Cl2N3O/c1-7-2-3-8(13)4-9(7)17-12(18)10-5-15-6-11(14)16-10/h2-6H,1H3,(H,17,18)",IQKLDOUABSLOBP-UHFFFAOYSA-N
OSM-S-230,TM 8,,,ClC1=CC(NC(C2=CN=CC(NN)=N2)=O)=CC=C1,"InChI=1S/C11H10ClN5O/c12-7-2-1-3-8(4-7)15-11(18)9-5-14-6-10(16-9)17-13/h1-6H,13H2,(H,15,18)(H,16,17)",SPRQPGUTUUOBSB-UHFFFAOYSA-N
OSM-S-23,PMY43; SBHK486,96680,,CC1=C(C(OCC)=O)C=NN1C2=CC=CC=C2,"InChI=1S/C13H14N2O2/c1-3-17-13(16)12-9-14-15(10(12)2)11-7-5-4-6-8-11/h4-9H,3H2,1-2H3",XYIOIOHRWLZCDM-UHFFFAOYSA-N
OSM-S-236,PMY37; AEW4; AEW23,57519182,,FC1=CC=C(N2C(C)=CC(COCC(N)=O)=C2C)C=C1,"InChI=1S/C15H17FN2O2/c1-10-7-12(8-20-9-15(17)19)11(2)18(10)14-5-3-13(16)4-6-14/h3-7H,8-9H2,1-2H3,(H2,17,19)",UFAJOCCDASJXPL-UHFFFAOYSA-N
OSM-S-24,PMY44; SBHK489,145221,,CC1=C(C(O)=O)C=NN1C2=CC=CC=C2,"InChI=1S/C11H10N2O2/c1-8-10(11(14)15)7-12-13(8)9-5-3-2-4-6-9/h2-7H,1H3,(H,14,15)",USSMIQWDLWJQDQ-UHFFFAOYSA-N
OSM-S-241,MJT2; MNR49,3654436,,FC1=CC=C(N2N=CC(C(OCC)=O)=C2C)C=C1,"InChI=1S/C13H13FN2O2/c1-3-18-13(17)12-8-15-16(9(12)2)11-6-4-10(14)5-7-11/h4-8H,3H2,1-2H3",JYHUUEYONFRPMV-UHFFFAOYSA-N
OSM-S-242,MJT3; MNR50,4270263,,FC1=CC=C(N2N=CC(C(O)=O)=C2C)C=C1,"InChI=1S/C11H9FN2O2/c1-7-10(11(15)16)6-13-14(7)9-4-2-8(12)3-5-9/h2-6H,1H3,(H,15,16)",KBQWFOMDKNVSAD-UHFFFAOYSA-N
OSM-S-243,PMY63,688689,,FC1=CC=C(N2N=CC(C(OCC)=O)=C2N)C=C1,"InChI=1S/C12H12FN3O2/c1-2-18-12(17)10-7-15-16(11(10)14)9-5-3-8(13)4-6-9/h3-7H,2,14H2,1H3",RPPPCKSHIYWAPW-UHFFFAOYSA-N
OSM-S-244,PMY64,14994516,,FC1=CC=C(N2N=CC(C(OCC)=O)=C2)C=C1,"InChI=1S/C12H11FN2O2/c1-2-17-12(16)9-7-14-15(8-9)11-5-3-10(13)4-6-11/h3-8H,2H2,1H3",MEUROLLIWZOVNK-UHFFFAOYSA-N
OSM-S-245,PMY65,3159617,,FC1=CC=C(N2N=CC(C(O)=O)=C2)C=C1,"InChI=1S/C10H7FN2O2/c11-8-1-3-9(4-2-8)13-6-7(5-12-13)10(14)15/h1-6H,(H,14,15)",VHGLETHNIUVDGO-UHFFFAOYSA-N
OSM-S-246,PMY60; PMY62; MNR62,57519180,,FC1=CC=C(N2C(C)=CC(C3=NC(C(N)=O)=CO3)=C2C)C=C1,"InChI=1S/C16H14FN3O2/c1-9-7-13(16-19-14(8-22-16)15(18)21)10(2)20(9)12-5-3-11(17)4-6-12/h3-8H,1-2H3,(H2,18,21)",WNDROPYDFOUQKN-UHFFFAOYSA-N
OSM-S-247,PMY45,57506926,,FC1=CC=C(N2C(C)=CC(C3=NC(C(OCC)=O)=CO3)=C2C)C=C1,"InChI=1S/C18H17FN2O3/c1-4-23-18(22)16-10-24-17(20-16)15-9-11(2)21(12(15)3)14-7-5-13(19)6-8-14/h5-10H,4H2,1-3H3",RFFSPTHAPOPEOX-UHFFFAOYSA-N
OSM-S-248,PMY62,,,FC1=CC=C(N2C(C)=CC(C3=NC(C(N)=O)CO3)=C2C)C=C1,"InChI=1S/C16H16FN3O2/c1-9-7-13(16-19-14(8-22-16)15(18)21)10(2)20(9)12-5-3-11(17)4-6-12/h3-7,14H,8H2,1-2H3,(H2,18,21)",MGUMGJAQHDKXDI-UHFFFAOYSA-N
OSM-S-249,PMY61,,,FC1=CC=C(N2C(C)=CC(C(N(C(C(N)=O)CO)[H])=O)=C2C)C=C1,"InChI=1S/C16H18FN3O3/c1-9-7-13(16(23)19-14(8-21)15(18)22)10(2)20(9)12-5-3-11(17)4-6-12/h3-7,14,21H,8H2,1-2H3,(H2,18,22)(H,19,23)",QKIMCWGLBIDDRP-UHFFFAOYSA-N
OSM-S-25,LMW1; AEW44,66518,,CC1=CC=C(C)N1C2=CC=CC=C2,"InChI=1S/C12H13N/c1-10-8-9-11(2)13(10)12-6-4-3-5-7-12/h3-9H,1-2H3",JNXIFVSGXLGULI-UHFFFAOYSA-N
OSM-S-250,MJT5,,,FC1=CC=C(N2N=CC(C(N(C(C(OC)=O)CO)[H])=O)=C2C)C=C1,"InChI=1S/C15H16FN3O4/c1-9-12(14(21)18-13(8-20)15(22)23-2)7-17-19(9)11-5-3-10(16)4-6-11/h3-7,13,20H,8H2,1-2H3,(H,18,21)",IFUMWRUBRMGAEV-UHFFFAOYSA-N
OSM-S-251,MJT4,,,FC1=CC=C(N2N=CC(C(N(C(C(N)=O)CO)[H])=O)=C2C)C=C1,"InChI=1S/C14H15FN4O3/c1-8-11(14(22)18-12(7-20)13(16)21)6-17-19(8)10-4-2-9(15)3-5-10/h2-6,12,20H,7H2,1H3,(H2,16,21)(H,18,22)",SYXYTYKMKDLUFU-UHFFFAOYSA-N
OSM-S-252,MJT1,,,CC1=C(C(N(C(C(OC)=O)CO)[H])=O)C=NN1C2=CC=CC=C2,"InChI=1S/C15H17N3O4/c1-10-12(14(20)17-13(9-19)15(21)22-2)8-16-18(10)11-6-4-3-5-7-11/h3-8,13,19H,9H2,1-2H3,(H,17,20)",MUYSFMFAFVZIPG-UHFFFAOYSA-N
OSM-S-253,MNR67,90957910,,O=C(OCC)C1=CN(C=C1)C2=CC=C(F)C=C2,"InChI=1S/C13H12FNO2/c1-2-17-13(16)10-7-8-15(9-10)12-5-3-11(14)4-6-12/h3-9H,2H2,1H3",KJIGTOSWXXKBEH-UHFFFAOYSA-N
OSM-S-254,TM 26-1,,MMV675947,O=C(NC1=CC(Cl)=CC=C1C)C2=CN=CC(N23)=NN=C3C4=CC=C(OC(F)F)C=C4,"InChI=1S/C20H14ClF2N5O2/c1-11-2-5-13(21)8-15(11)25-19(29)16-9-24-10-17-26-27-18(28(16)17)12-3-6-14(7-4-12)30-20(22)23/h2-10,20H,1H3,(H,25,29)",QKXZFYOMVFGRGS-UHFFFAOYSA-N
OSM-S-255,TM 31-1,,MMV675950,O=C(NC1=C(C)C(Cl)=CC=C1)C2=CN=CC(N23)=NN=C3C4=CC=C(OC)C=C4,"InChI=1S/C20H16ClN5O2/c1-12-15(21)4-3-5-16(12)23-20(27)17-10-22-11-18-24-25-19(26(17)18)13-6-8-14(28-2)9-7-13/h3-11H,1-2H3,(H,23,27)",LIAWHOKMZQICES-UHFFFAOYSA-N
OSM-S-256,TM 32-1,,MMV675951,O=C(NC1=C(F)C(Cl)=CC=C1)C2=CN=CC(N23)=NN=C3C4=CC=C(OC)C=C4,"InChI=1S/C19H13ClFN5O2/c1-28-12-7-5-11(6-8-12)18-25-24-16-10-22-9-15(26(16)18)19(27)23-14-4-2-3-13(20)17(14)21/h2-10H,1H3,(H,23,27)",FWGBPGUTIFKBOZ-UHFFFAOYSA-N
OSM-S-257,TM 33-1,,MMV675952,O=C(NC1=CC(Cl)=CC=C1C)C2=CN=CC(N23)=NN=C3C4=CC=C(OC)C=C4,"InChI=1S/C20H16ClN5O2/c1-12-3-6-14(21)9-16(12)23-20(27)17-10-22-11-18-24-25-19(26(17)18)13-4-7-15(28-2)8-5-13/h3-11H,1-2H3,(H,23,27)",NFXWTMUWMZSIFL-UHFFFAOYSA-N
OSM-S-258,JU 15,,MMV675949,ClC1=CC=CC=C1CCOC2=CN=CC3=NN=C(C4=CC=NC=C4)N32,"InChI=1S/C18H14ClN5O/c19-15-4-2-1-3-13(15)7-10-25-17-12-21-11-16-22-23-18(24(16)17)14-5-8-20-9-6-14/h1-6,8-9,11-12H,7,10H2",ONSVYVKJKRCBFG-UHFFFAOYSA-N
OSM-S-259,JU 17-1,,MMV675959,ClC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC4=CC=C(F)C(F)=C4)N32,"InChI=1S/C18H11ClF2N4O/c19-13-4-2-12(3-5-13)18-24-23-16-8-22-9-17(25(16)18)26-10-11-1-6-14(20)15(21)7-11/h1-9H,10H2",RFVLCVGXWWXLGJ-UHFFFAOYSA-N
OSM-S-26,LMW2,1908543,,CC1=CC=C(C)N1C2=CC=C(C)C=C2,"InChI=1S/C13H15N/c1-10-4-8-13(9-5-10)14-11(2)6-7-12(14)3/h4-9H,1-3H3",SWIUPUUNVWDJED-UHFFFAOYSA-N
OSM-S-260,JU 22-1,,MMV675960,FC1=C(F)C=CC(CCOC2=CN=CC3=NN=C(C4=CC=C(OC(F)F)C=C4)N32)=C1,"InChI=1S/C20H14F4N4O2/c21-15-6-1-12(9-16(15)22)7-8-29-18-11-25-10-17-26-27-19(28(17)18)13-2-4-14(5-3-13)30-20(23)24/h1-6,9-11,20H,7-8H2",DEEWBVYNQGALDU-UHFFFAOYSA-N
OSM-S-261,JU 23-1,,,ClC1=CC=C(C2=NN=C3C=NC=C(OC[C@H](N)CC4=CC=CC=C4)N32)C=C1,"InChI=1S/C20H18ClN5O/c21-16-8-6-15(7-9-16)20-25-24-18-11-23-12-19(26(18)20)27-13-17(22)10-14-4-2-1-3-5-14/h1-9,11-12,17H,10,13,22H2/t17-/m1/s1",IDYMXWVLOCEAKY-QGZVFWFLSA-N
OSM-S-262,TM 45-1,,MMV675961,O=C(NC1=CC(Cl)=CC=C1)C2=CN=CC(N23)=NN=C3C4=NC=CC=C4,"InChI=1S/C17H11ClN6O/c18-11-4-3-5-12(8-11)21-17(25)14-9-19-10-15-22-23-16(24(14)15)13-6-1-2-7-20-13/h1-10H,(H,21,25)",GCBSUHZLELOHDM-UHFFFAOYSA-N
OSM-S-263,TM 46-1,,MMV675962,O=C(NC1=CC(Cl)=CC=C1)C2=CN=CC(N23)=NN=C3C4=CN=CC=C4,"InChI=1S/C17H11ClN6O/c18-12-4-1-5-13(7-12)21-17(25)14-9-20-10-15-22-23-16(24(14)15)11-3-2-6-19-8-11/h1-10H,(H,21,25)",AQSNHWMTHMLNFL-UHFFFAOYSA-N
OSM-S-264,TM 47-1,,,ClC1=CC(NC(C(N23)=CN=CC2=NN=C3C4=CC=NC=C4)=O)=CC=C1,"InChI=1S/C17H11ClN6O/c18-12-2-1-3-13(8-12)21-17(25)14-9-20-10-15-22-23-16(24(14)15)11-4-6-19-7-5-11/h1-10H,(H,21,25)",OHGFCSWBHYTMRJ-UHFFFAOYSA-N
OSM-S-265,AEW 191-1,,MMV675948,N#CC(C=C1)=CC=C1C2=NN=C3N2C(OCC(OC)C4=CC=CC=C4)=CN=C3,"InChI=1S/C21H17N5O2/c1-27-18(16-5-3-2-4-6-16)14-28-20-13-23-12-19-24-25-21(26(19)20)17-9-7-15(11-22)8-10-17/h2-10,12-13,18H,14H2,1H3",QAGSTSUWCMAMBB-UHFFFAOYSA-N
OSM-S-266,AEW13; AEW14; AEW17,2349400,,FC1=CC=C(N2C(C)=CC(C(NN)=O)=C2C)C=C1,"InChI=1S/C13H14FN3O/c1-8-7-12(13(18)16-15)9(2)17(8)11-5-3-10(14)4-6-11/h3-7H,15H2,1-2H3,(H,16,18)",WKYACYFAJSKXRU-UHFFFAOYSA-N
OSM-S-267,AEW15,,,FC1=CC=C(N2C(C)=CC(C(NNC(C)=O)=O)=C2C)C=C1,"InChI=1S/C15H16FN3O2/c1-9-8-14(15(21)18-17-11(3)20)10(2)19(9)13-6-4-12(16)5-7-13/h4-8H,1-3H3,(H,17,20)(H,18,21)",YVXPWUQSCIIYMR-UHFFFAOYSA-N
OSM-S-268,AEW24,,,FC1=CC=C(N2C(C)=CC(C(NNC(C(OC)=O)=O)=O)=C2C)C=C1,"InChI=1S/C16H16FN3O4/c1-9-8-13(14(21)18-19-15(22)16(23)24-3)10(2)20(9)12-6-4-11(17)5-7-12/h4-8H,1-3H3,(H,18,21)(H,19,22)",GWWXOFBSHPNTFF-UHFFFAOYSA-N
OSM-S-269,AEW25; AEW27,,,FC1=CC=C(N2C(C)=CC(C3=NN=C(C(OC)=O)O3)=C2C)C=C1,"InChI=1S/C16H14FN3O3/c1-9-8-13(14-18-19-15(23-14)16(21)22-3)10(2)20(9)12-6-4-11(17)5-7-12/h4-8H,1-3H3",KCLKHKVKELEMKB-UHFFFAOYSA-N
OSM-S-27,LMW3,2737125,,CC1=CC=C(C)N1C2=CC=C(C(F)(F)F)C=C2,"InChI=1S/C13H12F3N/c1-9-3-4-10(2)17(9)12-7-5-11(6-8-12)13(14,15)16/h3-8H,1-2H3",UWHVRMCDWMXTOE-UHFFFAOYSA-N
OSM-S-270,TM 54-1,,,COC1=CC=C(C2=NN=C3C=NC=C(N32)C(NC4=CC=CC(Cl)=C4)=O)C=C1,"InChI=1S/C19H14ClN5O2/c1-27-15-7-5-12(6-8-15)18-24-23-17-11-21-10-16(25(17)18)19(26)22-14-4-2-3-13(20)9-14/h2-11H,1H3,(H,22,26)",PVPGYERJOUVPIJ-UHFFFAOYSA-N
OSM-S-271,TM 55-1,,MMV675963,O=C(NC1=CC(Cl)=CC=C1)C2=CN=CC(N23)=NN=C3C4=CC=C(OC(F)(F)F)C=C4,"InChI=1S/C19H11ClF3N5O2/c20-12-2-1-3-13(8-12)25-18(29)15-9-24-10-16-26-27-17(28(15)16)11-4-6-14(7-5-11)30-19(21,22)23/h1-10H,(H,25,29)",KPPYAXXEDYTONY-UHFFFAOYSA-N
OSM-S-272,AEW 302-1,,MMV639565,FC1=C(F)C=CC(CCOC2=CN=CC3=NN=C(C4=CC=C(Cl)C=C4)N32)=C1,"InChI=1S/C19H13ClF2N4O/c20-14-4-2-13(3-5-14)19-25-24-17-10-23-11-18(26(17)19)27-8-7-12-1-6-15(21)16(22)9-12/h1-6,9-11H,7-8H2",PMHUSEXABGDNGS-UHFFFAOYSA-N
OSM-S-273,INHERITED,,MMV669846,ClC(C=C1)=CC=C1C2=CN=C3C=NC=C(OCCC4=CC(F)=C(F)C=C4)N32,"InChI=1S/C20H14ClF2N3O/c21-15-4-2-14(3-5-15)18-10-25-19-11-24-12-20(26(18)19)27-8-7-13-1-6-16(22)17(23)9-13/h1-6,9-12H,7-8H2",MQHQNFQVEXYAMO-UHFFFAOYSA-N
OSM-S-274,INHERITED,,MMV670250,ClC(C=C1)=CC=C1C2=NC=C3C=NC=C(OCCC4=CC(F)=C(F)C=C4)N32,"InChI=1S/C20H14ClF2N3O/c21-15-4-2-14(3-5-15)20-25-11-16-10-24-12-19(26(16)20)27-8-7-13-1-6-17(22)18(23)9-13/h1-6,9-12H,7-8H2",JHORUMGXLQTHAD-UHFFFAOYSA-N
OSM-S-275,AEW 237-1,,MMV688892,OC(COc2cncc3nnc(C1CCCCC1)n23)c4ccccc4,"InChI=1S/C19H22N4O2/c24-16(14-7-3-1-4-8-14)13-25-18-12-20-11-17-21-22-19(23(17)18)15-9-5-2-6-10-15/h1,3-4,7-8,11-12,15-16,24H,2,5-6,9-10,13H2 AuxInfo=1/0/N:23,14,22,24,13,15,21,25,12,16,3,1,17,19,10,18,4,6,9,2,7,8,5,20,11/E:(3,4)(5,6)(7,8)(9,10)/rA:25CNCCNCNNCCOCCCCCCCCOCCCCC/rB:s1;d2;s3;s4;d1s5;d4;s7;s5d8;s9;s6;s10;s12;s13;s14;s10s15;s11;s17;s18;V18;d19;s21;d22;s23;s19d24;/rC:378,-218,0;378,-73,0;504,0,0;630,-73,0;630,-218,0;504,-291,0;768,-28,0;853,-145,0;768,-263,0;813,-401,0;504,-436,0;955,-431,0;1000,-570,0;903,-678,0;761,-648,0;715,-509,0;378,-509,0;378,-654,0;252,-727,0;504,-727,0;252,-873,0;126,-945,0;0,-873,0;0,-727,0;126,-654,0; ",LWDWZIVAQMSZHL-UHFFFAOYSA-N
OSM-S-276,AEW 238-1,,MMV688893,OC(COc1cncc2nnc(CC)n12)c3ccccc3,"InChI=1S/C15H16N4O2/c1-2-13-17-18-14-8-16-9-15(19(13)14)21-10-12(20)11-6-4-3-5-7-11/h3-9,12,20H,2,10H2,1H3 AuxInfo=1/0/N:12,10,19,18,20,17,21,3,1,13,15,14,9,4,6,2,8,7,5,16,11/E:(4,5)(6,7)/rA:21CNCCNCNNCCOCCCCOCCCCC/rB:s1;d2;s3;s4;d1s5;d4;s7;s5d8;s9;s6;s10;s11;s13;s14;V14;d15;s17;d18;s19;s15d20;/rC:395,-228,0;395,-76,0;527,0,0;659,-76,0;659,-228,0;527,-305,0;804,-29,0;893,-152,0;804,-276,0;851,-420,0;527,-457,0;1000,-452,0;395,-533,0;395,-685,0;263,-761,0;527,-761,0;263,-914,0;131,-990,0;0,-914,0;0,-761,0;131,-685,0;",ZMELTVBBQIUHNR-UHFFFAOYSA-N
OSM-S-277,AEW 230-1,,MMV688894,OC(COc2cncc3nnc(c1ccccc1)n23)c4ccccc4,"InChI=1S/C19H16N4O2/c24-16(14-7-3-1-4-8-14)13-25-18-12-20-11-17-21-22-19(23(17)18)15-9-5-2-6-10-15/h1-12,16,24H,13H2 AuxInfo=1/0/N:23,14,22,24,13,15,21,25,12,16,3,1,17,19,10,18,4,6,9,2,7,8,5,20,11/E:(3,4)(5,6)(7,8)(9,10)/rA:25CNCCNCNNCCOCCCCCCCCOCCCCC/rB:s1;d2;s3;s4;d1s5;d4;s7;s5d8;s9;s6;d10;s12;d13;s14;s10d15;s11;s17;s18;V18;d19;s21;d22;s23;s19d24;/rC:378,-218,0;378,-73,0;504,0,0;630,-73,0;630,-218,0;504,-291,0;768,-28,0;853,-145,0;768,-263,0;813,-401,0;504,-436,0;955,-431,0;1000,-570,0;903,-678,0;761,-648,0;715,-509,0;378,-509,0;378,-654,0;252,-727,0;504,-727,0;252,-873,0;126,-945,0;0,-873,0;0,-727,0;126,-654,0; ",HQWUAOFYEUBLBZ-UHFFFAOYSA-N
OSM-S-278,EGT 137-1,,MMV688895,OC(C1=CC=CC=C1)COC2=CN=CC3=NN=C(C4=CN=C(C(F)(F)F)C=C4)N32,"InChI=1S/C19H14F3N5O2/c20-19(21,22)15-7-6-13(8-24-15)18-26-25-16-9-23-10-17(27(16)18)29-11-14(28)12-4-2-1-3-5-12/h1-10,14,28H,11H2 AuxInfo=1/0/N:23,22,24,21,25,16,15,12,3,1,17,19,10,18,14,4,6,9,26,27,28,29,2,13,7,8,5,20,11/E:(2,3)(4,5)(20,21,22)/rA:29CNCCNCNNCCOCNCCCCCCOCCCCCCFFF/rB:s1;d2;s3;s4;d1s5;d4;s7;s5d8;s9;s6;d10;s12;d13;s14;s10d15;s11;s17;s18;V18;d19;s21;d22;s23;s19d24;s14;s26;s26;s26;/rC:348,-201,0;348,-67,0;464,0,0;580,-67,0;580,-201,0;464,-268,0;707,-25,0;786,-134,0;707,-242,0;749,-370,0;464,-402,0;880,-397,0;921,-525,0;832,-625,0;700,-596,0;659,-469,0;348,-469,0;348,-603,0;232,-670,0;464,-670,0;232,-804,0;116,-871,0;0,-804,0;0,-670,0;116,-603,0;873,-752,0;914,-879,0;1000,-711,0;746,-793,0; ",YUTTVQUFLHMVCQ-UHFFFAOYSA-N
OSM-S-279,AEW 236-1; EGT 119-2,,MMV688896,OC(C1=CC=CC=C1)COC2=CN=CC3=NN=C(C4=CC=C(OC(F)F)C=C4)N32,"InChI=1S/C20H16F2N4O3/c21-20(22)29-15-8-6-14(7-9-15)19-25-24-17-10-23-11-18(26(17)19)28-12-16(27)13-4-2-1-3-5-13/h1-11,16,20,27H,12H2 AuxInfo=1/0/N:23,22,24,21,25,12,16,13,15,3,1,17,19,10,14,18,4,6,9,27,28,29,2,7,8,5,20,11,26/E:(2,3)(4,5)(6,7)(8,9)(21,22)/rA:29CNCCNCNNCCOCCCCCCCCOCCCCCOCFF/rB:s1;d2;s3;s4;d1s5;d4;s7;s5d8;s9;s6;d10;s12;d13;s14;s10d15;s11;s17;s18;V18;d19;s21;d22;s23;s19d24;s14;s26;s27;s27;/rC:355,-205,0;355,-68,0;474,0,0;593,-68,0;593,-205,0;474,-274,0;723,-26,0;803,-137,0;723,-248,0;765,-378,0;474,-411,0;899,-406,0;941,-536,0;849,-638,0;716,-609,0;673,-479,0;355,-479,0;355,-616,0;237,-684,0;474,-684,0;237,-821,0;119,-890,0;0,-821,0;0,-684,0;119,-616,0;892,-768,0;800,-870,0;667,-841,0;843,-1000,0; ",GEHCMLKWLSBHDX-UHFFFAOYSA-N
OSM-S-28,LMW4; AEW49,66515,,CC(N1C2=CC=CC=C2)=CC(C=O)=C1C,"InChI=1S/C13H13NO/c1-10-8-12(9-15)11(2)14(10)13-6-4-3-5-7-13/h3-9H,1-2H3",LNROIXNEIZSESG-UHFFFAOYSA-N
OSM-S-280,,,MMV688897,FC(F)Oc1ccc(cc1)c2nnc3cncc(OC)n23,"InChI=1S/C13H10F2N4O2/c1-20-11-7-16-6-10-17-18-12(19(10)11)8-2-4-9(5-3-8)21-13(14)15/h2-7,13H,1H3 AuxInfo=1/0/N:21,12,16,13,15,3,1,10,14,4,6,9,18,19,20,2,7,8,5,11,17/E:(2,3)(4,5)(14,15)/rA:21CNCCNCNNCCOCCCCCOCFFC/rB:s1;d2;s3;s4;d1s5;d4;s7;s5d8;s9;s6;d10;s12;d13;s14;s10d15;s14;s17;s18;s18;s11;/rC:0,-205,0;0,-68,0;119,0,0;237,-68,0;237,-205,0;119,-274,0;367,-26,0;448,-137,0;367,-248,0;410,-378,0;119,-411,0;543,-406,0;586,-536,0;494,-638,0;360,-609,0;318,-479,0;536,-768,0;445,-870,0;311,-841,0;487,-1000,0;0,-479,0;",DEPSYKMVBIYBIU-UHFFFAOYSA-N
OSM-S-281,AEW 214-1,,MMV688898,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC[C@H](NC)C4=CC=CC=C4)N32,"InChI=1S/C21H19F2N5O2/c1-24-17(14-5-3-2-4-6-14)13-29-19-12-25-11-18-26-27-20(28(18)19)15-7-9-16(10-8-15)30-21(22)23/h2-12,17,21,24H,13H2,1H3",NXAYCBUWEUBZHA-UHFFFAOYSA-N
OSM-S-283,,,MMV688899,FC(F)Oc1ccc(cc1)c3nnc4cncc(OCC(N)c2ccccc2)n34,"InChI=1S/C20H17F2N5O2/c21-20(22)29-15-8-6-14(7-9-15)19-26-25-17-10-24-11-18(27(17)19)28-12-16(23)13-4-2-1-3-5-13/h1-11,16,20H,12,23H2 AuxInfo=1/0/N:23,22,24,21,25,12,16,13,15,3,1,17,19,10,14,18,4,6,9,27,28,29,20,2,7,8,5,11,26/E:(2,3)(4,5)(6,7)(8,9)(21,22)/rA:29CNCCNCNNCCOCCCCCCCCNCCCCCOCFF/rB:s1;d2;s3;s4;d1s5;d4;s7;s5d8;s9;s6;d10;s12;d13;s14;s10d15;s11;s17;s18;V18;d19;s21;d22;s23;s19d24;s14;s26;s27;s27;/rC:356,-205,0;356,-68,0;474,0,0;592,-68,0;592,-205,0;474,-274,0;722,-26,0;803,-137,0;722,-248,0;765,-378,0;474,-410,0;898,-406,0;941,-536,0;849,-638,0;715,-610,0;673,-479,0;356,-479,0;356,-616,0;237,-684,0;474,-684,0;237,-821,0;119,-889,0;0,-821,0;0,-684,0;119,-616,0;891,-768,0;800,-870,0;666,-841,0;842,-1000,0; ",APNVCAYADQJJBZ-UHFFFAOYSA-N
OSM-S-284,,9794037,,CN(CC(O)=N)CC1=CC=CC=C1,"InChI=1S/C10H14N2O/c1-12(8-10(11)13)7-9-5-3-2-4-6-9/h2-6H,7-8H2,1H3,(H2,11,13)",LBOHKDOTRDQHGM-UHFFFAOYSA-N
OSM-S-285,,151411,,[H]N(CC(N)=O)C,"InChI=1S/C3H8N2O/c1-5-2-3(4)6/h5H,2H2,1H3,(H2,4,6)",CBBFWSMELCDMPZ-UHFFFAOYSA-N
OSM-S-286,,939880,,OC(CS/1)=NC1=N\C2=CC=CC=C2,"InChI=1S/C9H8N2OS/c12-8-6-13-9(11-8)10-7-4-2-1-3-5-7/h1-5H,6H2,(H,10,11,12)",IYGBTPGRKGQPLW-UHFFFAOYSA-N
OSM-S-287,AEW 35-1,459085,,CC1=CC=C(C)N1C2=CC=C([N+]([O-])=O)C=C2,"InChI=1S/C12H12N2O2/c1-9-3-4-10(2)13(9)11-5-7-12(8-6-11)14(15)16/h3-8H,1-2H3",JXJRCFOGAIXRCU-UHFFFAOYSA-N
OSM-S-288,AEW 45-1,2879704,,O=C([H])C1=C(C)N(C2=CC=C([N+]([O-])=O)C=C2)C(C)=C1,"InChI=1S/C13H12N2O3/c1-9-7-11(8-16)10(2)14(9)12-3-5-13(6-4-12)15(17)18/h3-8H,1-2H3",PGDZGAUIBGMQFD-UHFFFAOYSA-N
OSM-S-289,AEW 36-1,608518,,CC1=CC=C(C)N1C2=CC=C(OC)C=C2,"InChI=1S/C13H15NO/c1-10-4-5-11(2)14(10)12-6-8-13(15-3)9-7-12/h4-9H,1-3H3",ZJXMRHDTQFPICU-UHFFFAOYSA-N
OSM-S-29,LMW5,818156,,CC1=CC=C(N2C(C)=C(C=O)C=C2C)C=C1,"InChI=1S/C14H15NO/c1-10-4-6-14(7-5-10)15-11(2)8-13(9-16)12(15)3/h4-9H,1-3H3",YGUWNSYHYBHIIC-UHFFFAOYSA-N
OSM-S-290,AEW 46-1,615288,,O=C([H])C1=C(C)N(C(C)=C1)C2=CC=C(OC)C=C2,"InChI=1S/C14H15NO2/c1-10-8-12(9-16)11(2)15(10)13-4-6-14(17-3)7-5-13/h4-9H,1-3H3",APTDNVFPUFIPJW-UHFFFAOYSA-N
OSM-S-291,SSP-2,,MMV689968,ClC(C=CC=C1)=C1C2=NN=C3N2C(OCCC4=CC=CC=C4)=CN=C3,"InChI=1S/C19H15ClN4O/c20-16-9-5-4-8-15(16)19-23-22-17-12-21-13-18(24(17)19)25-11-10-14-6-2-1-3-7-14/h1-9,12-13H,10-11H2",KVOZVIJYWCGSOW-UHFFFAOYSA-N
OSM-S-292,SSP-3,,MMV689969,ClC1=CC=CC(C2=NN=C3N2C(OCCC4=CC=CC=C4)=CN=C3)=C1,"InChI=1S/C19H15ClN4O/c20-16-8-4-7-15(11-16)19-23-22-17-12-21-13-18(24(17)19)25-10-9-14-5-2-1-3-6-14/h1-8,11-13H,9-10H2",CEOXEGPHOBLFBL-UHFFFAOYSA-N
OSM-S-293,SSP-4; EGT 90-1,,MMV663915,ClC(C=C1)=CC=C1C2=NN=C3N2C(OCCC4=CC=CC=C4)=CN=C3,"InChI=1S/C19H15ClN4O/c20-16-8-6-15(7-9-16)19-23-22-17-12-21-13-18(24(17)19)25-11-10-14-4-2-1-3-5-14/h1-9,12-13H,10-11H2",VURCFSOLNXCMTN-UHFFFAOYSA-N
OSM-S-294,SSP-1,,MMV689970,C12=NN=C(C3=CC=CC=C3)N1C(OCCC4=CC=CC=C4)=CN=C2,"InChI=1S/C19H16N4O/c1-3-7-15(8-4-1)11-12-24-18-14-20-13-17-21-22-19(23(17)18)16-9-5-2-6-10-16/h1-10,13-14H,11-12H2",YRTHPBSIEMFKFB-UHFFFAOYSA-N
OSM-S-295,BX3-1,,MMV689971,FC1=CC(C2=NN=C3N2C(OCCC4=CC=CC=C4)=CN=C3)=CC(F)=C1,"InChI=1S/C19H14F2N4O/c20-15-8-14(9-16(21)10-15)19-24-23-17-11-22-12-18(25(17)19)26-7-6-13-4-2-1-3-5-13/h1-5,8-12H,6-7H2",OKECEFJCMLFHAN-UHFFFAOYSA-N
OSM-S-296,CX4-1,,MMV689972,C12=NN=C(C3=CC(OCO4)=C4C=C3)N1C(OCCC5=CC=CC=C5)=CN=C2,"InChI=1S/C20H16N4O3/c1-2-4-14(5-3-1)8-9-25-19-12-21-11-18-22-23-20(24(18)19)15-6-7-16-17(10-15)27-13-26-16/h1-7,10-12H,8-9,13H2",MMRQZVYZGCDPOA-UHFFFAOYSA-N
OSM-S-297,TY4-1,,MMV689973,C12=NN=C(C3=CC(C=CC=C4)=C4C=C3)N1C(OCCC5=CC=CC=C5)=CN=C2,"InChI=1S/C23H18N4O/c1-2-6-17(7-3-1)12-13-28-22-16-24-15-21-25-26-23(27(21)22)20-11-10-18-8-4-5-9-19(18)14-20/h1-11,14-16H,12-13H2",SUHQKLHRXHBOST-UHFFFAOYSA-N
OSM-S-298,BX4-1,,MMV689974,FC1=CC(C2=NN=C3N2C(OCC4=NC=CC=C4)=CN=C3)=CC(F)=C1,"InChI=1S/C17H11F2N5O/c18-12-5-11(6-13(19)7-12)17-23-22-15-8-20-9-16(24(15)17)25-10-14-3-1-2-4-21-14/h1-9H,10H2",NQPLGASHZCSICG-UHFFFAOYSA-N
OSM-S-299,CX5-1,,MMV689975,C12=NN=C(C3=CC(OCO4)=C4C=C3)N1C(OCC5=NC=CC=C5)=CN=C2,"InChI=1S/C18H13N5O3/c1-2-6-20-13(3-1)10-24-17-9-19-8-16-21-22-18(23(16)17)12-4-5-14-15(7-12)26-11-25-14/h1-9H,10-11H2",UEDVUGBYRDYVEK-UHFFFAOYSA-N
OSM-S-3,"PMY6; JRC1; AEW7, MD1",57515633,,O=C(C1=C(C)N(C2=CC=C(F)C=C2)C(C)=C1)OCC,"InChI=1S/C15H16FNO2/c1-4-19-15(18)14-9-10(2)17(11(14)3)13-7-5-12(16)6-8-13/h5-9H,4H2,1-3H3",BFRWWAGLFICHEG-UHFFFAOYSA-N
OSM-S-30,LMW6,44122522,,CCOC(C1=C(C)N(C2=CC=C(C=C2)C)C(C)=C1)=O,"InChI=1S/C16H19NO2/c1-5-19-16(18)15-10-12(3)17(13(15)4)14-8-6-11(2)7-9-14/h6-10H,5H2,1-4H3",YFYVWGMFZWLSNW-UHFFFAOYSA-N
OSM-S-300,TY5-1,,MMV689976,C12=NN=C(C3=CC(C=CC=C4)=C4C=C3)N1C(OCC5=NC=CC=C5)=CN=C2,"InChI=1S/C21H15N5O/c1-2-6-16-11-17(9-8-15(16)5-1)21-25-24-19-12-22-13-20(26(19)21)27-14-18-7-3-4-10-23-18/h1-13H,14H2",GPNQKUMRVTXOHH-UHFFFAOYSA-N
OSM-S-301,AEW256-1,,MMV689977,FC(OC(C=C1)=CC=C1C2=NN=C3N2C(OCC4=NC=CC=C4)=CN=C3)F,"InChI=1S/C18H13F2N5O2/c19-18(20)27-14-6-4-12(5-7-14)17-24-23-15-9-21-10-16(25(15)17)26-11-13-3-1-2-8-22-13/h1-10,18H,11H2",APPUFQJFODJHGW-UHFFFAOYSA-N
OSM-S-302,AEW 85,,,ClC1=CN=CC(NN)=N1,"InChI=1S/C4H5ClN4/c5-3-1-7-2-4(8-3)9-6/h1-2H,6H2,(H,8,9)",FEDQSVIJHNBUHH-UHFFFAOYSA-N
OSM-S-303,JU 2; AEW 95,,,ClC1=CN=CC(N/N=C/C2=CC=C(C#N)C=C2)=N1,"InChI=1S/C12H8ClN5/c13-11-7-15-8-12(17-11)18-16-6-10-3-1-9(5-14)2-4-10/h1-4,6-8H,(H,17,18)/b16-6-",JXPYSNWZIOGOHZ-OMCISZLKSA-N
OSM-S-304,,,,ClC1=CN=CC(N/N=C/C2=CC=C(OC(F)(F)F)C=C2)=N1,"InChI=1S/C12H8ClF3N4O/c13-10-6-17-7-11(19-10)20-18-5-8-1-3-9(4-2-8)21-12(14,15)16/h1-7H,(H,19,20)/b18-5+",GUUAUYOTRNYECA-BLLMUTORSA-N
OSM-S-305,AEW 204; JU 18; EGT 24,,,ClC1=CN=CC(N/N=C/C2=CC=C(OC(F)F)C=C2)=N1,"InChI=1S/C12H9ClF2N4O/c13-10-6-16-7-11(18-10)19-17-5-8-1-3-9(4-2-8)20-12(14)15/h1-7,12H,(H,18,19)/b17-5+",CYDJTGOSSHSTHS-YAXRCOADSA-N
OSM-S-306,AEW 222,,,ClC1=CN=CC(N/N=C/C2=CC=CC=C2)=N1,"InChI=1S/C11H9ClN4/c12-10-7-13-8-11(15-10)16-14-6-9-4-2-1-3-5-9/h1-8H,(H,15,16)/b14-6",UCUKQBRUIXIMLG-MKMNVTDBSA-N
OSM-S-307,AEW 241,,,ClC1=CN=CC(N/N=C/C2=C(Cl)C=CC=C2)=N1,"InChI=1S/C11H8Cl2N4/c12-9-4-2-1-3-8(9)5-15-17-11-7-14-6-10(13)16-11/h1-7H,(H,16,17)/b15-5+",SNXIAAVENDVWTM-PJQLUOCWSA-N
OSM-S-308,AEW 242,,,ClC1=CN=CC(N/N=C/C2=CC(Cl)=CC=C2)=N1,"InChI=1S/C11H8Cl2N4/c12-9-3-1-2-8(4-9)5-15-17-11-7-14-6-10(13)16-11/h1-7H,(H,16,17)/b15-5+",FRLQOXBKEWQQKV-PJQLUOCWSA-N
OSM-S-309,JU7; BS16; BS17,,,ClC1=CN=CC(N/N=C/C2=CC=C(Cl)C=C2)=N1,"InChI=1S/C11H8Cl2N4/c12-9-3-1-8(2-4-9)5-15-17-11-7-14-6-10(13)16-11/h1-7H,(H,16,17)/b15-5+",IREXIIXDQDGVMX-PJQLUOCWSA-N
OSM-S-31,LMW8,2742171,,O=C(C1=C(C)N(C2=CC=CC=C2)C(C)=C1)OCC,"InChI=1S/C15H17NO2/c1-4-18-15(17)14-10-11(2)16(12(14)3)13-8-6-5-7-9-13/h5-10H,4H2,1-3H3",LNBCSWPBLZPWKQ-UHFFFAOYSA-N
OSM-S-310,BSX 1-1,,,ClC1=CN=CC(N/N=C/C2=CC(F)=CC(F)=C2)=N1,"InChI=1S/C11H7ClF2N4/c12-10-5-15-6-11(17-10)18-16-4-7-1-8(13)3-9(14)2-7/h1-6H,(H,17,18)/b16-4+",ATLJHIAAGRJQMF-AYSLTRBKSA-N
OSM-S-311,CX 2-1,,,ClC1=CN=CC(N/N=C/C2=CC=C(OCO3)C3=C2)=N1,"InChI=1S/C12H9ClN4O2/c13-11-5-14-6-12(16-11)17-15-4-8-1-2-9-10(3-8)19-7-18-9/h1-6H,7H2,(H,16,17)/b15-4+",PUQNFHOOSPMUIC-SYZQJQIISA-N
OSM-S-312,TY 2-1,,,ClC1=CN=CC(N/N=C/C2=CC=C(C=CC=C3)C3=C2)=N1,"InChI=1S/C15H11ClN4/c16-14-9-17-10-15(19-14)20-18-8-11-5-6-12-3-1-2-4-13(12)7-11/h1-10H,(H,19,20)/b18-8+",PQYRTCLHHVFISH-QGMBQPNBSA-N
OSM-S-313,AEW 225,,,ClC1=CN=CC(N/N=C/C2=CC=C(C(F)(F)F)N=C2)=N1,"InChI=1S/C11H7ClF3N5/c12-9-5-16-6-10(19-9)20-18-4-7-1-2-8(17-3-7)11(13,14)15/h1-6H,(H,19,20)/b18-4+",WGIQRWUYJGTEQZ-JJPRUIFNSA-N
OSM-S-314,AEW 244; MRLS 3,,,ClC1=CN=CC(N/N=C/C2CCCN(C2)C(OC(C)(C)C)=O)=N1,"InChI=1S/C15H22ClN5O2/c1-15(2,3)23-14(22)21-6-4-5-11(10-21)7-18-20-13-9-17-8-12(16)19-13/h7-9,11H,4-6,10H2,1-3H3,(H,19,20)/b18-7+",SFWCGERLWZCMLH-CNHKJKLMSA-N
OSM-S-315,AEW 224,,,ClC1=CN=CC(N/N=C/C2CCCCC2)=N1,"InChI=1S/C11H15ClN4/c12-10-7-13-8-11(15-10)16-14-6-9-4-2-1-3-5-9/h6-9H,1-5H2,(H,15,16)/b14-6+",HJIMKTGTAZWIDY-MKMNVTDBSA-N
OSM-S-316,AEW 217-1,,,ClC1=CN=CC(N/N=C/CC)=N1,"InChI=1S/C7H9ClN4/c1-2-3-10-12-7-5-9-4-6(8)11-7/h3-5H,2H2,1H3,(H,11,12)/b10-3+",WLEOFHUCRYXNSK-XCVCLJGOSA-N
OSM-S-317,AEW 251-1,,,ClC1=CN=CC2=NN=C(C3=CC=C(OC(F)(F)F)C=C3)N21,"InChI=1S/C12H6ClF3N4O/c13-9-5-17-6-10-18-19-11(20(9)10)7-1-3-8(4-2-7)21-12(14,15)16/h1-6H",SULQSGIMGSOUEQ-UHFFFAOYSA-N
OSM-S-318,JU 13,,,ClC1=NC(N/N=C/C2=CC=NC=C2)=CN=C1,"InChI=1S/C10H8ClN5/c11-9-6-13-7-10(15-9)16-14-5-8-1-3-12-4-2-8/h1-7H,(H,15,16)/b14-5+",JCWOMYIUAFLDIJ-LHHJGKSTSA-N
OSM-S-319,BSX 2-1,,,ClC(N12)=CN=CC1=NN=C2C3=CC(F)=CC(F)=C3,InChI=1S/C11H5ClF2N4/c12-9-4-15-5-10-16-17-11(18(9)10)6-1-7(13)3-8(14)2-6/h1-5H,NFVUSAFBLAWQND-UHFFFAOYSA-N
OSM-S-32,LMW9,57515640,,O=C(C1=C(C)N(C2=CC=C(C(F)(F)F)C=C2)C(C)=C1)OCC,"InChI=1S/C16H16F3NO2/c1-4-22-15(21)14-9-10(2)20(11(14)3)13-7-5-12(6-8-13)16(17,18)19/h5-9H,4H2,1-3H3",DSKJELKQHGKPCX-UHFFFAOYSA-N
OSM-S-320,AEW 227-1,,,ClC(N12)=CN=CC1=NN=C2C3=CN=C(C(F)(F)F)C=C3,"InChI=1S/C11H5ClF3N5/c12-8-4-16-5-9-18-19-10(20(8)9)6-1-2-7(17-3-6)11(13,14)15/h1-5H",CKNXMTZWYJZPBG-UHFFFAOYSA-N
OSM-S-321,AEW 226,,,ClC(N12)=CN=CC1=NN=C2C3CCCCC3,"InChI=1S/C11H13ClN4/c12-9-6-13-7-10-14-15-11(16(9)10)8-4-2-1-3-5-8/h6-8H,1-5H2",VQSQFDRQCNZKOD-UHFFFAOYSA-N
OSM-S-322,AEW 218,,,CCC1=NN=C2C=NC=C(N21)Cl,"InChI=1S/C7H7ClN4/c1-2-6-10-11-7-4-9-3-5(8)12(6)7/h3-4H,2H2,1H3",ABRDHKGOZVLFFA-UHFFFAOYSA-N
OSM-S-323,AEW 245,,,ClC(N12)=CN=CC1=NN=C2C3CCCN(C3)C(OC(C)(C)C)=O,"InChI=1S/C15H20ClN5O2/c1-15(2,3)23-14(22)20-6-4-5-10(9-20)13-19-18-12-8-17-7-11(16)21(12)13/h7-8,10H,4-6,9H2,1-3H3",GRNMIZRYYNSOPO-UHFFFAOYSA-N
OSM-S-324,AEW 205; JU 19,,,ClC1=CN=CC2=NN=C(C3=CC=C(OC(F)F)C=C3)N21,"InChI=1S/C12H7ClF2N4O/c13-9-5-16-6-10-17-18-11(19(9)10)7-1-3-8(4-2-7)20-12(14)15/h1-6,12H",DNBISPSZPAUUNV-UHFFFAOYSA-N
OSM-S-325,AEW 231,,,ClC(N12)=CN=CC1=NN=C2C3=CC=CC=C3,InChI=1S/C11H7ClN4/c12-9-6-13-7-10-14-15-11(16(9)10)8-4-2-1-3-5-8/h1-7H,SRHVJMRAKIWKAP-UHFFFAOYSA-N
OSM-S-326,TY 3-1,,,ClC(N12)=CN=CC1=NN=C2C3=CC(C=CC=C4)=C4C=C3,InChI=1S/C15H9ClN4/c16-13-8-17-9-14-18-19-15(20(13)14)12-6-5-10-3-1-2-4-11(10)7-12/h1-9H,ZSUGLDWMTRDRDG-UHFFFAOYSA-N
OSM-S-327,CX 3-1,,,ClC(N12)=CN=CC1=NN=C2C3=CC(OCO4)=C4C=C3,"InChI=1S/C12H7ClN4O2/c13-10-4-14-5-11-15-16-12(17(10)11)7-1-2-8-9(3-7)19-6-18-8/h1-5H,6H2",RQHTTXMVEFPWCL-UHFFFAOYSA-N
OSM-S-328,,,,OC1=CN=CC2=NN=C(C3=CC=C(OC(F)F)C=C3)N21,"InChI=1S/C12H8F2N4O2/c13-12(14)20-8-3-1-7(2-4-8)11-17-16-9-5-15-6-10(19)18(9)11/h1-6,12,19H",LKGFFHYSCHTNJQ-UHFFFAOYSA-N
OSM-S-329,AEW 102,,,FC1=C(F)C=C(C(C(O)=O)O)C=C1,"InChI=1S/C8H6F2O3/c9-5-2-1-4(3-6(5)10)7(11)8(12)13/h1-3,7,11H,(H,12,13)",BKHXODARAOCNDJ-UHFFFAOYSA-N
OSM-S-33,ZYH1,1800795,,CC1=CC=C(C)N1C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2,"InChI=1S/C14H11F6N/c1-8-3-4-9(2)21(8)12-6-10(13(15,16)17)5-11(7-12)14(18,19)20/h3-7H,1-2H3",KUDHKDYSHKOCTC-UHFFFAOYSA-N
OSM-S-330,AEW 127-1,,,FC1=C(F)C=C(C(C(OC)=O)OC)C=C1,"InChI=1S/C10H10F2O3/c1-14-9(10(13)15-2)6-3-4-7(11)8(12)5-6/h3-5,9H,1-2H3",HUBRZTQUTPZCPX-UHFFFAOYSA-N
OSM-S-331,AEW 144-1,,,FC1=C(F)C=C(C(CO)OC)C=C1,"InChI=1S/C9H10F2O2/c1-13-9(5-12)6-2-3-7(10)8(11)4-6/h2-4,9,12H,5H2,1H3",PUCLAEJNAPEKLS-UHFFFAOYSA-N
OSM-S-332,JU 14; AEW 203-1,,,ClC1=CN=CC2=NN=C(C3=CC=NC=C3)N21,InChI=1S/C10H6ClN5/c11-8-5-13-6-9-14-15-10(16(8)9)7-1-3-12-4-2-7/h1-6H,KTELFDVJLULJPK-UHFFFAOYSA-N
OSM-S-333,,,,ClC(N12)=CN=CC1=NN=C2C3=CC(Cl)=CC=C3,InChI=1S/C11H6Cl2N4/c12-8-3-1-2-7(4-8)11-16-15-10-6-14-5-9(13)17(10)11/h1-6H,IBCZRFPVYKMZGT-UHFFFAOYSA-N
OSM-S-334,,,,ClC(N12)=CN=CC1=NN=C2C3=C(Cl)C=CC=C3,InChI=1S/C11H6Cl2N4/c12-8-4-2-1-3-7(8)11-16-15-10-6-14-5-9(13)17(10)11/h1-6H,DLOREBWFAAUZAK-UHFFFAOYSA-N
OSM-S-335,,,,O=C(OCC)C(CO)C1=CC=CC=C1,"InChI=1S/C11H14O3/c1-2-14-11(13)10(8-12)9-6-4-3-5-7-9/h3-7,10,12H,2,8H2,1H3",NVWZHTVEPJITPR-UHFFFAOYSA-N
OSM-S-336,AEW 173,,,OC(C(OC)=O)C1=CC=CC=C1,"InChI=1S/C9H10O3/c1-12-9(11)8(10)7-5-3-2-4-6-7/h2-6,8,10H,1H3",ITATYELQCJRCCK-UHFFFAOYSA-N
OSM-S-337,AEW 184-1,,,O=C(OC)C(OC)C1=CC=CC=C1,"InChI=1S/C10H12O3/c1-12-9(10(11)13-2)8-6-4-3-5-7-8/h3-7,9H,1-2H3",SMHXGVJSDWUGKC-UHFFFAOYSA-N
OSM-S-338,AEW 187-1,,,OCC(OC)C1=CC=CC=C1,"InChI=1S/C9H12O2/c1-11-9(7-10)8-5-3-2-4-6-8/h2-6,9-10H,7H2,1H3",JDTUPLBMGDDPJS-UHFFFAOYSA-N
OSM-S-339,AEW 109; SJD 3; HM 5,,,O=C(OC)C(OC1OCCCC1)C2=CC=CC=C2,"InChI=1S/C14H18O4/c1-16-14(15)13(11-7-3-2-4-8-11)18-12-9-5-6-10-17-12/h2-4,7-8,12-13H,5-6,9-10H2,1H3",OIODXZPBINGTGA-UHFFFAOYSA-N
OSM-S-34,ZYH2,2781522,,CC1=C(C=O)C=C(C)N1C2=CC=C(C(F)(F)F)C=C2,"InChI=1S/C14H12F3NO/c1-9-7-11(8-19)10(2)18(9)13-5-3-12(4-6-13)14(15,16)17/h3-8H,1-2H3",FNMOTVDVAVQQDQ-UHFFFAOYSA-N
OSM-S-340,AEW 221; SJD 4,,,OCC(OC1OCCCC1)C2=CC=CC=C2,"InChI=1S/C13H18O3/c14-10-12(11-6-2-1-3-7-11)16-13-8-4-5-9-15-13/h1-3,6-7,12-14H,4-5,8-10H2",BCDVRNCZMZEOBT-UHFFFAOYSA-N
OSM-S-341,AEW 174,,,N[C@@H](CO)C1=CC=CC=C1,"InChI=1S/C8H11NO/c9-8(6-10)7-4-2-1-3-5-7/h1-5,8,10H,6,9H2/t8-/m0/s1",IJXJGQCXFSSHNL-QMMMGPOBSA-N
OSM-S-342,AEW 210,,,O=C(O)[C@H](NC(O)=O)C1=CC=CC=C1,"InChI=1S/C9H9NO4/c11-8(12)7(10-9(13)14)6-4-2-1-3-5-6/h1-5,7,10H,(H,11,12)(H,13,14)/t7-/m1/s1",RRTQTOBOLIGMED-SSDOTTSWSA-N
OSM-S-343,AEW 188; AEW 212,,,OC[C@H](NC)C1=CC=CC=C1,"InChI=1S/C9H13NO/c1-10-9(7-11)8-5-3-2-4-6-8/h2-6,9-11H,7H2,1H3",ULIMZYAYESNNIP-UHFFFAOYSA-N
OSM-S-344,AEW 261-1,,,OC[C@H](N(C)C)C1=CC=CC=C1,"InChI=1S/C10H15NO/c1-11(2)10(8-12)9-6-4-3-5-7-9/h3-7,10,12H,8H2,1-2H3",RDSMPQNNVZOQRI-UHFFFAOYSA-N
OSM-S-345,AEW 267-1,,,O=C(OCC)C(C1=CC=CC=C1)COC2=CN=CC3=NN=C(C4=CC=C(OC(F)F)C=C4)N32,"InChI=1S/C23H20F2N4O4/c1-2-31-22(30)18(15-6-4-3-5-7-15)14-32-20-13-26-12-19-27-28-21(29(19)20)16-8-10-17(11-9-16)33-23(24)25/h3-13,18,23H,2,14H2,1H3",QJIQBIRQSSHLPV-UHFFFAOYSA-N
OSM-S-346,AEW 284-1,,MMV693148,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC(C)C4=CC=C(Cl)C(Cl)=C4)N32,"InChI=1S/C20H14Cl2F2N4O2/c1-11(13-4-7-15(21)16(22)8-13)29-18-10-25-9-17-26-27-19(28(17)18)12-2-5-14(6-3-12)30-20(23)24/h2-11,20H,1H3",ILDZQTSEZGQWFR-UHFFFAOYSA-N
OSM-S-347,AEW 285-1,,MMV693149,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC4=CC=C(Cl)C(Cl)=C4)N32,"InChI=1S/C19H12Cl2F2N4O2/c20-14-6-1-11(7-15(14)21)10-28-17-9-24-8-16-25-26-18(27(16)17)12-2-4-13(5-3-12)29-19(22)23/h1-9,19H,10H2",CSHOSFVEVPHTHZ-UHFFFAOYSA-N
OSM-S-348,AEW 286-1,,MMV693150,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC4=CC=C(Cl)C=C4)N32,"InChI=1S/C19H13ClF2N4O2/c20-14-5-1-12(2-6-14)11-27-17-10-23-9-16-24-25-18(26(16)17)13-3-7-15(8-4-13)28-19(21)22/h1-10,19H,11H2",ROAUWAVERUYYHI-UHFFFAOYSA-N
OSM-S-349,AEW 290-1,,MMV693151,FC(C=C1)=C(F)C=C1C2=NN=C3C=NC=C(OCCC4=CC=CC=C4)N32,"InChI=1S/C19H14F2N4O/c20-15-7-6-14(10-16(15)21)19-24-23-17-11-22-12-18(25(17)19)26-9-8-13-4-2-1-3-5-13/h1-7,10-12H,8-9H2",DNQWZOZQWWSJTR-UHFFFAOYSA-N
OSM-S-35,ZYH3; PMY47; MNR93,6016153,MMV689018,CC1=C(/C=C2S/C(NC\2=O)=N\C3=CC=CC=C3)C=C(C)N1C4=CC=CC=C4,"InChI=1S/C22H19N3OS/c1-15-13-17(16(2)25(15)19-11-7-4-8-12-19)14-20-21(26)24-22(27-20)23-18-9-5-3-6-10-18/h3-14H,1-2H3,(H,23,24,26)/b20-14-",QTDBAHFMTAMGMZ-ZHZULCJRSA-N
OSM-S-350,AEW 291-1,,MMV693152,ClC(C=C1)=C(Cl)C=C1C2=NN=C3C=NC=C(OCCC4=CC=CC=C4)N32,"InChI=1S/C19H14Cl2N4O/c20-15-7-6-14(10-16(15)21)19-24-23-17-11-22-12-18(25(17)19)26-9-8-13-4-2-1-3-5-13/h1-7,10-12H,8-9H2",DJLRRTBQGVDDPH-UHFFFAOYSA-N
OSM-S-351,AEW 292-1,,MMV693153,ClC1=CC=CC(C2=NN=C3C=NC=C(OCCC4=CC=CC=C4)N32)=C1Cl,"InChI=1S/C19H14Cl2N4O/c20-15-8-4-7-14(18(15)21)19-24-23-16-11-22-12-17(25(16)19)26-10-9-13-5-2-1-3-6-13/h1-8,11-12H,9-10H2",NMFGGQYGCNANQR-UHFFFAOYSA-N
OSM-S-352,AEW 293-1,,MMV693154,FC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCCC4=CC=CC=C4)N32,"InChI=1S/C19H15FN4O/c20-16-8-6-15(7-9-16)19-23-22-17-12-21-13-18(24(17)19)25-11-10-14-4-2-1-3-5-14/h1-9,12-13H,10-11H2",QCWQNZCCYWUBQM-UHFFFAOYSA-N
OSM-S-353,AEW 270-1; AEW 294-1; AEW 317-1,,MMV693155,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(C4=CC=CC=C4)CO)N32,"InChI=1S/C21H18F2N4O3/c22-21(23)30-17-8-6-15(7-9-17)20-26-25-18-10-24-11-19(27(18)20)29-13-16(12-28)14-4-2-1-3-5-14/h1-11,16,21,28H,12-13H2",MGANJQKOPZQELF-UHFFFAOYSA-N
OSM-S-354,AEW 295-1,,,OC(C)(C)COC1=CN=CC2=NN=C(C3=CC=C(OC(F)(F)F)C=C3)N21,"InChI=1S/C16H15F3N4O3/c1-15(2,24)9-25-13-8-20-7-12-21-22-14(23(12)13)10-3-5-11(6-4-10)26-16(17,18)19/h3-8,24H,9H2,1-2H3",DFKSAMALDVOYGD-UHFFFAOYSA-N
OSM-S-355,,,,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(C4=CC=CC=C4)CN)N32,"InChI=1S/C21H19F2N5O2/c22-21(23)30-17-8-6-15(7-9-17)20-27-26-18-11-25-12-19(28(18)20)29-13-16(10-24)14-4-2-1-3-5-14/h1-9,11-12,16,21H,10,13,24H2",ZAYFESUSYJEUPU-UHFFFAOYSA-N
OSM-S-356,,,,OC(C1=CC=CC=C1)COC2=CN=CC3=NN=C(C4=NC=CC=C4)N32,"InChI=1S/C18H15N5O2/c24-15(13-6-2-1-3-7-13)12-25-17-11-19-10-16-21-22-18(23(16)17)14-8-4-5-9-20-14/h1-11,15,24H,12H2",LPWNUIYBRNJSHM-UHFFFAOYSA-N
OSM-S-357,,,,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(C)(C)OC)N32,"InChI=1S/C17H18F2N4O3/c1-17(2,24-3)10-25-14-9-20-8-13-21-22-15(23(13)14)11-4-6-12(7-5-11)26-16(18)19/h4-9,16H,10H2,1-3H3",QPGDQEMNKJULOO-UHFFFAOYSA-N
OSM-S-358,,,,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(C4=CC=CC=C4)N(C)C)N32,"InChI=1S/C22H21F2N5O2/c1-28(2)18(15-6-4-3-5-7-15)14-30-20-13-25-12-19-26-27-21(29(19)20)16-8-10-17(11-9-16)31-22(23)24/h3-13,18,22H,14H2,1-2H3",WSXRPWJACRAQOI-UHFFFAOYSA-N
OSM-S-359,EGT 48-1,,MMV693161,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(SCC4=CC=CC=C4)N32,"InChI=1S/C19H14F2N4OS/c20-19(21)26-15-8-6-14(7-9-15)18-24-23-16-10-22-11-17(25(16)18)27-12-13-4-2-1-3-5-13/h1-11,19H,12H2",KEZIWQVAJDNGBM-UHFFFAOYSA-N
OSM-S-36,ZYH4,57515641,,CC1=C(C=O)C=C(C)N1C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2,"InChI=1S/C15H11F6NO/c1-8-3-10(7-23)9(2)22(8)13-5-11(14(16,17)18)4-12(6-13)15(19,20)21/h3-7H,1-2H3",ZPNXIXBDNHGLNY-UHFFFAOYSA-N
OSM-S-360,EGT 45-1,,MMV693162,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(S(CC4=CC=CC=C4)=O)N32,"InChI=1S/C19H14F2N4O2S/c20-19(21)27-15-8-6-14(7-9-15)18-24-23-16-10-22-11-17(25(16)18)28(26)12-13-4-2-1-3-5-13/h1-11,19H,12H2",HSYPMILIAZBMAQ-UHFFFAOYSA-N
OSM-S-361,EGT 39-1,,MMV693163,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(S(CC4=CC=CC=C4)(=O)=O)N32,"InChI=1S/C19H14F2N4O3S/c20-19(21)28-15-8-6-14(7-9-15)18-24-23-16-10-22-11-17(25(16)18)29(26,27)12-13-4-2-1-3-5-13/h1-11,19H,12H2",OCXPXTXAACVDON-UHFFFAOYSA-N
OSM-S-362,EGT 51-4,,MMV693165,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(N4N=NC(C5=CC=CC=C5)=C4)N32,"InChI=1S/C20H13F2N7O/c21-20(22)30-15-8-6-14(7-9-15)19-26-25-17-10-23-11-18(29(17)19)28-12-16(24-27-28)13-4-2-1-3-5-13/h1-12,20H",WUWMNWSXMOOYGG-UHFFFAOYSA-N
OSM-S-363,EGT 52-1,,MMV693164,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(SCCC4=CC=CC=C4)N32,"InChI=1S/C20H16F2N4OS/c21-20(22)27-16-8-6-15(7-9-16)19-25-24-17-12-23-13-18(26(17)19)28-11-10-14-4-2-1-3-5-14/h1-9,12-13,20H,10-11H2",GFJJCWGNCVLFNL-UHFFFAOYSA-N
OSM-S-364,EGT 63-1,,MMV693167,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(S(CCC4=CC=CC=C4)=O)N32,"InChI=1S/C20H16F2N4O2S/c21-20(22)28-16-8-6-15(7-9-16)19-25-24-17-12-23-13-18(26(17)19)29(27)11-10-14-4-2-1-3-5-14/h1-9,12-13,20H,10-11H2",XRLPEWWQEWQISU-UHFFFAOYSA-N
OSM-S-365,EGT 60-1,,MMV693166,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(S(CCC4=CC=CC=C4)(=O)=O)N32,"InChI=1S/C20H16F2N4O3S/c21-20(22)29-16-8-6-15(7-9-16)19-25-24-17-12-23-13-18(26(17)19)30(27,28)11-10-14-4-2-1-3-5-14/h1-9,12-13,20H,10-11H2",VHMNWOXAYNBRAI-UHFFFAOYSA-N
OSM-S-366,"AEW 296-1, PCCBTAK-0272",,MMV670936,FC(F)(F)C(C=C1)=NC=C1C2=NN=C3C=NC=C(OCCC4=CC(F)=C(F)C=C4)N32,"InChI=1S/C19H12F5N5O/c20-13-3-1-11(7-14(13)21)5-6-30-17-10-25-9-16-27-28-18(29(16)17)12-2-4-15(26-8-12)19(22,23)24/h1-4,7-10H,5-6H2",GIBSJTKADOSTIA-UHFFFAOYSA-N
OSM-S-367,EGT 95-3,,MMV670246,O=C(NC1=CC=C(Cl)C=C1)C2=CN=CC3=NN=C(C4=CC=C(OC(F)F)C=C4)N32,"InChI=1S/C19H12ClF2N5O2/c20-12-3-5-13(6-4-12)24-18(28)15-9-23-10-16-25-26-17(27(15)16)11-1-7-14(8-2-11)29-19(21)22/h1-10,19H,(H,24,28)",CAFUHAVOTBMKAN-UHFFFAOYSA-N
OSM-S-368,EGT 96-1,,MMV897697,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC4=CC=CC=C4)N32,"InChI=1S/C19H14F2N4O2/c20-19(21)27-15-8-6-14(7-9-15)18-24-23-16-10-22-11-17(25(16)18)26-12-13-4-2-1-3-5-13/h1-11,19H,12H2",BHCAOWNYTVGIBQ-UHFFFAOYSA-N
OSM-S-369,EGT 92-1,,MMV897698,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCCC4=CC=CC=C4)N32,"InChI=1S/C20H16F2N4O2/c21-20(22)28-16-8-6-15(7-9-16)19-25-24-17-12-23-13-18(26(17)19)27-11-10-14-4-2-1-3-5-14/h1-9,12-13,20H,10-11H2",AVBCIJLYABLIRW-UHFFFAOYSA-N
OSM-S-37 ,ZYH5; AEW76,57515642,MMV689019,CC1=C(/C=C2S/C(NC\2=O)=N\C3=CC=CC=C3)C=C(C)N1C4=CC=C(C)C=C4,"InChI=1S/C23H21N3OS/c1-15-9-11-20(12-10-15)26-16(2)13-18(17(26)3)14-21-22(27)25-23(28-21)24-19-7-5-4-6-8-19/h4-14H,1-3H3,(H,24,25,27)/b21-14-",XCTPMKNSBDOHRB-STZFKDTASA-N
OSM-S-370,EGT 64-1,,MMV897699,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCCCC45C6C7C4C8C5C6C87)N32,"InChI=1S/C23H20F2N4O2/c24-22(25)31-11-4-2-10(3-5-11)21-28-27-12-8-26-9-13(29(12)21)30-7-1-6-23-18-15-14-16(18)20(23)17(14)19(15)23/h2-5,8-9,14-20,22H,1,6-7H2",VWHKKURDRVBXMI-UHFFFAOYSA-N
OSM-S-371,EGT 65-1,,MMV897700,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCCC4(C56)C7C6C8C5C4C87)N32,"InChI=1S/C22H18F2N4O2/c23-21(24)30-10-3-1-9(2-4-10)20-27-26-11-7-25-8-12(28(11)20)29-6-5-22-17-14-13-15(17)19(22)16(13)18(14)22/h1-4,7-8,13-19,21H,5-6H2",RXAWCKZPAXRRNE-UHFFFAOYSA-N
OSM-S-372,EGT 82-1,,MMV897701,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC4=CN(CC5=CC=CC=C5)N=N4)N32,"InChI=1S/C22H17F2N7O2/c23-22(24)33-18-8-6-16(7-9-18)21-28-27-19-10-25-11-20(31(19)21)32-14-17-13-30(29-26-17)12-15-4-2-1-3-5-15/h1-11,13,22H,12,14H2",MWSSDSZTHFIITL-UHFFFAOYSA-N
OSM-S-373,EGT 101-1,,MMV897702,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(N=N4)=CN4C5=CC=CC=C5)N32,"InChI=1S/C21H15F2N7O2/c22-21(23)32-17-8-6-14(7-9-17)20-27-26-18-10-24-11-19(30(18)20)31-13-15-12-29(28-25-15)16-4-2-1-3-5-16/h1-12,21H,13H2",JAWVVMAXICVBNV-UHFFFAOYSA-N
OSM-S-374,EGT 105-2,,MMV897703,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC4=CN(C5=NC(Cl)=CN=C5)N=N4)N32,"InChI=1S/C19H12ClF2N9O2/c20-14-5-23-6-15(25-14)30-9-12(26-29-30)10-32-17-8-24-7-16-27-28-18(31(16)17)11-1-3-13(4-2-11)33-19(21)22/h1-9,19H,10H2",LHPHPSWVDUENHC-UHFFFAOYSA-N
OSM-S-375,EGT 117-1,,MMV897704,IC12C(C3C1C4C52)C5C34C6=NN=C7C=NC=C(OCCC8=CC(F)=C(F)C=C8)N76,"InChI=1S/C21H15F2IN4O/c22-9-2-1-8(5-10(9)23)3-4-29-12-7-25-6-11-26-27-19(28(11)12)20-13-16-14(20)18-15(20)17(13)21(16,18)24/h1-2,5-7,13-18H,3-4H2",XDGWZNAHVCGVML-UHFFFAOYSA-N
OSM-S-376,AEW 314-1,,MMV897708,OC(C1=CC(F)=C(F)C=C1)COC2=CN=CC3=NN=C(C4=CC=C(C#N)C=C4)N32,"InChI=1S/C20H13F2N5O2/c21-15-6-5-14(7-16(15)22)17(28)11-29-19-10-24-9-18-25-26-20(27(18)19)13-3-1-12(8-23)2-4-13/h1-7,9-10,17,28H,11H2",HHHWRCNBDNZMPN-UHFFFAOYSA-N
OSM-S-377,INHERITED,,MMV670652,FC(C=C1)=C(F)C=C1C(OC(F)F)COC2=CN=CC3=NN=C(C4=CC=C(C#N)C=C4)N32,"InChI=1S/C21H13F4N5O2/c22-15-6-5-14(7-16(15)23)17(32-21(24)25)11-31-19-10-27-9-18-28-29-20(30(18)19)13-3-1-12(8-26)2-4-13/h1-7,9-10,17,21H,11H2",LHSRVKYAEUESTK-UHFFFAOYSA-N
OSM-S-378,EGT 145-2,,MMV897707,FC1=C(F)C=CC(C(N(C)C)COC2=CN=CC3=NN=C(C4=CC=C(C#N)C=C4)N32)=C1,"InChI=1S/C22H18F2N6O/c1-29(2)19(16-7-8-17(23)18(24)9-16)13-31-21-12-26-11-20-27-28-22(30(20)21)15-5-3-14(10-25)4-6-15/h3-9,11-12,19H,13H2,1-2H3",MQNJSHHRLBVVLU-UHFFFAOYSA-N
OSM-S-379,EGT 141-1,,MMV670767,FC(C(Cl)=C1)=CC=C1NC(C2=CN=CC3=NN=C(C4=CC=C(OC(F)F)C=C4)N32)=O,"InChI=1S/C19H11ClF3N5O2/c20-13-7-11(3-6-14(13)21)25-18(29)15-8-24-9-16-26-27-17(28(15)16)10-1-4-12(5-2-10)30-19(22)23/h1-9,19H,(H,25,29)",WFJPUMPZNOYIKX-UHFFFAOYSA-N
OSM-S-38,ZYH6,57515643,,CC1=CC(/C=C(C(N/2)=O)\SC2=N/C3=CC=CC=C3)=C(C)N1C(C=C4)=CC=C4C(F)(F)F,"InChI=1S/C23H18F3N3OS/c1-14-12-16(15(2)29(14)19-10-8-17(9-11-19)23(24,25)26)13-20-21(30)28-22(31-20)27-18-6-4-3-5-7-18/h3-13H,1-2H3,(H,27,28,30)/b20-13-",YBBWTVGRVHTTDD-MOSHPQCFSA-N
OSM-S-380,PCCBTAK-0194,,MMV669848,FC(OC(C=C1)=CC=C1C2=NN=C3C=NC=C(CN4CC(C=CC=C5)=C5C4)N32)F,"InChI=1S/C21H17F2N5O/c22-21(23)29-18-7-5-14(6-8-18)20-26-25-19-10-24-9-17(28(19)20)13-27-11-15-3-1-2-4-16(15)12-27/h1-10,21H,11-13H2",
OSM-S-381,INHERITED,,MMV670947,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(CO)C4=CC(F)=C(F)C=C4)N32,"InChI=1S/C21H16F4N4O3/c22-16-6-3-13(7-17(16)23)14(10-30)11-31-19-9-26-8-18-27-28-20(29(18)19)12-1-4-15(5-2-12)32-21(24)25/h1-9,14,21,30H,10-11H2",MKSKANAVVSFYNL-UHFFFAOYSA-N
OSM-S-382,EGT 123-1,,MMV897710,IC12C3C4C5(C3C1C5C24)C6=NN=C7C=NC=C(C(NC8=CC(C(F)(F)F)=NC=C8)=O)N76,"InChI=1S/C20H12F3IN6O/c21-20(22,23)8-3-6(1-2-26-8)27-16(31)7-4-25-5-9-28-29-17(30(7)9)18-10-13-11(18)15-12(18)14(10)19(13,15)24/h1-5,10-15H,(H,26,27,31)",BCBDEZPMCZDSAL-UHFFFAOYSA-N
OSM-S-383,EGT 147-1,,MMV897711,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCCC4=CC(OC)=CC=C4)N32,"InChI=1S/C21H18F2N4O3/c1-28-17-4-2-3-14(11-17)9-10-29-19-13-24-12-18-25-26-20(27(18)19)15-5-7-16(8-6-15)30-21(22)23/h2-8,11-13,21H,9-10H2,1H3",QAMQLYPPZOESDX-UHFFFAOYSA-N
OSM-S-384,EGT 148-1,,MMV897712,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCCC4=CC=C(OC)C=C4)N32,"InChI=1S/C21H18F2N4O3/c1-28-16-6-2-14(3-7-16)10-11-29-19-13-24-12-18-25-26-20(27(18)19)15-4-8-17(9-5-15)30-21(22)23/h2-9,12-13,21H,10-11H2,1H3",LPQFPIUFNNSFCQ-UHFFFAOYSA-N
OSM-S-385,EGT 159-1,,MMV897713,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC(C)C4=CC=C(F)C(F)=C4)N32,"InChI=1S/C20H14F4N4O2/c1-11(13-4-7-15(21)16(22)8-13)29-18-10-25-9-17-26-27-19(28(17)18)12-2-5-14(6-3-12)30-20(23)24/h2-11,20H,1H3",RNNQYJKGWRNSLV-UHFFFAOYSA-N
OSM-S-386,EGT 160-1,,MMV897714,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC(C)C4=CC=C(C#N)C=C4)N32,"InChI=1S/C21H15F2N5O2/c1-13(15-4-2-14(10-24)3-5-15)29-19-12-25-11-18-26-27-20(28(18)19)16-6-8-17(9-7-16)30-21(22)23/h2-9,11-13,21H,1H3",OXTDVKYGNRAXGV-UHFFFAOYSA-N
OSM-S-387,EGT 151-1,,MMV897706,FC(C=C1)=C(F)C=C1CCOC2=CN=CC3=NN=CN32,"InChI=1S/C13H10F2N4O/c14-10-2-1-9(5-11(10)15)3-4-20-13-7-16-6-12-18-17-8-19(12)13/h1-2,5-8H,3-4H2",YHNADHDORQAQNL-UHFFFAOYSA-N
OSM-S-388,HM 8-1,,MMV897705,OC1=CN=CC2=NN=C(N3CCCCC3)N21,"InChI=1S/C10H13N5O/c16-9-7-11-6-8-12-13-10(15(8)9)14-4-2-1-3-5-14/h6-7,16H,1-5H2",SMLXPIMVJWUYAO-UHFFFAOYSA-N
OSM-S-389,EGT 169-1,,MMV897763,FC1=C(C=CC(C(COC2=CN=CC3=NN=C(N32)C4=CC=C(OC(F)F)C=C4)N(C)C)=C1)F,"InChI=1S/C22H19F4N5O2/c1-30(2)18(14-5-8-16(23)17(24)9-14)12-32-20-11-27-10-19-28-29-21(31(19)20)13-3-6-15(7-4-13)33-22(25)26/h3-11,18,22H,12H2,1-2H3",PMIWBIXSAYKRGF-UHFFFAOYSA-N
OSM-S-390,EGT 171-1,,MMV672687,FC(OC1=CC=C(C2=NN=C3C=NC=C(N32)OCC(C4=CC(F)=C(C=C4)F)O)C=C1)F,"InChI=1S/C20H14F4N4O3/c21-14-6-3-12(7-15(14)22)16(29)10-30-18-9-25-8-17-26-27-19(28(17)18)11-1-4-13(5-2-11)31-20(23)24/h1-9,16,20,29H,10H2",BXEWPSCIVPVASC-UHFFFAOYSA-N
OSM-S-391,EGT 176-1,,,IC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCCC4=CC(F)=C(F)C=C4)N32,"InChI=1S/C19H13F2IN4O/c20-15-6-1-12(9-16(15)21)7-8-27-18-11-23-10-17-24-25-19(26(17)18)13-2-4-14(22)5-3-13/h1-6,9-11H,7-8H2",SYOXDOQMLHMQGB-UHFFFAOYSA-N
OSM-S-392,EGT 190-3,,,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(C4=CC(F)=C(F)C=C4)=O)N32,"InChI=1S/C20H12F4N4O3/c21-14-6-3-12(7-15(14)22)16(29)10-30-18-9-25-8-17-26-27-19(28(17)18)11-1-4-13(5-2-11)31-20(23)24/h1-9,20H,10H2",OPCIMEMUOABUMK-UHFFFAOYSA-N
OSM-S-393,EGT 191-1,,,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(OC)(OC)C4=CC(F)=C(F)C=C4)N32,"InChI=1S/C22H18F4N4O4/c1-31-22(32-2,14-5-8-16(23)17(24)9-14)12-33-19-11-27-10-18-28-29-20(30(18)19)13-3-6-15(7-4-13)34-21(25)26/h3-11,21H,12H2,1-2H3",HFRRKTROCJVLKP-UHFFFAOYSA-N
OSM-S-394,EGT 212-1,,,FS(F)(F)(F)(F)C(C=C1)=CC=C1C2=NN=C3C=NC=C(OCCC4=CC=CC=C4)N32,"InChI=1S/C19H15F5N4OS/c20-30(21,22,23,24)16-8-6-15(7-9-16)19-27-26-17-12-25-13-18(28(17)19)29-11-10-14-4-2-1-3-5-14/h1-9,12-13H,10-11H2",PEMORNCGKKXBCP-UHFFFAOYSA-N
OSM-S-395,EGT 213-1,,,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCCC4(CC5C6)CC6C[C@@H](C5)C4)N32,"InChI=1S/C24H26F2N4O2/c25-23(26)32-19-3-1-18(2-4-19)22-29-28-20-13-27-14-21(30(20)22)31-6-5-24-10-15-7-16(11-24)9-17(8-15)12-24/h1-4,13-17,23H,5-12H2/t15-,16?,17?,24?",BSXLJNOXQMXUOB-CRFYJIHUSA-N
OSM-S-396,EGT 215-1,,,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC(C)CC4=CC=CC=C4)N32,"InChI=1S/C21H18F2N4O2/c1-14(11-15-5-3-2-4-6-15)28-19-13-24-12-18-25-26-20(27(18)19)16-7-9-17(10-8-16)29-21(22)23/h2-10,12-14,21H,11H2,1H3",HJOHTEUEFDSADX-UHFFFAOYSA-N
OSM-S-397,EGT 220-1,,,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC45C[C@@H](C[C@@H](C5)C6)C[C@@H]6C4)N32,"InChI=1S/C23H24F2N4O2/c24-22(25)31-18-3-1-17(2-4-18)21-28-27-19-11-26-12-20(29(19)21)30-13-23-8-14-5-15(9-23)7-16(6-14)10-23/h1-4,11-12,14-16,22H,5-10,13H2/t14-,15+,16-,23?",PIOOGPDPQVQAFQ-QUXYOMGYSA-N
OSM-S-398,EGT 222-1,,,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC4C[C@H]5C=C[C@@H]4C5)N32,"InChI=1S/C20H18F2N4O2/c21-20(22)28-16-5-3-13(4-6-16)19-25-24-17-9-23-10-18(26(17)19)27-11-15-8-12-1-2-14(15)7-12/h1-6,9-10,12,14-15,20H,7-8,11H2/t12-,14+,15?/m0/s1",OMOCZBKUEFTIAC-DJIKBVBFSA-N
OSM-S-399,EGT 224-1,,,CC1(C)[C@@H]2C[C@H]1C(CCOC3=CN=CC4=NN=C(C5=CC=C(OC(F)F)C=C5)N43)=CC2,"InChI=1S/C23H24F2N4O2/c1-23(2)16-6-3-14(18(23)11-16)9-10-30-20-13-26-12-19-27-28-21(29(19)20)15-4-7-17(8-5-15)31-22(24)25/h3-5,7-8,12-13,16,18,22H,6,9-11H2,1-2H3/t16-,18-/m0/s1",PQILDBPUDLGKJU-WMZOPIPTSA-N
OSM-S-400,EGT 225-1,,,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(C4=CC=CC=C4)=O)N32,"InChI=1S/C20H14F2N4O3/c21-20(22)29-15-8-6-14(7-9-15)19-25-24-17-10-23-11-18(26(17)19)28-12-16(27)13-4-2-1-3-5-13/h1-11,20H,12H2",MQSMCJANEPVRGE-UHFFFAOYSA-N
OSM-S-401,SSP 6a1,,,ClC(C=C1)=CC(Cl)=C1C2=NN=C3C=NC=C(OCC45C[C@@H](C[C@@H](C5)C6)C[C@@H]6C4)N32,"InChI=1S/C22H22Cl2N4O/c23-16-1-2-17(18(24)6-16)21-27-26-19-10-25-11-20(28(19)21)29-12-22-7-13-3-14(8-22)5-15(4-13)9-22/h1-2,6,10-11,13-15H,3-5,7-9,12H2/t13-,14+,15-,22?",XRHQAPBKYTXPOW-HBJUSLLUSA-N
OSM-S-402,SSP 6a2,,,ClC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC45C[C@@H](C[C@@H](C5)C6)C[C@@H]6C4)N32,"InChI=1S/C22H23ClN4O/c23-18-3-1-17(2-4-18)21-26-25-19-11-24-12-20(27(19)21)28-13-22-8-14-5-15(9-22)7-16(6-14)10-22/h1-4,11-12,14-16H,5-10,13H2/t14-,15+,16-,22?",MFXXXMMQULKXIX-GGTBJBEQSA-N
OSM-S-403,SSP 6c1,,,CC1(C)[C@@H]2C[C@H]1C(CCOC3=CN=CC4=NN=C(C5=C(Cl)C=C(Cl)C=C5)N43)=CC2,"InChI=1S/C22H22Cl2N4O/c1-22(2)14-4-3-13(17(22)9-14)7-8-29-20-12-25-11-19-26-27-21(28(19)20)16-6-5-15(23)10-18(16)24/h3,5-6,10-12,14,17H,4,7-9H2,1-2H3/t14-,17-/m0/s1",OYFPJLPMJIFAIS-YOEHRIQHSA-N
OSM-S-404,SSP 6c2,,,CC1(C)[C@@H]2C[C@H]1C(CCOC3=CN=CC4=NN=C(C5=CC=C(Cl)C=C5)N43)=CC2,"InChI=1S/C22H23ClN4O/c1-22(2)16-6-3-14(18(22)11-16)9-10-28-20-13-24-12-19-25-26-21(27(19)20)15-4-7-17(23)8-5-15/h3-5,7-8,12-13,16,18H,6,9-11H2,1-2H3/t16-,18-/m0/s1",BDWPPKIAXRRNII-WMZOPIPTSA-N
OSM-S-405,SSP 6d1,,,ClC(C=C1)=CC(Cl)=C1C2=NN=C3C=NC=C(OCC4C[C@H]5C=C[C@@H]4C5)N32,"InChI=1S/C19H16Cl2N4O/c20-14-3-4-15(16(21)7-14)19-24-23-17-8-22-9-18(25(17)19)26-10-13-6-11-1-2-12(13)5-11/h1-4,7-9,11-13H,5-6,10H2/t11-,12+,13?/m0/s1",OLAUIVKJLBCHFE-LAGVYOHYSA-N
OSM-S-406,SSP 6d2,,,ClC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC4C[C@H]5C=C[C@@H]4C5)N32,"InChI=1S/C19H17ClN4O/c20-16-5-3-13(4-6-16)19-23-22-17-9-21-10-18(24(17)19)25-11-15-8-12-1-2-14(15)7-12/h1-6,9-10,12,14-15H,7-8,11H2/t12-,14+,15?/m0/s1",OWTVMOKESSEJOP-DJIKBVBFSA-N
OSM-S-407,CG59-1,,,O=C(NC1=CC=NC=C1)C2=CN=CC3=NN=C(C4=CC=CC=C4)N32,"InChI=1S/C17H12N6O/c24-17(20-13-6-8-18-9-7-13)14-10-19-11-15-21-22-16(23(14)15)12-4-2-1-3-5-12/h1-11H,(H,18,20,24)",HSTAGCWQAIXJQM-UHFFFAOYSA-N
OSM-S-408,CG60-2,,,C12=NN=C(C3=CC=NC=C3)N1C(OCCC4=CC=CC=C4)=CN=C2,"InChI=1S/C18H15N5O/c1-2-4-14(5-3-1)8-11-24-17-13-20-12-16-21-22-18(23(16)17)15-6-9-19-10-7-15/h1-7,9-10,12-13H,8,11H2",BSTOZULDVQMNLS-UHFFFAOYSA-N
OSM-S-409,EGT 237-2,,,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC/C(C4=CC=CC=C4)=N/O)N32,"InChI=1S/C20H15F2N5O3/c21-20(22)30-15-8-6-14(7-9-15)19-25-24-17-10-23-11-18(27(17)19)29-12-16(26-28)13-4-2-1-3-5-13/h1-11,20,28H,12H2/b26-16-",VJSBQKQNONLQQJ-QQXSKIMKSA-N
OSM-S-410,,,MMV1557863,FC(F)OC(C=C1)=CC=C1C2=NN=C3C(NC=C(C(NC4=CC=C(Cl)C=C4)=O)N32)=O,"InChI=1S/C19H12ClF2N5O3/c20-11-3-5-12(6-4-11)24-17(28)14-9-23-18(29)16-26-25-15(27(14)16)10-1-7-13(8-2-10)30-19(21)22/h1-9,19H,(H,23,29)(H,24,28)",SOVUBMPMKMEPEE-UHFFFAOYSA-N
OSM-S-411,,,MMV1557864,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NC4=CC=[N+]([O-])C(C(F)(F)F)=C4)=O)N32,"InChI=1S/C19H11F5N6O3/c20-18(21)33-12-3-1-10(2-4-12)16-28-27-15-9-25-8-13(30(15)16)17(31)26-11-5-6-29(32)14(7-11)19(22,23)24/h1-9,18H,(H,26,31)",HAVDPBNWKHGTHN-UHFFFAOYSA-N
OSM-S-412,,,MMV1557865,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(CO)C4=CC=C(O)C=C4)N32,"InChI=1S/C21H18F2N4O4/c22-21(23)31-17-7-3-14(4-8-17)20-26-25-18-9-24-10-19(27(18)20)30-12-15(11-28)13-1-5-16(29)6-2-13/h1-10,15,21,28-29H,11-12H2",BCDILCAJSSYWKE-UHFFFAOYSA-N
OSM-S-413,,,,FC(C=C1)=C(F)C=C1[C@@H](OC)COC2=CN=CC3=NN=C(C4=CC=C(C#N)C=C4)N32,"InChI=1S/C21H15F2N5O2/c1-29-18(15-6-7-16(22)17(23)8-15)12-30-20-11-25-10-19-26-27-21(28(19)20)14-4-2-13(9-24)3-5-14/h2-8,10-11,18H,12H2,1H3",PERKBMZWWUEZNJ-UHFFFAOYSA-N
OSM-S-414,,,,FC(C=C1)=C(F)C=C1[C@H](OC)COC2=CN=CC3=NN=C(C4=CC=C(C#N)C=C4)N32,"InChI=1S/C21H15F2N5O2/c1-29-18(15-6-7-16(22)17(23)8-15)12-30-20-11-25-10-19-26-27-21(28(19)20)14-4-2-13(9-24)3-5-14/h2-8,10-11,18H,12H2,1H3",PERKBMZWWUEZNJ-UHFFFAOYSA-N
OSM-S-39,ZYH7,57515644,MMV689020,CC1=C(/C=C2S/C(NC\2=O)=N\C3=CC=CC=C3)C=C(C)N1C4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4,"InChI=1S/C24H17F6N3OS/c1-13-8-15(9-20-21(34)32-22(35-20)31-18-6-4-3-5-7-18)14(2)33(13)19-11-16(23(25,26)27)10-17(12-19)24(28,29)30/h3-12H,1-2H3,(H,31,32,34)/b20-9",GVGNOLWIUGQIHW-UKWGHVSLSA-N
OSM-S-4,PMY3; PMY8; JRC2; AEW10; MNR57,5008278,,,"InChI=1S/C13H12FNO2/c1-8-7-12(13(16)17)9(2)15(8)11-5-3-10(14)4-6-11/h3-7H,1-2H3,(H,16,17)",UHSNGSYVRLIXCX-UHFFFAOYSA-N
OSM-S-40,ZYH8,702059,,CC1=CC=C(C)N1C2=CC=C(C(OCC)=O)C=C2,"InChI=1S/C15H17NO2/c1-4-18-15(17)13-7-9-14(10-8-13)16-11(2)5-6-12(16)3/h5-10H,4H2,1-3H3",FIQJDBIRRVQTJN-UHFFFAOYSA-N
OSM-S-41,ZYH9; AEW40,5324088,,CC1=CC=C(C)N1C2=CC=CC=N2,"InChI=1S/C11H12N2/c1-9-6-7-10(2)13(9)11-5-3-4-8-12-11/h3-8H,1-2H3",IIIQRAJKCBNLIZ-UHFFFAOYSA-N
OSM-S-42,ZYH10-2A,,,CC(N1C2=CC=C(C(F)(F)F)C=C2)=C(/C=C(C(N/3CC#N)=O)\SC3=N/C4=CC=CC=C4)C=C1C,"InChI=1S/C25H19F3N4OS/c1-16-14-18(17(2)32(16)21-10-8-19(9-11-21)25(26,27)28)15-22-23(33)31(13-12-29)24(34-22)30-20-6-4-3-5-7-20/h3-11,14-15H,13H2,1-2H3/b22-15-,30-24+",CYTCJKBOZWMCAR-DDABIZCTSA-N
OSM-S-43,ZYH10-2B,57515645,,CC(N1C2=CC=C(C(F)(F)F)C=C2)=C(/C=C3SC(N(CC#N)C4=CC=CC=C4)=NC\3=O)C=C1C,"InChI=1S/C25H19F3N4OS/c1-16-14-18(17(2)32(16)21-10-8-19(9-11-21)25(26,27)28)15-22-23(33)30-24(34-22)31(13-12-29)20-6-4-3-5-7-20/h3-11,14-15H,13H2,1-2H3/b22-15-",ZNJGLEUSFVBSML-JCMHNJIXSA-N
OSM-S-44,ZYH11,977062,,CC1=C(C=O)C=C(C)N1C2=CC=CC=N2,"InChI=1S/C12H12N2O/c1-9-7-11(8-15)10(2)14(9)12-5-3-4-6-13-12/h3-8H,1-2H3",PQMMSSQLSQUPNY-UHFFFAOYSA-N
OSM-S-45,ZYH12,57515647,,O=C(N=C(S/1)N(C(C)=O)C2=CC=CC=C2)C1=C\C3=C(C)N(C4=CC=C(C=C4)C(F)(F)F)C(C)=C3,"InChI=1S/C25H20F3N3O2S/c1-15-13-18(16(2)30(15)21-11-9-19(10-12-21)25(26,27)28)14-22-23(33)29-24(34-22)31(17(3)32)20-7-5-4-6-8-20/h4-14H,1-3H3/b22-14-",KOJDOQBSBJSPKC-HMAPJEAMSA-N
OSM-S-46,ZYH13,601797,,CC1=C(C=O)C=C(C)N1C2=CC=C(C(OCC)=O)C=C2,CC1=C(C=O)C=C(C)N1C2=CC=C(C(OCC)=O)C=C2,INHIPLWUOJQIIQ-UHFFFAOYSA-N
OSM-S-47,ZYH14; SBBH1-7,,,O=C1CS/C(N1C2=CC=CC=C2)=N\C3=CC=CC=C3,"InChI=1S/C15H12N2OS/c18-14-11-19-15(16-12-7-3-1-4-8-12)17(14)13-9-5-2-6-10-13/h1-10H,11H2/b16-15-",RAVFWIXHMXTJQU-NXVVXOECSA-N
OSM-S-48,ZYH15,1914356,,CCOC(C1=CC=C(N2C(C)=CC(/C=C(C(N/3)=O)\SC3=N/C4=CC=CC=C4)=C2C)C=C1)=O,"InChI=1S/C25H23N3O3S/c1-4-31-24(30)18-10-12-21(13-11-18)28-16(2)14-19(17(28)3)15-22-23(29)27-25(32-22)26-20-8-6-5-7-9-20/h5-15H,4H2,1-3H3,(H,26,27,29)/b22-15-",RDXBLRRUYBTFEI-JCMHNJIXSA-N
OSM-S-49,ZYH16,57515648,,O=C(N=C(S/1)N(C2=CC=CC=C2)C(C)=O)C1=C\C3=C(C)N(C4=CC=CC=C4)C(C)=C3,"InChI=1S/C24H21N3O2S/c1-16-14-19(17(2)26(16)20-10-6-4-7-11-20)15-22-23(29)25-24(30-22)27(18(3)28)21-12-8-5-9-13-21/h4-15H,1-3H3/b22-15-",HYCHBJJSXVXDSY-JCMHNJIXSA-N
OSM-S-5,TCMDC123812; CHEMBL549220; PMY10; JRC3; AEW5,2434563,MMV019247,FC1=CC=C(N2C(C)=CC(C(OCC(N)=O)=O)=C2C)C=C1,"InChI=1S/C15H15FN2O3/c1-9-7-13(15(20)21-8-14(17)19)10(2)18(9)12-5-3-11(16)4-6-12/h3-7H,8H2,1-2H3,(H2,17,19)",YSUCFIZUNLQZDX-UHFFFAOYSA-N
OSM-S-50,ZYH17; AEW79,57515649,,O=C(N=C(S/1)N(C2=CC=CC=C2)C(C)=O)C1=C\C3=C(C)N(C4=CC=C(C)C=C4)C(C)=C3,"InChI=1S/C25H23N3O2S/c1-16-10-12-22(13-11-16)27-17(2)14-20(18(27)3)15-23-24(30)26-25(31-23)28(19(4)29)21-8-6-5-7-9-21/h5-15H,1-4H3/b23-15-",RZFIAJJLMRMIBB-HAHDFKILSA-N
OSM-S-51,ZYH18,57515650,MMV689021,CC1=C(/C=C2S/C(NC\2=O)=N\C3=CC=CC=C3)C=C(C)N1C4=NC=CC=C4,"InChI=1S/C21H18N4OS/c1-14-12-16(15(2)25(14)19-10-6-7-11-22-19)13-18-20(26)24-21(27-18)23-17-8-4-3-5-9-17/h3-13H,1-2H3,(H,23,24,26)/b18-13- ",WFGBKPBKZGJAHY-AQTBWJFISA-N
OSM-S-52,ZYH19,,,CC(N1C2=CC=C(C(F)(F)F)C=C2)=CC(/C=C(C(N/3C4=CC=CC=C4)=O)\SC3=N/C5=CC=CC=C5)=C1C,"InChI=1S/C29H22F3N3OS/c1-19-17-21(20(2)34(19)25-15-13-22(14-16-25)29(30,31)32)18-26-27(36)35(24-11-7-4-8-12-24)28(37-26)33-23-9-5-3-6-10-23/h3-18H,1-2H3/b26-18-,33-28+",SACGGTIRNSKYBF-USPGIJFQSA-N
OSM-S-53,ZYH20,853886,,S=C(NC(C)=O)NC1=CC=CC=C1,"InChI=1S/C9H10N2OS/c1-7(12)10-9(13)11-8-5-3-2-4-6-8/h2-6H,1H3,(H2,10,11,12,13)",DBOBDMZHSHKLSJ-UHFFFAOYSA-N
OSM-S-54,ZYH22,,,CC(N1C2=CC=C(C(F)(F)F)C=C2)=C(/C=C(C(N/3C4CCCC4)=O)\SC3=N/C5=CC=CC=C5)C=C1C,"InChI=1S/C28H26F3N3OS/c1-18-16-20(19(2)33(18)24-14-12-21(13-15-24)28(29,30)31)17-25-26(35)34(23-10-6-7-11-23)27(36-25)32-22-8-4-3-5-9-22/h3-5,8-9,12-17,23H,6-7,10-11H2,1-2H3/b25-17-,32-27-",BDDWBUPMEFMPPN-BUWRXKIYSA-N
OSM-S-55,ZYH23,1274334,,O=C(N/C1=N/C2=CC=CC=C2)/C(S1)=C/C3=CC=CC=C3,"InChI=1S/C16H12N2OS/c19-15-14(11-12-7-3-1-4-8-12)20-16(18-15)17-13-9-5-2-6-10-13/h1-11H,(H,17,18,19)/b14-11-",AXMGOWZVQOLCDR-KAMYIIQDSA-N
OSM-S-56,JRC12,,,O=S(N(C)C1=CC=C(Cl)C=C1)(C2=NN(C(N(C)C)=O)C=N2)=O,"InChI=1S/C12H14ClN5O3S/c1-16(2)12(19)18-8-14-11(15-18)22(20,21)17(3)10-6-4-9(13)5-7-10/h4-8H,1-3H3",UHTDBMSUJGJAMB-UHFFFAOYSA-N
OSM-S-57,PMY50; SBHK523,34276657,,O=C(OCC(N)=O)C1=C(C)N(N=C1)C2=CC=CC=C2,"InChI=1S/C13H13N3O3/c1-9-11(13(18)19-8-12(14)17)7-15-16(9)10-5-3-2-4-6-10/h2-7H,8H2,1H3,(H2,14,17)",FIEILXFXISZANS-UHFFFAOYSA-N
OSM-S-58,PMY38,60208758,,FC(C=C1)=CC=C1N2C(C)=C(CNCC(N)=O)C=C2C,"InChI=1S/C15H18FN3O/c1-10-7-12(8-18-9-15(17)20)11(2)19(10)14-5-3-13(16)4-6-14/h3-7,18H,8-9H2,1-2H3,(H2,17,20)",WMIDAZMYWJQDQN-UHFFFAOYSA-N
OSM-S-59,PMY55; AEW60,60208759,,FC(C=C1)=CC=C1N2C(C)=C(C(N(C)CC(N)=O)=O)C=C2C,"InChI=1S/C16H18FN3O2/c1-10-8-14(16(22)19(3)9-15(18)21)11(2)20(10)13-6-4-12(17)5-7-13/h4-8H,9H2,1-3H3,(H2,18,21)",HJRHAMSFPNSXOR-UHFFFAOYSA-N
OSM-S-6,TCMDC123794; CHEMBL533269; PMY11,2369167,,CC(N1C2=CC=C(F)C=C2)=CC(C(OCC(NC(C3=O)=C(N(N3C4=CC=CC=C4)C)C)=O)=O)=C1C,"InChI=1S/C26H25FN4O4/c1-16-14-22(17(2)30(16)20-12-10-19(27)11-13-20)26(34)35-15-23(32)28-24-18(3)29(4)31(25(24)33)21-8-6-5-7-9-21/h5-14H,15H2,1-4H3,(H,28,32)",OFHDGHFNTKVFPI-UHFFFAOYSA-N
OSM-S-60,PMY56; AEW83,60208757,,FC(C=C1)=CC=C1N2C(C)=C(CN(C)CC(N)=O)C=C2C,"InChI=1S/C16H20FN3O/c1-11-8-13(9-19(3)10-16(18)21)12(2)20(11)15-6-4-14(17)5-7-15/h4-8H,9-10H2,1-3H3,(H2,18,21)",GTOBCWQFLJRCDF-UHFFFAOYSA-N
OSM-S-61,PMY57; PMY67,71456265,,FC(C=C1)=CC=C1N2C(C)=C(C(NC(CO)C(OC)=O)=O)C=C2C,"InChI=1S/C17H19FN2O4/c1-10-8-14(16(22)19-15(9-21)17(23)24-3)11(2)20(10)13-6-4-12(18)5-7-13/h4-8,15,21H,9H2,1-3H3,(H,19,22)/t15-/m0/s1",VIRSIBPHMPQEFV-HNNXBMFYSA-N
OSM-S-62,PMY46; PMY58,71458072,,FC(C=C1)=CC=C1N2C(C)=C(C3=NC(C(OC)=O)=CO3)C=C2C,"InChI=1S/C17H15FN2O3/c1-10-8-14(16-19-15(9-23-16)17(21)22-3)11(2)20(10)13-6-4-12(18)5-7-13/h4-9H,1-3H3",PMPFPBFKDATMLY-UHFFFAOYSA-N
OSM-S-63,PMY58,71449145,,FC(C=C1)=CC=C1N2C(C)=C(C(OC3)=NC3C(OC)=O)C=C2C,"InChI=1S/C17H17FN2O3/c1-10-8-14(16-19-15(9-23-16)17(21)22-3)11(2)20(10)13-6-4-12(18)5-7-13/h4-8,15H,9H2,1-3H3/t15-/m0/s1",RIWRQJDQRQUGKI-HNNXBMFYSA-N
OSM-S-64,,,,n1cnc3ccsc3c1N2CCOCC2,"InChI=1S/C10H11N3OS/c1-6-15-9-8(1)11-7-12-10(9)13-2-4-14-5-3-13/h1,6-7H,2-5H2",ZEWWLZDNTOZATC-UHFFFAOYSA-N
OSM-S-65,,,,Oc1ncnc2cc(I)sc12,"InChI=1S/C6H3IN2OS/c7-4-1-3-5(11-4)6(10)9-2-8-3/h1-2H,(H,8,9,10)",YNWYDHQWPQXICN-UHFFFAOYSA-N
OSM-S-66,,,,C1(CSC2=NNC=N2)=CC=CC=C1,"InChI=1S/C9H9N3S/c1-2-4-8(5-3-1)6-13-9-10-7-11-12-9/h1-5,7H,6H2,(H,10,11,12)",IQQYSQRJFHUASD-UHFFFAOYSA-N
OSM-S-67,,,,O=C(N(C)C)N(C=N1)N=C1SCC2=CC=CC=C2,"InChI=1S/C12H14N4OS/c1-15(2)12(17)16-9-13-11(14-16)18-8-10-6-4-3-5-7-10/h3-7,9H,8H2,1-2H3",CSNLCDUKFLSTLH-UHFFFAOYSA-N
OSM-S-68,AEW6; MD5,57519179,,FC(C=C1)=CC=C1N2C(C)=C(C(OC(C)(C)C(N)=O)=O)C=C2C,"InChI=1S/C17H19FN2O3/c1-10-9-14(15(21)23-17(3,4)16(19)22)11(2)20(10)13-7-5-12(18)6-8-13/h5-9H,1-4H3,(H2,19,22)",LODBHTKIGFXDSJ-UHFFFAOYSA-N
OSM-S-69,,,,O=CNc1ccsc1C(=O)OC,"InChI=1S/C7H7NO3S/c1-11-7(10)6-5(8-4-9)2-3-12-6/h2-4H,1H3,(H,8,9)",LBYBTIGBOUMNTH-UHFFFAOYSA-N
OSM-S-7,PMY12-1-A,57515634,,FC1=CC=C(N2C(C)=CC(C(N(C(NC3CCCCC3)=O)C4CCCCC4)=O)=C2C)C=C1,"InChI=1S/C26H34FN3O2/c1-18-17-24(19(2)29(18)23-15-13-20(27)14-16-23)25(31)30(22-11-7-4-8-12-22)26(32)28-21-9-5-3-6-10-21/h13-17,21-22H,3-12H2,1-2H3,(H,28,32)",RLPVOMUFRGFVJT-UHFFFAOYSA-N
OSM-S-70,,,,ClC1=C2C(C=CS2)=NC=N1,InChI=1S/C6H3ClN2S/c7-6-5-4(1-2-10-5)8-3-9-6/h1-3H,TWTODSLDHCDLDR-UHFFFAOYSA-N
OSM-S-71,,,,NC1=C2C(C=CS2)=NC=N1,"InChI=1S/C6H5N3S/c7-6-5-4(1-2-10-5)8-3-9-6/h1-3H,(H2,7,8,9)",QIZMFTNGJPBSBT-UHFFFAOYSA-N
OSM-S-72,,,,O=S(NC1=C2C(SC(C3=CC=CC=C3)=C2)=NC=N1)(C4=CC=CC=C4)=O,"InChI=1S/C18H13N3O2S2/c22-25(23,14-9-5-2-6-10-14)21-17-15-11-16(13-7-3-1-4-8-13)24-18(15)20-12-19-17/h1-12H,(H,19,20,21)",RVVYQPLURRLHLR-UHFFFAOYSA-N
OSM-S-73,,,,CC(C(S([H])(=O)=O)=C1)=CC=C1NC2=C3C(C=CS3)=NC=N2,"InChI=1S/C13H11N3O2S2/c1-8-2-3-9(6-11(8)20(17)18)16-13-12-10(4-5-19-12)14-7-15-13/h2-7,20H,1H3,(H,14,15,16)",ANUSJERLXROAHO-UHFFFAOYSA-N
OSM-S-74,,,,COC(C=C1)=CC=C1C2=CC3=NC=NC(NCC4=CC=C(S(NC)(=O)=O)S4)=C3S2,"InChI=1S/C19H18N4O3S3/c1-20-29(24,25)17-8-7-14(27-17)10-21-19-18-15(22-11-23-19)9-16(28-18)12-3-5-13(26-2)6-4-12/h3-9,11,20H,10H2,1-2H3,(H,21,22,23)",YJIZHXKJHLSNJU-UHFFFAOYSA-N
OSM-S-75,,,,O=S(N(CC1)CCC1NC2=C3C(C=CS3)=NC=N2)(C4=CC=C(OC)C=C4)=O,"InChI=1S/C18H20N4O3S2/c1-25-14-2-4-15(5-3-14)27(23,24)22-9-6-13(7-10-22)21-18-17-16(8-11-26-17)19-12-20-18/h2-5,8,11-13H,6-7,9-10H2,1H3,(H,19,20,21)",AIOKEIOAHBEYFV-UHFFFAOYSA-N
OSM-S-76,,,,C[C@@H](C1=CC=CC(S(N)(=O)=O)=C1)NC2=C3C(C=CS3)=NC=N2,"InChI=1S/C14H14N4O2S2/c1-9(10-3-2-4-11(7-10)22(15,19)20)18-14-13-12(5-6-21-13)16-8-17-14/h2-9H,1H3,(H2,15,19,20)(H,16,17,18)/t9-/m0/s1",BTENSVAFLZSYCS-VIFPVBQESA-N
OSM-S-77,,,,O=S(C1=C(OCC)C=CC(NC2=C3C(C=CS3)=NC=N2)=C1)(N(C)C)=O,"InChI=1S/C16H18N4O3S2/c1-4-23-13-6-5-11(9-14(13)25(21,22)20(2)3)19-16-15-12(7-8-24-15)17-10-18-16/h5-10H,4H2,1-3H3,(H,17,18,19)",AFXZPMPMWGUDRD-UHFFFAOYSA-N
OSM-S-78,,,,NS(C(C=C1)=CC=C1CNC2=C3C(C=CC=C3)=NC(C4=CSC=C4)=N2)(=O)=O,"InChI=1S/C19H16N4O2S2/c20-27(24,25)15-7-5-13(6-8-15)11-21-19-16-3-1-2-4-17(16)22-18(23-19)14-9-10-26-12-14/h1-10,12H,11H2,(H2,20,24,25)(H,21,22,23)",XAYZAAZFNXFGQQ-UHFFFAOYSA-N
OSM-S-79,,,,NS(C1=CC=CC(CNC2=C3C(C=CS3)=NC=N2)=C1)(=O)=O,"InChI=1S/C13H12N4O2S2/c14-21(18,19)10-3-1-2-9(6-10)7-15-13-12-11(4-5-20-12)16-8-17-13/h1-6,8H,7H2,(H2,14,18,19)(H,15,16,17)",MONLYHVADJHNFV-UHFFFAOYSA-N
OSM-S-8,PMY12-5; AEW62,24407955,,FC1=CC=C(N2C(C)=CC(C(NC3=C(C)N(C)N(C4=CC=CC=C4)C3=O)=O)=C2C)C=C1,"InChI=1S/C24H23FN4O2/c1-15-14-21(16(2)28(15)19-12-10-18(25)11-13-19)23(30)26-22-17(3)27(4)29(24(22)31)20-8-6-5-7-9-20/h5-14H,1-4H3,(H,26,30)",NVKLEDPUHCCJRE-UHFFFAOYSA-N
OSM-S-80,,,,COC(C=C1)=CC=C1C2=CC3=NC=NC(OC4=CC=C(S(N5CCOCC5)(=O)=O)C=C4)=C3S2,"InChI=1S/C23H21N3O5S2/c1-29-17-4-2-16(3-5-17)21-14-20-22(32-21)23(25-15-24-20)31-18-6-8-19(9-7-18)33(27,28)26-10-12-30-13-11-26/h2-9,14-15H,10-13H2,1H3",YDWOOXMJPIUVKR-UHFFFAOYSA-N
OSM-S-81,,31785230,,CC1=CC(=C(C)[N]1C2=CC=CC=C2)C(=NCC(N(C)C)=O)O,"InChI=1S/C17H21N3O2/c1-12-10-15(17(22)18-11-16(21)19(3)4)13(2)20(12)14-8-6-5-7-9-14/h5-10H,11H2,1-4H3,(H,18,22)",DDLCZYHXOGBCGL-UHFFFAOYSA-N
OSM-S-82,AEW18,2466757,,CC1=CC(=C(C)[N]1C2=CC=C(C=C2)F)C(=O)OCC(=NC)O,"InChI=1S/C16H17FN2O3/c1-10-8-14(16(21)22-9-15(20)18-3)11(2)19(10)13-6-4-12(17)5-7-13/h4-8H,9H2,1-3H3,(H,18,20)",FXSYKCLPBZPYNU-UHFFFAOYSA-N
OSM-S-83,,40231419,,CC1=CC(=C(C)[N]1C2=CC=CC=C2)C(N3CCN=C(C3)O)=O,"InChI=1S/C17H19N3O2/c1-12-10-15(17(22)19-9-8-18-16(21)11-19)13(2)20(12)14-6-4-3-5-7-14/h3-7,10H,8-9,11H2,1-2H3,(H,18,21)",MQCAVDAWVKBHML-UHFFFAOYSA-N
OSM-S-84,,53514054,,CC1=CC(=C(C)[N]1C2=CC=C(C=C2)Br)C(N(C)CC(=NC)O)=O,"InChI=1S/C17H20BrN3O2/c1-11-9-15(17(23)20(4)10-16(22)19-3)12(2)21(11)14-7-5-13(18)6-8-14/h5-9H,10H2,1-4H3,(H,19,22)",QCKWSPHQOGLUNM-UHFFFAOYSA-N
OSM-S-85,,2402326,,CC1=CC(=C(C)[N]1C2=CC=CC=C2)C3=NN=C(O3)SCC(=NC4=CC(=CC=C4)OC)O,"InChI=1S/C23H22N4O3S/c1-15-12-20(16(2)27(15)18-9-5-4-6-10-18)22-25-26-23(30-22)31-14-21(28)24-17-8-7-11-19(13-17)29-3/h4-13H,14H2,1-3H3,(H,24,28)",YMUQXVXRPYOASK-UHFFFAOYSA-N
OSM-S-86,,36170225,,CCN(CC(=NC1=C(C=CC=C1F)F)O)C(C2=C(C)[N](C(=C2)C)C3=CC=C(C=C3)F)=O,"InChI=1S/C23H22F3N3O2/c1-4-28(13-21(30)27-22-19(25)6-5-7-20(22)26)23(31)18-12-14(2)29(15(18)3)17-10-8-16(24)9-11-17/h5-12H,4,13H2,1-3H3,(H,27,30)",BLFMPEAPTFWYHH-UHFFFAOYSA-N
OSM-S-87,,47014811,,CC1=CC(=CC=C1)[N]2C(=CC(=C2C)C(N(C)CC(N=C3C=C(C)ON3)=O)=O)C,"InChI=1S/C21H24N4O3/c1-13-7-6-8-17(9-13)25-14(2)10-18(16(25)4)21(27)24(5)12-20(26)22-19-11-15(3)28-23-19/h6-11H,12H2,1-5H3,(H,22,23,26)",QMAXUZVAVZMAMU-UHFFFAOYSA-N
OSM-S-88,,38056956,,CC1=CC(=C(C)[N]1C2=CC=C(C=C2)Cl)CNC3CCN(CC3)CC(=NC)O,"InChI=1S/C21H29ClN4O/c1-15-12-17(16(2)26(15)20-6-4-18(22)5-7-20)13-24-19-8-10-25(11-9-19)14-21(27)23-3/h4-7,12,19,24H,8-11,13-14H2,1-3H3,(H,23,27)",HQRQGAAJRGIERF-UHFFFAOYSA-N
OSM-S-89,,56716039,,CCN=C([C@@H]1C[C@H](CN1CC2=C(C)[N](C(=C2)C)C3=CC=CC=C3Cl)N)O,"InChI=1S/C20H27ClN4O/c1-4-23-20(26)19-10-16(22)12-24(19)11-15-9-13(2)25(14(15)3)18-8-6-5-7-17(18)21/h5-9,16,19H,4,10-12,22H2,1-3H3,(H,23,26)/t16-,19+/m1/s1",ZUKQHVDBUYFYRN-APWZRJJASA-N
OSM-S-9,PMY14; PMY35,57515635,,FC1=CC=C(C=C1)N2C(C)=CC(/C=C(SC(N(C3=CC=CC=C3)C(C)=O)=N4)/C4=O)=C2C,"InChI=1S/C24H20FN3O2S/c1-15-13-18(16(2)27(15)21-11-9-19(25)10-12-21)14-22-23(30)26-24(31-22)28(17(3)29)20-7-5-4-6-8-20/h4-14H,1-3H3/b22-14-",WFLINPFRLHPFGO-HMAPJEAMSA-N
OSM-S-90,,20888173,,CCC1=CC=C(C=C1)[N]2C(=CC(=C2C)CN3CCC(CC3)C(=O)O)C,"InChI=1S/C21H28N2O2/c1-4-17-5-7-20(8-6-17)23-15(2)13-19(16(23)3)14-22-11-9-18(10-12-22)21(24)25/h5-8,13,18H,4,9-12,14H2,1-3H3,(H,24,25)",UCFMYMVVPFGNQX-UHFFFAOYSA-N
OSM-S-91,,2458246,,CC1=CC(=C(C)[N]1C2=CC=C(C=C2)F)C(=O)OCC(N(C)C)=O,"InChI=1S/C17H19FN2O3/c1-11-9-15(17(22)23-10-16(21)19(3)4)12(2)20(11)14-7-5-13(18)6-8-14/h5-9H,10H2,1-4H3",UBASAKWAWFZWGG-UHFFFAOYSA-N
OSM-S-92,PMY66,57519188,,FC(C=C1)=CC=C1N2C=C(C(OCC(N)=O)=O)C=N2,"InChI=1S/C12H10FN3O3/c13-9-1-3-10(4-2-9)16-6-8(5-15-16)12(18)19-7-11(14)17/h1-6H,7H2,(H2,14,17)",DNDQGXCXOJEWIK-UHFFFAOYSA-N
OSM-S-93,AEW16,47101511,,FC(C=C1)=CC=C1N2C(C)=C(C(N(C)C)=O)C=C2C,"InChI=1S/C15H17FN2O/c1-10-9-14(15(19)17(3)4)11(2)18(10)13-7-5-12(16)6-8-13/h5-9H,1-4H3",ODHQTLKXAQYLEM-UHFFFAOYSA-N
OSM-S-94,AEW12,71456266,,FC(C=C1)=CC=C1N2C(C)=C(CN3CCCC3)C=C2C,"InChI=1S/C17H21FN2/c1-13-11-15(12-19-9-3-4-10-19)14(2)20(13)17-7-5-16(18)6-8-17/h5-8,11H,3-4,9-10,12H2,1-2H3",LPRVJXBPLZQOJQ-UHFFFAOYSA-N
OSM-S-95,AEW9,71461677,,FC(C=C1)=CC=C1N2C(C)=CC(CNC3CCN(CC4=CC=CC=C4)CC3)=C2C,"InChI=1S/C25H30FN3/c1-19-16-22(20(2)29(19)25-10-8-23(26)9-11-25)17-27-24-12-14-28(15-13-24)18-21-6-4-3-5-7-21/h3-11,16,24,27H,12-15,17-18H2,1-2H3",OBFANJWJASKEMA-UHFFFAOYSA-N
OSM-S-96,MJT6,71458075,,FC1=CC=C(N2N=CC(C3=NC(C(OC)=O)=CO3)=C2C)C=C1,"InChI=1S/C15H12FN3O3/c1-9-12(14-18-13(8-22-14)15(20)21-2)7-17-19(9)11-5-3-10(16)4-6-11/h3-8H,1-2H3",MXBGFPWDTSYZMH-UHFFFAOYSA-N
OSM-S-97,MNR51,71459965,,FC1=CC=C(N2C(C)=CC(C(CCC(O)=O)=O)=C2C)C=C1,"InChI=1S/C16H16FNO3/c1-10-9-14(15(19)7-8-16(20)21)11(2)18(10)13-5-3-12(17)4-6-13/h3-6,9H,7-8H2,1-2H3,(H,20,21)",GNRWSIUEZUQINP-UHFFFAOYSA-N
OSM-S-98,MNR52,71461678,,FC1=CC=C(N2C(C)=CC(C(CCC(N(C)C)=O)=O)=C2C)C=C1,"InChI=1S/C18H21FN2O2/c1-12-11-16(17(22)9-10-18(23)20(3)4)13(2)21(12)15-7-5-14(19)6-8-15/h5-8,11H,9-10H2,1-4H3",JSMYECUHSRLQOF-UHFFFAOYSA-N
OSM-S-99,AEW71; MD17,71454531,,FC1=CC=C(N2C(C)=CC(C(OC(C)C(OCC)=O)=O)=C2C)C=C1,"InChI=1S/C18H20FNO4/c1-5-23-17(21)13(4)24-18(22)16-10-11(2)20(12(16)3)15-8-6-14(19)7-9-15/h6-10,13H,5H2,1-4H3",HHNXZDCXTDKCEN-UHFFFAOYSA-N
OSM-W-1,CCS-3-2,,,ClC(C=C1)=CC=C1C2=NN=C3C=NC=C(N=[N+]=[N-])N32,InChI=1S/C11H6ClN7/c12-8-3-1-7(2-4-8)11-17-15-9-5-14-6-10(16-18-13)19(9)11/h1-6H,PXBKPHRFNKPFAH-UHFFFAOYSA-N
OSM-W-2,CCS-4-1,,,NC1=CN=CC2=NN=C(C3=CC=C(Cl)C=C3)N21,"InChI=1S/C11H8ClN5/c12-8-3-1-7(2-4-8)11-16-15-10-6-14-5-9(13)17(10)11/h1-6H,13H2",XCGFGSSHPVTERR-UHFFFAOYSA-N
OSM-W-3,KL-8-1,,,FC(C=C1)=CC=C1CCOC2=CN=CC3=NN=C(C4=CC=C(S(C)(=O)=O)C=C4)N32,"InChI=1S/C20H17FN4O3S/c1-29(26,27)17-8-4-15(5-9-17)20-24-23-18-12-22-13-19(25(18)20)28-11-10-14-2-6-16(21)7-3-14/h2-9,12-13H,10-11H2,1H3",HQWGUOKCAHGSFB-UHFFFAOYSA-N
OSM-W-4,PD-5-3,,,[H]N(C1=NN=C(C2=CC=CC=C2)S1)C3=NC(OCCC4=CC=C(F)C=C4)=CN=C3,"InChI=1S/C20H16FN5OS/c21-16-8-6-14(7-9-16)10-11-27-18-13-22-12-17(23-18)24-20-26-25-19(28-20)15-4-2-1-3-5-15/h1-9,12-13H,10-11H2,(H,23,24,26)",ATSWIRSPSBQXBQ-UHFFFAOYSA-N
,JS 10-1,,,ClC1=CC=CC(N/N=C/C2=CC=C(C#N)C=C2)=N1,"InChI=1S/C13H9ClN4/c14-12-2-1-3-13(17-12)18-16-9-11-6-4-10(8-15)5-7-11/h1-7,9H,(H,17,18)/b16-9+",WOEMAXIGZYIWII-CXUHLZMHSA-N
,JS 11-1,,,ClC1=CC=CC2=NN=C(C3=CC=C(C#N)C=C3)N21,InChI=1S/C13H7ClN4/c14-11-2-1-3-12-16-17-13(18(11)12)10-6-4-9(8-15)5-7-10/h1-7H,ROKQDRVNUIOPKS-UHFFFAOYSA-N
,JS 12-1,,,ClC1=CC=CC(C(NC2=CC(C(F)(F)F)=NC=C2)=O)=N1,"InChI=1S/C12H7ClF3N3O/c13-10-3-1-2-8(19-10)11(20)18-7-4-5-17-9(6-7)12(14,15)16/h1-6H,(H,17,18,20)",VNCOWSRRKZJWES-UHFFFAOYSA-N
,JS 15-1,,,O=C(NC1=CC=NC(C(F)(F)F)=C1)C2=CC=CC(N/N=C/C3=CC=C(C#N)C=C3)=N2,"InChI=1S/C20H13F3N6O/c21-20(22,23)17-10-15(8-9-25-17)27-19(30)16-2-1-3-18(28-16)29-26-12-14-6-4-13(11-24)5-7-14/h1-10,12H,(H,28,29)(H,25,27,30)/b26-12+",HITQOKWUFWDBPF-RPPGKUMJSA-N
,JS 16-1,,,O=C(NC1=CC=NC(C(F)(F)F)=C1)C2=CC=CC3=NN=C(C4=CC=C(C#N)C=C4)N32,"InChI=1S/C20H11F3N6O/c21-20(22,23)16-10-14(8-9-25-16)26-19(30)15-2-1-3-17-27-28-18(29(15)17)13-6-4-12(11-24)5-7-13/h1-10H,(H,25,26,30)",PGPJMFWOQCDCCV-UHFFFAOYSA-N
,JS 19-1,,,ClC(C=CC=C1)=C1CCOC2=CC=CC3=NN=C(C4=CC=C(C#N)C=C4)N32,"InChI=1S/C21H15ClN4O/c22-18-5-2-1-4-16(18)12-13-27-20-7-3-6-19-24-25-21(26(19)20)17-10-8-15(14-23)9-11-17/h1-11H,12-13H2",APTFJFHOJWNXBX-UHFFFAOYSA-N
,JS 20-1,,,N#CC(C=C1)=CC=C1C2=NN=C3C=CC=C(OCCC4=CC=CC=C4)N32,"InChI=1S/C21H16N4O/c22-15-17-9-11-18(12-10-17)21-24-23-19-7-4-8-20(25(19)21)26-14-13-16-5-2-1-3-6-16/h1-12H,13-14H2",PLXIJFIDAXQTSX-UHFFFAOYSA-N
,JS 21-1,,,FC(C(F)=C1)=CC=C1CCOC2=CC=CC3=NN=C(C4=CC=C(C#N)C=C4)N32,"InChI=1S/C21H14F2N4O/c22-17-9-6-14(12-18(17)23)10-11-28-20-3-1-2-19-25-26-21(27(19)20)16-7-4-15(13-24)5-8-16/h1-9,12H,10-11H2",JCMCKOQZSFBPIN-UHFFFAOYSA-N
,INHERITED,,MMV670763,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC[C@H](NC)C4=CC(F)=C(F)C=C4)N32,"InChI=1S/C21H17F4N5O2/c1-26-17(13-4-7-15(22)16(23)8-13)11-31-19-10-27-9-18-28-29-20(30(18)19)12-2-5-14(6-3-12)32-21(24)25/h2-10,17,21,26H,11H2,1H3/t17-/m0/s1",YFUIAROYVNJDHR-KRWDZBQOSA-N
,INHERITED,,MMV671933,FC(F)OC1=CC=C(C=C1)C2=NN=C3N2C(O[C@H]4CN(C5CC5)[C@H]4C6=CC=C(F)C(F)=C6)=CN=C3,"InChI=1S/C24H19F4N5O2/c25-17-8-3-14(9-18(17)26)22-19(12-32(22)15-4-5-15)35-21-11-29-10-20-30-31-23(33(20)21)13-1-6-16(7-2-13)34-24(27)28/h1-3,6-11,15,19,22,24H,4-5,12H2/t19-,22-/m0/s1",WHJQMHNZFFDXED-UGKGYDQZSA-N
,INHERITED,,MMV671934,FC(F)OC1=CC=C(C=C1)C2=NN=C3N2C(O[C@H]4C(N(C5CC5)[C@H]4C6=CC=C(F)C(F)=C6)=O)=CN=C3,"InChI=1S/C24H17F4N5O3/c25-16-8-3-13(9-17(16)26)20-21(23(34)32(20)14-4-5-14)36-19-11-29-10-18-30-31-22(33(18)19)12-1-6-15(7-2-12)35-24(27)28/h1-3,6-11,14,20-21,24H,4-5H2/t20-,21+/m0/s1",QKWQBQSIFWCCDO-LEWJYISDSA-N
,INHERITED,,MMV672689,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(O[C@H]4CN(C5CC5)[C@@H]4C6=CC(F)=C(F)C=C6)N32,"InChI=1S/C24H19F4N5O2/c25-17-8-3-14(9-18(17)26)22-19(12-32(22)15-4-5-15)35-21-11-29-10-20-30-31-23(33(20)21)13-1-6-16(7-2-13)34-24(27)28/h1-3,6-11,15,19,22,24H,4-5,12H2/t19-,22+/m0/s1",WHJQMHNZFFDXED-SIKLNZKXSA-N
,INHERITED,,MMV672619,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC(O[C@@H]4C(N(C5CC5)[C@@H]4C6=CC=C(F)C(F)=C6)=O)=CN32,"InChI=1S/C24H17F4N5O3/c25-16-8-3-13(9-17(16)26)20-21(23(34)33(20)14-4-5-14)36-19-11-32-18(10-29-19)30-31-22(32)12-1-6-15(7-2-12)35-24(27)28/h1-3,6-11,14,20-21,24H,4-5H2/t20-,21+/m1/s1",NWJYDZNWZUIDSH-RTWAWAEBSA-N
,INHERITED,,MMV672727,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(C)(F)C4=CC(F)=C(F)C=C4)N32,"InChI=1S/C21H15F5N4O2/c1-21(26,13-4-7-15(22)16(23)8-13)11-31-18-10-27-9-17-28-29-19(30(17)18)12-2-5-14(6-3-12)32-20(24)25/h2-10,20H,11H2,1H3",MHMDPQOWBHVFHN-UHFFFAOYSA-N
,INHERITED,,MMV672723,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(C)(O)C4=CC(F)=C(F)C=C4)N32,"InChI=1S/C21H16F4N4O3/c1-21(30,13-4-7-15(22)16(23)8-13)11-31-18-10-26-9-17-27-28-19(29(17)18)12-2-5-14(6-3-12)32-20(24)25/h2-10,20,30H,11H2,1H3",NBSLUXDUMZFLCA-UHFFFAOYSA-N
,INHERITED,,MMV672936,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(F)C4=CC=C(F)C(F)=C4)N32,"InChI=1S/C20H13F5N4O2/c21-14-6-3-12(7-15(14)22)16(23)10-30-18-9-26-8-17-27-28-19(29(17)18)11-1-4-13(5-2-11)31-20(24)25/h1-9,16,20H,10H2",LWSXCRQHVHDFGX-UHFFFAOYSA-N
,INHERITED,,MMV669025,FC(F)OC(C=C1)=CC=C1C2=NN=C3C(NC=C(OCCC4=CC(F)=C(F)C=C4)N32)=O,"InChI=1S/C20H14F4N4O3/c21-14-6-1-11(9-15(14)22)7-8-30-16-10-25-19(29)18-27-26-17(28(16)18)12-2-4-13(5-3-12)31-20(23)24/h1-6,9-10,20H,7-8H2,(H,25,29)",ZXMYJCVYBZFJIJ-UHFFFAOYSA-N
,INHERITED,,MMV669544,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(CNC(C4=CC(Cl)=CC=C4)=O)N32,"InChI=1S/C20H14ClF2N5O2/c21-14-3-1-2-13(8-14)19(29)25-10-15-9-24-11-17-26-27-18(28(15)17)12-4-6-16(7-5-12)30-20(22)23/h1-9,11,20H,10H2,(H,25,29)",MBAFXUKPARBNKZ-UHFFFAOYSA-N
,INHERITED,,MMV672626,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC(C(F)(F)F)C4(CC4)C5=CC(F)=C(F)C=C5)N32,"InChI=1S/C23H15F7N4O2/c24-15-6-3-13(9-16(15)25)22(7-8-22)20(23(28,29)30)36-18-11-31-10-17-32-33-19(34(17)18)12-1-4-14(5-2-12)35-21(26)27/h1-6,9-11,20-21H,7-8H2",LNNLHAVRECQEJD-UHFFFAOYSA-N
,INHERITED,,MMV672992,N#CC(C=C1)=CC=C1C2=NN=C3C=CC(NCCC4=CC=CN=C4)=NN32,"InChI=1S/C19H15N7/c20-12-14-3-5-16(6-4-14)19-24-23-18-8-7-17(25-26(18)19)22-11-9-15-2-1-10-21-13-15/h1-8,10,13H,9,11H2,(H,22,25)",SGPGHQWZSGYQTQ-UHFFFAOYSA-N
,INHERITED,,MMV672942,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=CC(NCCC4=CC=C(F)C=C4)=NN32,"InChI=1S/C20H16F3N5O/c21-15-5-1-13(2-6-15)11-12-24-17-9-10-18-25-26-19(28(18)27-17)14-3-7-16(8-4-14)29-20(22)23/h1-10,20H,11-12H2,(H,24,27)",POFIVTHXYFQSHM-UHFFFAOYSA-N
,INHERITED,,MMV672939,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=CC(OCCC4=CC=C(F)C(F)=C4)=NN32,"InChI=1S/C20H14F4N4O2/c21-15-6-1-12(11-16(15)22)9-10-29-18-8-7-17-25-26-19(28(17)27-18)13-2-4-14(5-3-13)30-20(23)24/h1-8,11,20H,9-10H2",POGWIRSWBGSGTG-UHFFFAOYSA-N
,INHERITED,,MMV669304,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(CCCC4=CC=CC=C4)N32,"InChI=1S/C21H18F2N4O/c22-21(23)28-18-11-9-16(10-12-18)20-26-25-19-14-24-13-17(27(19)20)8-4-7-15-5-2-1-3-6-15/h1-3,5-6,9-14,21H,4,7-8H2",FVXHZUZPPRAVJU-UHFFFAOYSA-N
,INHERITED,,MMV669310,FC(F)OC(C=C1)=CC=C1C2=NN=C3CNCC(CCCC4=CC=CC=C4)N32,"InChI=1S/C21H22F2N4O/c22-21(23)28-18-11-9-16(10-12-18)20-26-25-19-14-24-13-17(27(19)20)8-4-7-15-5-2-1-3-6-15/h1-3,5-6,9-12,17,21,24H,4,7-8,13-14H2",XZRWDQJUYUQTBS-UHFFFAOYSA-N
,INHERITED,,MMV669305,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(CCN4CCOCC4)N32,"InChI=1S/C18H19F2N5O2/c19-18(20)27-15-3-1-13(2-4-15)17-23-22-16-12-21-11-14(25(16)17)5-6-24-7-9-26-10-8-24/h1-4,11-12,18H,5-10H2",ABRPYUCAABEXTH-UHFFFAOYSA-N
,INHERITED,,MMV668956,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4CN(C5=CC(F)=C(F)C=C5)C4)N32,"InChI=1S/C21H15F4N5O2/c22-16-6-3-13(7-17(16)23)29-10-15(11-29)31-19-9-26-8-18-27-28-20(30(18)19)12-1-4-14(5-2-12)32-21(24)25/h1-9,15,21H,10-11H2",FFDOLPKXJUAFAH-UHFFFAOYSA-N
,INHERITED,,MMV670438,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC4(COC4)C5=CC(F)=C(F)C=C5)N32,"InChI=1S/C22H16F4N4O3/c23-16-6-3-14(7-17(16)24)22(10-31-11-22)12-32-19-9-27-8-18-28-29-20(30(18)19)13-1-4-15(5-2-13)33-21(25)26/h1-9,21H,10-12H2",OJUVKHOEBUOJFA-UHFFFAOYSA-N
,INHERITED,,MMV672990,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC(NC(CC4=CC(Cl)=CC=C4)=O)=CN32,"InChI=1S/C20H14ClF2N5O2/c21-14-3-1-2-12(8-14)9-18(29)25-16-11-28-17(10-24-16)26-27-19(28)13-4-6-15(7-5-13)30-20(22)23/h1-8,10-11,20H,9H2,(H,25,29)",WVWDZRMVJLISBP-UHFFFAOYSA-N
,INHERITED,,MMV671655,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC(NC4=CC(F)=C(F)C=C4)=CN32,"InChI=1S/C18H11F4N5O/c19-13-6-3-11(7-14(13)20)24-15-9-27-16(8-23-15)25-26-17(27)10-1-4-12(5-2-10)28-18(21)22/h1-9,18,24H",JCBPTHDURYGLBR-UHFFFAOYSA-N
,INHERITED,,MMV670949,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC(NCC4=CC(F)=C(F)C=C4)=CN32,"InChI=1S/C19H13F4N5O/c20-14-6-1-11(7-15(14)21)8-24-16-10-28-17(9-25-16)26-27-18(28)12-2-4-13(5-3-12)29-19(22)23/h1-7,9-10,19,24H,8H2",HQILIKFLQAQYLT-UHFFFAOYSA-N
,INHERITED,,MMV671927,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC(NCCC4=CC=C(F)C=C4)=CN32,"InChI=1S/C20H16F3N5O/c21-15-5-1-13(2-6-15)9-10-24-17-12-28-18(11-25-17)26-27-19(28)14-3-7-16(8-4-14)29-20(22)23/h1-8,11-12,20,24H,9-10H2",GVXYAEXVJYZTBB-UHFFFAOYSA-N
,INHERITED,,MMV671926,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC(OC4=CC(F)=C(F)C=C4)=CN32,"InChI=1S/C18H10F4N4O2/c19-13-6-5-12(7-14(13)20)27-16-9-26-15(8-23-16)24-25-17(26)10-1-3-11(4-2-10)28-18(21)22/h1-9,18H",FIPLRRUMZPXECW-UHFFFAOYSA-N
,INHERITED,,MMV670946,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC(OCC4=CC(F)=C(F)C=C4)=CN32,"InChI=1S/C19H12F4N4O2/c20-14-6-1-11(7-15(14)21)10-28-17-9-27-16(8-24-17)25-26-18(27)12-2-4-13(5-3-12)29-19(22)23/h1-9,19H,10H2",PPYIQNQWTQZDBZ-UHFFFAOYSA-N
,INHERITED,,MMV670945,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC(OCCC4=CC=C(F)C(F)=C4)=CN32,"InChI=1S/C20H14F4N4O2/c21-15-6-1-12(9-16(15)22)7-8-29-18-11-28-17(10-25-18)26-27-19(28)13-2-4-14(5-3-13)30-20(23)24/h1-6,9-11,20H,7-8H2",PHGWNHSKOAAQGR-UHFFFAOYSA-N
,INHERITED,,MMV668822,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=[N+]([O-])C=C(OCCC4=CC(F)=C(F)C=C4)N32,"InChI=1S/C20H14F4N4O3/c21-15-6-1-12(9-16(15)22)7-8-30-18-11-27(29)10-17-25-26-19(28(17)18)13-2-4-14(5-3-13)31-20(23)24/h1-6,9-11,20H,7-8H2",CUNPWKYJVCNHNZ-UHFFFAOYSA-N
,INHERITED,,MMV671677,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NCC4=C(Cl)C(C(F)(F)F)=CC=C4)=O)N32,"InChI=1S/C21H13ClF5N5O2/c22-17-12(2-1-3-14(17)21(25,26)27)8-29-19(33)15-9-28-10-16-30-31-18(32(15)16)11-4-6-13(7-5-11)34-20(23)24/h1-7,9-10,20H,8H2,(H,29,33)",YLYCMIJACQNNRW-UHFFFAOYSA-N
,INHERITED,,MMV671676,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NCC4=C(Cl)C=CC(Cl)=C4)=O)N32,"InChI=1S/C20H13Cl2F2N5O2/c21-13-3-6-15(22)12(7-13)8-26-19(30)16-9-25-10-17-27-28-18(29(16)17)11-1-4-14(5-2-11)31-20(23)24/h1-7,9-10,20H,8H2,(H,26,30)",CPOFXXWYWLQUAV-UHFFFAOYSA-N
,INHERITED,,MMV669543,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NCC4=CC(F)=C(F)C=C4)=O)N32,"InChI=1S/C20H13F4N5O2/c21-14-6-1-11(7-15(14)22)8-26-19(30)16-9-25-10-17-27-28-18(29(16)17)12-2-4-13(5-3-12)31-20(23)24/h1-7,9-10,20H,8H2,(H,26,30)",WYPSTIZOCCDRJV-UHFFFAOYSA-N
,INHERITED,,MMV672618,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=C(N(C)C=C5)C5=C4)N32,"InChI=1S/C21H15F2N5O2/c1-27-9-8-14-10-16(6-7-17(14)27)29-19-12-24-11-18-25-26-20(28(18)19)13-2-4-15(5-3-13)30-21(22)23/h2-12,21H,1H3",PIGKBNOMLGKKHV-UHFFFAOYSA-N
,INHERITED,,MMV668962,FC(F)OC(C=C1)=CC=C1C2=NN=C3CN(C(CN)=O)CCN32,"InChI=1S/C14H15F2N5O2/c15-14(16)23-10-3-1-9(2-4-10)13-19-18-11-8-20(12(22)7-17)5-6-21(11)13/h1-4,14H,5-8,17H2",OUDHTFLYUDWELS-UHFFFAOYSA-N
,INHERITED,,MMV669541,FC(F)OC(C=C1)=CC=C1C2=NN=C3C(C)=NC=C(OCCC4=CC(F)=C(F)C=C4)N32,"InChI=1S/C21H16F4N4O2/c1-12-19-27-28-20(14-3-5-15(6-4-14)31-21(24)25)29(19)18(11-26-12)30-9-8-13-2-7-16(22)17(23)10-13/h2-7,10-11,21H,8-9H2,1H3",ZOSZOZWECBRIDQ-UHFFFAOYSA-N
,INHERITED,,MMV668823,FC(F)OC(C=C1)=CC=C1C2=NN=C3C(Cl)=NC=C(OCCC4=CC(F)=C(F)C=C4)N32,"InChI=1S/C20H13ClF4N4O2/c21-17-19-28-27-18(12-2-4-13(5-3-12)31-20(24)25)29(19)16(10-26-17)30-8-7-11-1-6-14(22)15(23)9-11/h1-6,9-10,20H,7-8H2",FOQQXRIKYKUBGB-UHFFFAOYSA-N
,INHERITED,,MMV669311,FC(F)OC(C=C1)=CC=C1C2=NN=C3C(N)=NC=C(OCCC4=CC(F)=C(F)C=C4)N32,"InChI=1S/C20H15F4N5O2/c21-14-6-1-11(9-15(14)22)7-8-30-16-10-26-17(25)19-28-27-18(29(16)19)12-2-4-13(5-3-12)31-20(23)24/h1-6,9-10,20H,7-8H2,(H2,25,26)",XAQYLJFKZCILRM-UHFFFAOYSA-N
,INHERITED,,MMV669102,FC(F)OC(C=C1)=CC=C1C2=NN=C3C(N(CC)CC)=NC=C(OCCC4=CC(F)=C(F)C=C4)N32,"InChI=1S/C24H23F4N5O2/c1-3-32(4-2)22-23-31-30-21(16-6-8-17(9-7-16)35-24(27)28)33(23)20(14-29-22)34-12-11-15-5-10-18(25)19(26)13-15/h5-10,13-14,24H,3-4,11-12H2,1-2H3",XEJMUSAAKCRDEX-UHFFFAOYSA-N
,INHERITED,,MMV668960,FC(F)OC(C=C1)=CC=C1C2=NN=C3CNCCN32,"InChI=1S/C12H12F2N4O/c13-12(14)19-9-3-1-8(2-4-9)11-17-16-10-7-15-5-6-18(10)11/h1-4,12,15H,5-7H2",QETDXPHMFLDYRQ-UHFFFAOYSA-N
,INHERITED,,MMV669105,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(N(C)CC4=CC(Cl)=CC=C4)=O)N32,"InChI=1S/C21H16ClF2N5O2/c1-28(12-13-3-2-4-15(22)9-13)20(30)17-10-25-11-18-26-27-19(29(17)18)14-5-7-16(8-6-14)31-21(23)24/h2-11,21H,12H2,1H3",UIQMDRDWZSXMKZ-UHFFFAOYSA-N
,,,MMV669021,c1ncc2n(c1C(=O)N[C@H](c1ccccc1)C)c(nn2)c1ccc(cc1)OC(F)F,"InChI=1S/C21H17F2N5O2/c1-13(14-5-3-2-4-6-14)25-20(29)17-11-24-12-18-26-27-19(28(17)18)15-7-9-16(10-8-15)30-21(22)23/h2-13,21H,1H3,(H,25,29)/t13-/m0/s1 AuxInfo=1/1/N:17,14,13,15,12,16,22,26,23,25,1,3,10,11,21,24,6,4,18,7,28,29,30,2,9,20,19,5,8,27/E:(3,4)(5,6)(7,8)(9,10)(22,23)/it:im/rA:30CNCCNCCONC.eCCCCCCCCNNCCCCCCOCFF/rB:s1;d2;s3;s4;d1s5;s6;d7;s7;s9;s10;d11;s12;d13;s14;s11d15;P10;s5;d18;d4s19;s18;d21;s22;d23;s24;s21d25;s24;s27;s28;s28;/rC:6.2576,3.6128,0;6.2576,2.0728,0;4.9239,1.3028,0;3.5902,2.0728,0;3.5902,3.6128,0;4.9239,4.3828,0;4.9239,5.9228,0;3.5902,6.6928,0;6.2576,6.6928,0;6.2576,8.2328,0;7.5913,9.0028,0;7.5913,10.5428,0;8.925,11.3128,0;10.2586,10.5428,0;10.2586,9.0028,0;8.925,8.2328,0;4.9239,9.0028,0;2.1256,4.0887,0;1.2204,2.8428,0;2.1256,1.5969,0;1.6497,5.5533,0;.1434,5.8735,0;-.3325,7.3382,0;.698,8.4826,0;2.2043,8.1624,0;2.6802,6.6978,0;.2221,9.9472,0;-1.2843,10.2674,0;-2.3147,9.123,0;-1.7602,11.732,0;",MLKRVCDSVIMHCB-ZDUSSCGKSA-N
,INHERITED,,MMV670768,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(N4C(C=CC(F)=C5)=C5CC4)=O)N32,"InChI=1S/C21H14F3N5O2/c22-14-3-6-16-13(9-14)7-8-28(16)20(30)17-10-25-11-18-26-27-19(29(17)18)12-1-4-15(5-2-12)31-21(23)24/h1-6,9-11,21H,7-8H2",FHJDERXELJTUQL-UHFFFAOYSA-N
,INHERITED,,MMV671654,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NC4=CC=C(F)C=C4Cl)=O)N32,"InChI=1S/C19H11ClF3N5O2/c20-13-7-11(21)3-6-14(13)25-18(29)15-8-24-9-16-26-27-17(28(15)16)10-1-4-12(5-2-10)30-19(22)23/h1-9,19H,(H,25,29)",UDYGHIAMQUSWIO-UHFFFAOYSA-N
,INHERITED,,MMV672624,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NC4CCC5=C4C=CC(Cl)=C5)=O)N32,"InChI=1S/C22H16ClF2N5O2/c23-14-4-7-16-13(9-14)3-8-17(16)27-21(31)18-10-26-11-19-28-29-20(30(18)19)12-1-5-15(6-2-12)32-22(24)25/h1-2,4-7,9-11,17,22H,3,8H2,(H,27,31)",HNBNSRMVIRFWNX-UHFFFAOYSA-N
,INHERITED,,MMV672625,O=C(NC1=CC=NC(C(F)(F)F)=C1)C2=CN=CC3=NN=C(C4=C(C)N(C5=CC=C(F)C=C5)N=C4C)N32,"InChI=1S/C23H16F4N8O/c1-12-20(13(2)35(33-12)16-5-3-14(24)4-6-16)21-32-31-19-11-28-10-17(34(19)21)22(36)30-15-7-8-29-18(9-15)23(25,26)27/h3-11H,1-2H3,(H,29,30,36)",XBUPBXHBMRAQPD-UHFFFAOYSA-N
,INHERITED,,MMV669027,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NCCC4=CC=CC=C4)=O)N32,"InChI=1S/C21H17F2N5O2/c22-21(23)30-16-8-6-15(7-9-16)19-27-26-18-13-24-12-17(28(18)19)20(29)25-11-10-14-4-2-1-3-5-14/h1-9,12-13,21H,10-11H2,(H,25,29)",VPVKOTUNZQTQGJ-UHFFFAOYSA-N
,INHERITED,,MMV669026,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NC4=CC=CC=N4)=O)N32,"InChI=1S/C18H12F2N6O2/c19-18(20)28-12-6-4-11(5-7-12)16-25-24-15-10-21-9-13(26(15)16)17(27)23-14-3-1-2-8-22-14/h1-10,18H,(H,22,23,27)",LMNKFRDAYYFGDY-UHFFFAOYSA-N
,INHERITED,,MMV669002,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NCC4=C(Cl)C=CC=C4)=O)N32,"InChI=1S/C20H14ClF2N5O2/c21-15-4-2-1-3-13(15)9-25-19(29)16-10-24-11-17-26-27-18(28(16)17)12-5-7-14(8-6-12)30-20(22)23/h1-8,10-11,20H,9H2,(H,25,29)",KXOGBDHDGOMMBL-UHFFFAOYSA-N
,INHERITED,,MMV670243,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(CCCC4=CC(F)=C(F)C=C4)N32,"InChI=1S/C21H16F4N4O/c22-17-9-4-13(10-18(17)23)2-1-3-15-11-26-12-19-27-28-20(29(15)19)14-5-7-16(8-6-14)30-21(24)25/h4-12,21H,1-3H2",LRAREZHFBCZJIU-UHFFFAOYSA-N
,INHERITED,,MMV669312,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(CCN4CC(C=CC=C5)=C5C4)N32,"InChI=1S/C22H19F2N5O/c23-22(24)30-19-7-5-15(6-8-19)21-27-26-20-12-25-11-18(29(20)21)9-10-28-13-16-3-1-2-4-17(16)14-28/h1-8,11-12,22H,9-10,13-14H2",GQXSFCDTPDFAAJ-UHFFFAOYSA-N
,INHERITED,,MMV668824,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(CCO)N32,"InChI=1S/C14H12F2N4O2/c15-14(16)22-11-3-1-9(2-4-11)13-19-18-12-8-17-7-10(5-6-21)20(12)13/h1-4,7-8,14,21H,5-6H2",VHAPEQORRZDNKC-UHFFFAOYSA-N
,INHERITED,,MMV668955,FC(F)OC(C=C1)=CC=C1C2=NN=C3CNCC(CCO)N32,"InChI=1S/C14H16F2N4O2/c15-14(16)22-11-3-1-9(2-4-11)13-19-18-12-8-17-7-10(5-6-21)20(12)13/h1-4,10,14,17,21H,5-8H2",PSSFFOLKPUSBCU-UHFFFAOYSA-N
,INHERITED,,MMV669360,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(COCC4=CC(F)=C(F)C=C4)N32,"InChI=1S/C20H14F4N4O2/c21-16-6-1-12(7-17(16)22)10-29-11-14-8-25-9-18-26-27-19(28(14)18)13-2-4-15(5-3-13)30-20(23)24/h1-9,20H,10-11H2",ZFZFBHJVOPWPMU-UHFFFAOYSA-N
,INHERITED,,MMV671652,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(N[C@H](C4=CC=C(F)C(F)=C4)CO)N32,"InChI=1S/C20H15F4N5O2/c21-14-6-3-12(7-15(14)22)16(10-30)26-17-8-25-9-18-27-28-19(29(17)18)11-1-4-13(5-2-11)31-20(23)24/h1-9,16,20,26,30H,10H2/t16-/m0/s1",SVFYCNYIUKOGIZ-INIZCTEOSA-N
,INHERITED,,MMV668957,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(N4CCC(C5=CC=CC=C5)C4)N32,"InChI=1S/C22H19F2N5O/c23-22(24)30-18-8-6-16(7-9-18)21-27-26-19-12-25-13-20(29(19)21)28-11-10-17(14-28)15-4-2-1-3-5-15/h1-9,12-13,17,22H,10-11,14H2",DHFJQIXVZGXHFA-UHFFFAOYSA-N
,INHERITED,,MMV671678,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(N4C=CN=C4CC5=CC=C(F)C(F)=C5)N32,"InChI=1S/C22H14F4N6O/c23-16-6-1-13(9-17(16)24)10-18-28-7-8-31(18)20-12-27-11-19-29-30-21(32(19)20)14-2-4-15(5-3-14)33-22(25)26/h1-9,11-12,22H,10H2",IWRWYQUIBQGAAF-UHFFFAOYSA-N
,INHERITED,,MMV671653,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(N4N=CC(C5=CC(F)=C(F)C=C5)=C4)N32,"InChI=1S/C21H12F4N6O/c22-16-6-3-13(7-17(16)23)14-8-27-30(11-14)19-10-26-9-18-28-29-20(31(18)19)12-1-4-15(5-2-12)32-21(24)25/h1-11,21H",ZWEIKBFHIWDMSU-UHFFFAOYSA-N
,INHERITED,,MMV670934,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(NC4=CC=C(Cl)C(Cl)=C4)N32,"InChI=1S/C18H11Cl2F2N5O/c19-13-6-3-11(7-14(13)20)24-15-8-23-9-16-25-26-17(27(15)16)10-1-4-12(5-2-10)28-18(21)22/h1-9,18,24H",TZGDENMOWJZOCE-UHFFFAOYSA-N
,INHERITED,,MMV671651,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC[C@H](N)C4=CC(F)=C(F)C=C4)N32,"InChI=1S/C20H15F4N5O2/c21-14-6-3-12(7-15(14)22)16(25)10-30-18-9-26-8-17-27-28-19(29(17)18)11-1-4-13(5-2-11)31-20(23)24/h1-9,16,20H,10,25H2/t16-/m0/s1",BIGCWGPLTSPPFJ-INIZCTEOSA-N
,INHERITED,,MMV671650,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC(C(F)(F)F)=C(Cl)C=C4)N32,"InChI=1S/C19H10ClF5N4O2/c20-14-6-5-12(7-13(14)19(23,24)25)30-16-9-26-8-15-27-28-17(29(15)16)10-1-3-11(4-2-10)31-18(21)22/h1-9,18H",JMNZLRAAYWFJSK-UHFFFAOYSA-N
,INHERITED,,MMV670765,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC(Cl)=C(Cl)C=C4)N32,"InChI=1S/C18H10Cl2F2N4O2/c19-13-6-5-12(7-14(13)20)27-16-9-23-8-15-24-25-17(26(15)16)10-1-3-11(4-2-10)28-18(21)22/h1-9,18H",XMEKRAWNUWCYBR-UHFFFAOYSA-N
,INHERITED,,MMV672620,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC(N=C(C(F)(F)F)C=C5)=C5C=C4)N32,"InChI=1S/C22H12F5N5O2/c23-21(24)34-14-5-2-13(3-6-14)20-31-30-18-10-28-11-19(32(18)20)33-15-7-1-12-4-8-17(22(25,26)27)29-16(12)9-15/h1-11,21H",INVOZROXGPLPEO-UHFFFAOYSA-N
,INHERITED,,MMV670659,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC(C=CC=C5)=C5C=C4)N32,"InChI=1S/C22H14F2N4O2/c23-22(24)30-17-8-6-15(7-9-17)21-27-26-19-12-25-13-20(28(19)21)29-18-10-5-14-3-1-2-4-16(14)11-18/h1-13,22H",OICXVTBHLZSJIW-UHFFFAOYSA-N
,INHERITED,,MMV671649,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC(CCCC5)=C5C=C4)N32,"InChI=1S/C22H18F2N4O2/c23-22(24)30-17-8-6-15(7-9-17)21-27-26-19-12-25-13-20(28(19)21)29-18-10-5-14-3-1-2-4-16(14)11-18/h5-13,22H,1-4H2",FYSOARLAJJFNEA-UHFFFAOYSA-N
,INHERITED,,MMV672989,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC5=NC(OC)=CC=C5C=C4)N32,"InChI=1S/C22H15F2N5O3/c1-30-19-9-5-13-2-8-16(10-17(13)26-19)31-20-12-25-11-18-27-28-21(29(18)20)14-3-6-15(7-4-14)32-22(23)24/h2-12,22H,1H3",GCCMQYNBUCBGOJ-UHFFFAOYSA-N
,INHERITED,,MMV671929,ClC(C(Cl)=C1)=CC=C1OC2=CN=CC3=NN=C(C4=C(C)N(C5=CC=C(F)C=C5)N=C4C)N32,"InChI=1S/C22H15Cl2FN6O/c1-12-21(13(2)31(29-12)15-5-3-14(25)4-6-15)22-28-27-19-10-26-11-20(30(19)22)32-16-7-8-17(23)18(24)9-16/h3-11H,1-2H3",GLBSIKNHNLXVTJ-UHFFFAOYSA-N
,INHERITED,,MMV671648,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=C(C(C)(C)C)C=C4)N32,"InChI=1S/C22H20F2N4O2/c1-22(2,3)15-6-10-16(11-7-15)29-19-13-25-12-18-26-27-20(28(18)19)14-4-8-17(9-5-14)30-21(23)24/h4-13,21H,1-3H3",ZOWPQULSJIFHAL-UHFFFAOYSA-N
,INHERITED,,MMV670764,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=C(C(F)(F)F)C=C4)N32,"InChI=1S/C19H11F5N4O2/c20-18(21)30-14-5-1-11(2-6-14)17-27-26-15-9-25-10-16(28(15)17)29-13-7-3-12(4-8-13)19(22,23)24/h1-10,18H",CONUSWGEFVYDPG-UHFFFAOYSA-N
,INHERITED,,MMV669784,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=C(Cl)C=C4)N32,"InChI=1S/C18H11ClF2N4O2/c19-12-3-7-13(8-4-12)26-16-10-22-9-15-23-24-17(25(15)16)11-1-5-14(6-2-11)27-18(20)21/h1-10,18H",WXNPYOXFQUYIOI-UHFFFAOYSA-N
,INHERITED,,MMV671680,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=C(S(F)(F)(F)(F)F)C=C4)N32,"InChI=1S/C18H11F7N4O2S/c19-18(20)31-13-3-1-11(2-4-13)17-28-27-15-9-26-10-16(29(15)17)30-12-5-7-14(8-6-12)32(21,22,23,24)25/h1-10,18H",JRUPFXIUMYRPCH-UHFFFAOYSA-N
,INHERITED,,MMV672622,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=C(C(C)=CC(C)(C)O5)C5=C4)N32,"InChI=1S/C24H20F2N4O3/c1-14-11-24(2,3)33-19-10-17(8-9-18(14)19)31-21-13-27-12-20-28-29-22(30(20)21)15-4-6-16(7-5-15)32-23(25)26/h4-13,23H,1-3H3",JSLPLPVOHWRSQR-UHFFFAOYSA-N
,INHERITED,,MMV672940,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=C(C=C(F)C(F)=C5)C5=C4)N32,"InChI=1S/C22H12F4N4O2/c23-17-8-13-3-6-16(7-14(13)9-18(17)24)31-20-11-27-10-19-28-29-21(30(19)20)12-1-4-15(5-2-12)32-22(25)26/h1-11,22H",NJZAMAPESVYMRZ-UHFFFAOYSA-N
,INHERITED,,MMV672941,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=C(C(F)=CC(F)=C5)C5=C4)N32,"InChI=1S/C22H12F4N4O2/c23-14-7-13-8-16(5-6-17(13)18(24)9-14)31-20-11-27-10-19-28-29-21(30(19)20)12-1-3-15(4-2-12)32-22(25)26/h1-11,22H",DTSQOCXVVNBKAJ-UHFFFAOYSA-N
,INHERITED,,MMV672730,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=C(N=C(C(F)(F)F)N=C5)C5=C4)N32,"InChI=1S/C21H11F5N6O2/c22-20(23)34-13-3-1-11(2-4-13)18-31-30-16-9-27-10-17(32(16)18)33-14-5-6-15-12(7-14)8-28-19(29-15)21(24,25)26/h1-10,20H",HMMAXUVKMPWCSS-UHFFFAOYSA-N
,INHERITED,,MMV672623,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=C(C=NN5C)C5=C4)N32,"InChI=1S/C20H14F2N6O2/c1-27-16-8-15(7-4-13(16)9-24-27)29-18-11-23-10-17-25-26-19(28(17)18)12-2-5-14(6-3-12)30-20(21)22/h2-11,20H,1H3",ZBBRDTJSXGCMJO-UHFFFAOYSA-N
,INHERITED,,MMV672686,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC5=NN(C)C=C5C=C4)N32,"InChI=1S/C20H14F2N6O2/c1-27-11-13-4-7-15(8-16(13)26-27)29-18-10-23-9-17-24-25-19(28(17)18)12-2-5-14(6-3-12)30-20(21)22/h2-11,20H,1H3",DWADAQMBGKHLCV-UHFFFAOYSA-N
,INHERITED,,MMV672621,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=C(C(C)=NO5)C5=C4)N32,"InChI=1S/C20H13F2N5O3/c1-11-15-7-6-14(8-16(15)30-26-11)28-18-10-23-9-17-24-25-19(27(17)18)12-2-4-13(5-3-12)29-20(21)22/h2-10,20H,1H3",WSIIGDBXJAXHGJ-UHFFFAOYSA-N
,INHERITED,,MMV672937,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=C(C=CS5)C5=C4)N32,"InChI=1S/C20H12F2N4O2S/c21-20(22)28-14-4-2-13(3-5-14)19-25-24-17-10-23-11-18(26(17)19)27-15-6-1-12-7-8-29-16(12)9-15/h1-11,20H",MLBNXJTXHVBPEC-UHFFFAOYSA-N
,INHERITED,,MMV670935,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=CC(Cl)=C4)N32,"InChI=1S/C18H11ClF2N4O2/c19-12-2-1-3-14(8-12)26-16-10-22-9-15-23-24-17(25(15)16)11-4-6-13(7-5-11)27-18(20)21/h1-10,18H",KXCPLUGLCFKSCH-UHFFFAOYSA-N
,INHERITED,,MMV672725,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC4=CC=CC(OC5=CC=CC=N5)=C4)N32,"InChI=1S/C23H15F2N5O3/c24-23(25)33-16-9-7-15(8-10-16)22-29-28-19-13-26-14-21(30(19)22)32-18-5-3-4-17(12-18)31-20-6-1-2-11-27-20/h1-14,23H",FPATVVYYDYTPJA-UHFFFAOYSA-N
,INHERITED,,MMV671647,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(N4CCOCC4)C5=CC(F)=C(F)C=C5)N32,"InChI=1S/C24H21F4N5O3/c25-18-6-3-16(11-19(18)26)20(32-7-9-34-10-8-32)14-35-22-13-29-12-21-30-31-23(33(21)22)15-1-4-17(5-2-15)36-24(27)28/h1-6,11-13,20,24H,7-10,14H2",MTYMSRWFPISKOF-UHFFFAOYSA-N
,INHERITED,,MMV671679,FC(C=C1)=CC=C1N(N=C2C)C(C)=C2C3=NN=C4C=NC=C(OCC(F)(F)F)N43,"InChI=1S/C18H14F4N6O/c1-10-16(11(2)28(26-10)13-5-3-12(19)4-6-13)17-25-24-14-7-23-8-15(27(14)17)29-9-18(20,21)22/h3-8H,9H2,1-2H3",LZBDIFIBPJUBOJ-UHFFFAOYSA-N
,INHERITED,,MMV670762,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC(F)(F)F)N32,"InChI=1S/C14H9F5N4O2/c15-13(16)25-9-3-1-8(2-4-9)12-22-21-10-5-20-6-11(23(10)12)24-7-14(17,18)19/h1-6,13H,7H2",VZIMTSNALAAOKI-UHFFFAOYSA-N
,INHERITED,,MMV672726,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC4CCC5=C4C=CC(Cl)=C5)N32,"InChI=1S/C22H17ClF2N4O2/c23-16-5-8-18-14(9-16)1-2-15(18)12-30-20-11-26-10-19-27-28-21(29(19)20)13-3-6-17(7-4-13)31-22(24)25/h3-11,15,22H,1-2,12H2",VIJBNSUMCSOTCB-UHFFFAOYSA-N
,INHERITED,,MMV668961,FC(C=C1)=C(F)C=C1CCOC2=CN=CC3=NN=C(C4CCN(C(C)=O)CC4)N32,"InChI=1S/C20H21F2N5O2/c1-13(28)26-7-4-15(5-8-26)20-25-24-18-11-23-12-19(27(18)20)29-9-6-14-2-3-16(21)17(22)10-14/h2-3,10-12,15H,4-9H2,1H3",QWBQVZOVKHIBBF-UHFFFAOYSA-N
,INHERITED,,MMV668959,FC(C=C1)=C(F)C=C1CCOC2=CN=CC3=NN=C(C4CCOCC4)N32,"InChI=1S/C18H18F2N4O2/c19-14-2-1-12(9-15(14)20)3-8-26-17-11-21-10-16-22-23-18(24(16)17)13-4-6-25-7-5-13/h1-2,9-11,13H,3-8H2",ROEPXHXLRPOTHS-UHFFFAOYSA-N
,INHERITED,,MMV669028,FC(C=C1)=C(F)C=C1CCOC2=CN=CC3=NN=C(N4CC(C=CC=C5)=C5C4)N32,"InChI=1S/C21H17F2N5O/c22-17-6-5-14(9-18(17)23)7-8-29-20-11-24-10-19-25-26-21(28(19)20)27-12-15-3-1-2-4-16(15)13-27/h1-6,9-11H,7-8,12-13H2",JAQFKPHMBHLZPF-UHFFFAOYSA-N
,INHERITED,,MMV669009,FC(C=C1)=C(F)C=C1CCOC2=CN=CC3=NN=C(N4CCCCC4)N32,"InChI=1S/C18H19F2N5O/c19-14-5-4-13(10-15(14)20)6-9-26-17-12-21-11-16-22-23-18(25(16)17)24-7-2-1-3-8-24/h4-5,10-12H,1-3,6-9H2",ZKHZGOFEMNTIFA-UHFFFAOYSA-N
,INHERITED,,MMV669006,FC1=CC(NC2=NN=C3C=NC=C(OCCC4=CC(F)=C(F)C=C4)N32)=CC=C1F,"InChI=1S/C19H13F4N5O/c20-13-3-1-11(7-15(13)22)5-6-29-18-10-24-9-17-26-27-19(28(17)18)25-12-2-4-14(21)16(23)8-12/h1-4,7-10H,5-6H2,(H,25,27)",MBKZMCLRDLFTKO-UHFFFAOYSA-N
,INHERITED,,MMV669850,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NC4=CC=C(F)C(F)=C4)=O)N32,"InChI=1S/C19H11F4N5O2/c20-13-6-3-11(7-14(13)21)25-18(29)15-8-24-9-16-26-27-17(28(15)16)10-1-4-12(5-2-10)30-19(22)23/h1-9,19H,(H,25,29)",KKUPIUJNLQIEQB-UHFFFAOYSA-N
,INHERITED,,MMV669849,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NC4=CC=C(F)C=C4)=O)N32,"InChI=1S/C19H12F3N5O2/c20-12-3-5-13(6-4-12)24-18(28)15-9-23-10-16-25-26-17(27(15)16)11-1-7-14(8-2-11)29-19(21)22/h1-10,19H,(H,24,28)",JMGKRETUBOTWAE-UHFFFAOYSA-N
,INHERITED,,MMV672688,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCC4=CC=CC5=C4C=CC=C5)N32,"InChI=1S/C23H16F2N4O2/c24-23(25)31-18-10-8-16(9-11-18)22-28-27-20-12-26-13-21(29(20)22)30-14-17-6-3-5-15-4-1-2-7-19(15)17/h1-13,23H,14H2",XGANTNHUKSSASO-UHFFFAOYSA-N
,INHERITED,,MMV670249,FC1=C(F)C=CC(CCOC2=CN=CC3=NN=C(N4CCC5=C4C=CC(F)=C5)N32)=C1,"InChI=1S/C21H16F3N5O/c22-15-2-4-18-14(10-15)5-7-28(18)21-27-26-19-11-25-12-20(29(19)21)30-8-6-13-1-3-16(23)17(24)9-13/h1-4,9-12H,5-8H2",LWJNQMYILRVGSA-UHFFFAOYSA-N
,INHERITED,,MMV669103,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(NS(CC4=CC=C(C(F)(F)F)C=C4)(=O)=O)N32,"InChI=1S/C20H14F5N5O3S/c21-19(22)33-15-7-3-13(4-8-15)18-28-27-16-9-26-10-17(30(16)18)29-34(31,32)11-12-1-5-14(6-2-12)20(23,24)25/h1-10,19,29H,11H2",ZOJHYLYRVAQAKL-UHFFFAOYSA-N
,INHERITED,,MMV669353,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(N4CC(C5=CC=CC=C5)C4)N32,"InChI=1S/C21H17F2N5O/c22-21(23)29-17-8-6-15(7-9-17)20-26-25-18-10-24-11-19(28(18)20)27-12-16(13-27)14-4-2-1-3-5-14/h1-11,16,21H,12-13H2",RLJNNQICWGMQFO-UHFFFAOYSA-N
,INHERITED,,MMV669008,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(N4CC(OC5=CC(F)=C(F)C=C5)C4)N32,"InChI=1S/C21H15F4N5O2/c22-16-6-5-14(7-17(16)23)31-15-10-29(11-15)19-9-26-8-18-27-28-20(30(18)19)12-1-3-13(4-2-12)32-21(24)25/h1-9,15,21H,10-11H2",QERLPIHUXGRHKE-UHFFFAOYSA-N
,INHERITED,,MMV670437,FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(OC[C@H](N(C)C)C4=CC(F)=C(F)C=C4)N32,"InChI=1S/C22H19F4N5O2/c1-30(2)18(14-5-8-16(23)17(24)9-14)12-32-20-11-27-10-19-28-29-21(31(19)20)13-3-6-15(7-4-13)33-22(25)26/h3-11,18,22H,12H2,1-2H3/t18-/m0/s1",PMIWBIXSAYKRGF-SFHVURJKSA-N
,TF 16-1,,,NC1=C2C(C=C(C3CC=CC(S(=O)(N4CCCC4)=O)=C3)S2)=NC=N1,"InChI=1S/C16H18N4O2S2/c17-16-15-13(18-10-19-16)9-14(23-15)11-4-3-5-12(8-11)24(21,22)20-6-1-2-7-20/h3,5,8-11H,1-2,4,6-7H2,(H2,17,18,19)",WJXQKMZKHUBIMH-UHFFFAOYSA-N
,TF 17-1,,,NC1=C2C(C=C(C3CC=CC(S(=O)(NC)=O)=C3)S2)=NC=N1,"InChI=1S/C13H14N4O2S2/c1-15-21(18,19)9-4-2-3-8(5-9)11-6-10-12(20-11)13(14)17-7-16-10/h2,4-8,15H,3H2,1H3,(H2,14,16,17)",JKCCHEYITLJPCL-UHFFFAOYSA-N
,TF 18-1,,,NC1=C2C(C=C(C3CC=CC(S(=O)(N(C)C)=O)=C3)S2)=NC=N1,"InChI=1S/C14H16N4O2S2/c1-18(2)22(19,20)10-5-3-4-9(6-10)12-7-11-13(21-12)14(15)17-8-16-11/h3,5-9H,4H2,1-2H3,(H2,15,16,17)",KNJTYVZQHQMSEV-UHFFFAOYSA-N
,TF 3-1,,,NC1=C2C(C(C)=C(C3=CC=CC(S(=O)(N)=O)=C3)S2)=NC=N1,"InChI=1S/C13H12N4O2S2/c1-7-10-12(13(14)17-6-16-10)20-11(7)8-3-2-4-9(5-8)21(15,18)19/h2-6H,1H3,(H2,14,16,17)(H2,15,18,19)",JIUOPNISLOOEPA-UHFFFAOYSA-N
,TF 4-1,,,NC1=C2C(C(C)=C(C3C(C)C=CC(S(=O)(N)=O)=C3)S2)=NC=N1,"InChI=1S/C14H16N4O2S2/c1-7-3-4-9(22(16,19)20)5-10(7)12-8(2)11-13(21-12)14(15)18-6-17-11/h3-7,10H,1-2H3,(H2,15,17,18)(H2,16,19,20)",OTALAHLJTGALQU-UHFFFAOYSA-N
,TF 7-1,,,OCCNC1=C2C(C=C(C3=CC=CC(S(=O)(N)=O)=C3)S2)=NC=N1,"InChI=1S/C14H14N4O3S2/c15-23(20,21)10-3-1-2-9(6-10)12-7-11-13(22-12)14(16-4-5-19)18-8-17-11/h1-3,6-8,19H,4-5H2,(H2,15,20,21)(H,16,17,18)",MMGBHQAWBVFGDD-UHFFFAOYSA-N
,TF 8-1,,,OCCCNC1=C2C(C=C(C3CC=CC(S(=O)(N)=O)=C3)S2)=NC=N1,"InChI=1S/C15H18N4O3S2/c16-24(21,22)11-4-1-3-10(7-11)13-8-12-14(23-13)15(19-9-18-12)17-5-2-6-20/h1,4,7-10,20H,2-3,5-6H2,(H2,16,21,22)(H,17,18,19)",JMGQLUQOLFPKPG-UHFFFAOYSA-N
OSM-W-5,KH-7-1,,,FC(C(F)=C1)=CC=C1CCOC2=CN=CC3=NN=C(C4=CC=C(S(C)(=O)=O)C=C4)N32,"InChI=1S/C20H16F2N4O3S/c1-30(27,28)15-5-3-14(4-6-15)20-25-24-18-11-23-12-19(26(18)20)29-9-8-13-2-7-16(21)17(22)10-13/h2-7,10-12H,8-9H2,1H3",ISCYIQSGKXBNIC-UHFFFAOYSA-N
OSM-W-6,JH-5-2,,,O=C(CC1=CC=C(F)C(F)=C1)NC2=CN=CC3=NN=C(C4=CC=C(C#N)C=C4)N32,"InChI=1S/C20H12F2N6O/c21-15-6-3-13(7-16(15)22)8-19(29)25-17-10-24-11-18-26-27-20(28(17)18)14-4-1-12(9-23)2-5-14/h1-7,10-11H,8H2,(H,25,29)",WXNSEGHVFXDZGF-UHFFFAOYSA-N
OSM-W-7,JH-7-1,,,O=C(CCC1=CC(F)=C(F)C=C1)NC2=CN=CC3=NN=C(C4=CC=C(C#N)C=C4)N32,"InChI=1S/C21H14F2N6O/c22-16-7-3-13(9-17(16)23)4-8-20(30)26-18-11-25-12-19-27-28-21(29(18)19)15-5-1-14(10-24)2-6-15/h1-3,5-7,9,11-12H,4,8H2,(H,26,30)",SMRNZXNRFZNBAW-UHFFFAOYSA-N

Full details are here https://www.europeanleadfactory.eu/early-career-researcher-event/.

Free participation (incl. reimbursement of travel costs up to € 250, accommodation, access to the social get-together) at the conference.

The draft agenda is here.

A great opportunity for those just starting on their drug discovery career.

• “Fragment Space” is smaller than “Chemical Space” and can be more effectively probed with a relatively small library
• A million compounds cover only a small fraction of the suggested 10⁶⁰ Chemical Space, whilst 2000 compounds can probe much of the 10⁶ Fragment Space
• Protein requirements should be smaller
• Binding Efficiency for small molecules is likely to be higher
• Hit rates for Fragment-based screening appear to be higher, typically 3-10%.

Whilst there are a number of biophysical methods used for Fragment-based screening structural information is often a critical step in moving the programme forward. X-ray crystallography is a very powerful technology for use in converting a "hit" into a lead for drug discovery. However, the experimental overheads have historically been too high for it to be widely used for primary screening. The X-Chem project at Diamond aims to make the technology more widely accessible.

At Diamond beamline I04-1, the full X-ray screening experiment has now been implemented as a highly streamlined process, allowing up to 1000 compounds to be screened individually in less than a week (including 36 hours' unattended beamtime). The process covers soaking, harvesting, automatic data collection, and data analysis; fragment libraries are available, though users can bring their own.

An overview of the process is available here in practice, users must generate the crystals in their home lab, and are required to come and perform soaking and harvesting themselves. Users do not need to be present for the X-ray data collection when data is collected automatically. Data analysis builds on the existing automatic data processing, and they have developed tools to streamline density interpretation and refinement (PanDDA and XChemExplorer). Use of these tools at Diamond is optional but highly recommended.

Whilst users are free to bring their own libraries a number of libraries are also available these include the Maybridge 1000, Edelris fragments, and Diamond-SGC Poised Library (DSPL), a fragment library designed to allow rapid, cheap follow-up synthesis to provide quick SAR data. The calculated physicochemical properties of the DSPL fragment collection are shown below.

For more details on the design of the library O. B. Cox, K. Krojer, P. Collins, O. Monteiro, R. Talon, A. Bradley, O. Fedorov, J. Amin, B. D. Marsden, J. Spencer, F. von Delft, P. E. Brennan, A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain. Chem. Sci.,2016. 7: p. 2322-2330 DOI.

There is more information in this podcast https://www.ndm.ox.ac.uk/frank-von-delft-x-rays-for-drug-discovery

In 2011, an evaluation of 246 antibodies used in epigenetic studies found that one-quarter failed tests for specificity, meaning that they often bound to more than one target. Four antibodies were perfectly specific — but to the wrong target.

The issue of antibody selectivity has again been flagged as a concern in oestrogen receptor beta research DOI. This is a major target for breast cancer research and there are multiple ongoing clinical trials https://clinicaltrials.gov/ct2/results?term=ERβ.

We here perform a rigorous validation of 13 anti-ERβ antibodies, using well-characterized controls and a panel of validation methods. We conclude that only one antibody, the rarely used monoclonal PPZ0506, specifically targets ERβ in immunohistochemistry.

Applying this antibody for protein expression profiling in 44 normal and 21 malignant human tissues, we detect ERβ protein in testis, ovary, lymphoid cells, granulosa cell tumours, and a subset of malignant melanoma and thyroid cancers. We do not find evidence of expression in normal or cancerous human breast.

Perhaps more worryingly the authors comment.

While our study focuses on ERβ, we do not think that antibodies towards ERβ are significantly poorer than those targeting other proteins, and it is not unlikely that this problem generates similar obstacles in many other fields.

As I wrote on the Target Validation page

Remember this is an absolutely critical step, almost everything else can be fixed.

For this reason I was particularly interested to read about a potential novel treatment for ALS arising from work between Benevolnet.ai and Sheffield Institute for Translational Neuroscience.

The study, led by Dr. Richard Mead and Dr. Laura Ferraiuolo at SITraN, assessed the efficacy of a drug candidate proposed by BenevolentAI's artificial Intelligence technology for Motor Neuron Disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS). SITraN found there are significant and reproducible indications that the drug prevents the death of motor neurones in patient cell models, and delayed the onset of the disease in the gold standard model of ALS…Dr. Richard Mead of SITraN commented: "This is an exciting development in our research for a treatment for ALS. BenevolentAI came to us with some newly identified compounds discovered by their technology - two of which were new to us in the field and, following this research, are now looking very promising. Our plan now is to conduct further detailed testing and continue to quickly progress towards a potential treatment for ALS."

SITraN expect to publish an abstract at the Motor Neurone Disease Association 28th International Symposium in Boston in December 2017.

Human induced pluripotent stem cell-derived cardiomyocytes were cultured as a model system, and used to validate the platform with an excitation–contraction decoupling chemical. Preliminary data using the platform to investigate the effect of the drug norepinephrine are combined with computational efforts. This platform provides a quantitative and predictive assay system that can potentially be used for comprehensive assessment of cardiac toxicity earlier in the drug discovery process. DOI.

• 2,101,843 compound records
• 1,735,442 compounds (of which 1,727,112 have mol files)
• 14,675,320 activities
• 1,302,147 assays
• 11,538 targets
• 67,722 source documents

Data can be downloaded from the ChEMBL ftp site: ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_23
Also includes

Deposited Data Sets
CO-ADD, The Community for Open Antimicrobial Drug Discovery, is a global open-access screening initiative launched in February 2015 to uncover significant and rich chemical diversity held outside of corporate screening collections. CO-ADD provides unencumbered free antimicrobial screening for any interested academic researcher.  CO-ADD has been recognised as a novel approach in the fight against superbugs by the Wellcome Trust, who have provided funding through their Strategic Awards initiative. Open Source Malaria (OSM) is aimed at finding new medicines for malaria using open source drug discovery, where all data and ideas are freely shared, there are no barriers to participation, and no restriction by patents. The initial set of deposited data from the CO-ADD project consists of OSM compounds screened in CO-ADD assays (DOI = 10.6019/CHEMBL3832881).

Modelled on the Malaria Box, the MMV Pathogen Box contains 400 diverse, drug-like molecules active against neglected diseases of interest and is available free of charge (http://www.pathogenbox.org). The Pathogen Box compounds are supplied in 96-well plates, containing 10 uL of a 10mM dimethyl sulfoxide (DMSO) solution of each compound. Upon request, researchers around the world will receive a Pathogen Box of molecules to help catalyse neglected disease drug discovery. In return, researchers are asked to share any data generated in the public domain within 2 years, creating an open and collaborative forum for neglected diseases drug research. The initial set of assay data provided by MMV has now been included in ChEMBL (DOI = 10.6019/CHEMBL3832761).

Read More…

There are several other examples of the H to D change to reduce the rate of metabolism and improve pharmacokinetics.

As can be seen, many of the compounds are on the large size with molecular weights >450, a third of them have ionisable groups which serves to bring down the calculated LogD. All molecules contain an aromatic ring, indeed many contain multiple rings. Interestingly we see a number of examples where a biphenyl ring system bears multiple ortho substituents presumably locking the two aryl rings orthogonal, no mention of atrope isomers though. This might also reduce the planarity and increase the 3D shape.

The sdf file is available here FirstDisclosures.sdf.zip if anyone spots any errors in the structures please let me know.

In particular I've added a section on target prediction tools, updated the section on Analysis of HTS data, and expanded the section on aggregation in bioassays to include a recent publication giving an example of target specific aggregation.

The crystal structure showing the interaction is available (PDB 5MU8) and is displayed below using 3Dmol.js, the ligand (JNJ525) is shown in red..

Show surface

Mouse Controls

In addition I've updated the section on molecular interactions.

Highlights include the European Lead Factory recently reached the milestone of having received over 1,000 chemical library proposals for consideration. To date, 143,529 novel compounds, out of the 200,000 prospected compounds for the Public Compound Collection, have been synthesized, which means that the ELF compound collection grows daily by approximately 250 novel compounds to eventually constitute the 500,000 Joint European Compound Library (JECL).

Parkinson’s UK and the University of Sheffield have launched a joint venture biotech company, Keapstone Therapeutics. Parkinson’s UK has allocated 1 million GBP over the next sixteen months to further develop compounds that boost the internal cellular defence mechanisms against oxidative stress. These compounds were discovered by European Lead Factory.

Call for Posters
Contributions from the whole field of medicinal chemistry are invited. Flash presentation sessions are planned which will involve a two-minute presentation of poster highlights. Poster abstract submissions should be sent to the secretariat by 16th April if you wish to take advantage of the early-bird registration fee and indicate whether or not you would like to be included for consideration in the flash presentation session. The final deadline for submission of posters is 21st July.

Registration is now open and delegates are encouraged to book early to ensure places at this very popular meeting. Discounted rates are available to RSC and SCI student members, and some student bursaries are available. Applications are invited from PhD and post-doctoral students studying at European academic institutions, preferably members of the RSC, SCI or EFMC. Those submitting abstracts for poster presentation will be favoured. To apply for a student bursary, please complete and return the bursary application form by 21st July.

A couple of quotes will give you an idea of the content

Alarmingly, up to 80–100% of initial hits from screening can be artefacts if appropriate control experiments are not employed.

it is important to realize that no PAINS-containing drug has ever been developed starting from a protein-reactive PAINS target-based screening hit

They also emphasise the critical need for experimental validation for any screening hit.

Such validation experiments include classic dose response curves, lack of incubation effects, imperviousness to mild reductants, and specificity versus counter-screening targets. If a molecule is flagged as a potential PAINS or aggregator using published patterns but is well-behaved by these criteria, it may be a true, well-behaved ligand. Ultimately, genuine SAR combined with careful mechanistic study provides the most convincing evidence for a specific interaction. Covalent and spectroscopic interference molecules act via specific physical mechanisms, for which controls are known. Colloidal aggregation, fortunately, is readily identified by rapid mechanistic tests and by counter-screening.

In addition you need to consider compound identify and purity, reproducing the activity with an authentic sample is essential.

Whilst time-consuming this validation work will save a fortune in the future.

In the main there are two types of drug discovery programmes: those that hit serious problems and those that are going to hit serious problems. The difference between success and failure is how we, as medicinal chemists, tackle and resolve the problems

Sounds a great meeting both for those starting out in their careers and for those looking to pick up new tips.

The list highlights in particular the threat of gram-negative bacteria that are resistant to multiple antibiotics. These bacteria have built-in abilities to find new ways to resist treatment and can pass along genetic material that allows other bacteria to become drug-resistant as well.

WHO priority pathogens list for R&D of new antibiotics

Priority 1: CRITICAL

• Acinetobacter baumannii, carbapenem-resistant
• Pseudomonas aeruginosa, carbapenem-resistant
• Enterobacteriaceae, carbapenem-resistant, ESBL-producing

Priority 2: HIGH

• Enterococcus faecium, vancomycin-resistant
• Staphylococcus aureus, methicillin-resistant, vancomycin-intermediate and resistant
• Helicobacter pylori, clarithromycin-resistant
• Campylobacter spp., fluoroquinolone-resistant
• Salmonellae, fluoroquinolone-resistant
• Neisseria gonorrhoeae, cephalosporin-resistant, fluoroquinolone-resistant

Priority 3: MEDIUM

• Streptococcus pneumoniae, penicillin-non-susceptible
• Haemophilus influenzae, ampicillin-resistant
• Shigella spp., fluoroquinolone-resistant

Update

The Community for Open Antibiotic Drug Discovery (CO-ADD) screen compounds for antimicrobial activity for academic research groups for free. The screening includes the top 5 pathogens listed in the WHO priority list, as well as the fungi C. neoformans and C. albicans. Details on how to send compounds are here. All they require is 1mg (or 50uL at 10 mg/mL) of pure compound which will be used for primary screening, hit confirmation, and if active will be used for a broader antimicrobial screening, cytotoxicity and a check for its purity.

These predictions may aid understanding of molecular mechanisms underlying the molecules bioactivity and predicting potential side effects or cross-reactivity.

A variety of options are summarised on this page.

PPIase enzyme targets are of increasing interest in drug discovery due to the extensive potential of small molecule inhibitors in a range of therapeutic areas, including infection, inflammation, cancer and neuroprotection.

Selcia have now expanded the range of Peptidyl-Prolyl cis-trans Isomerase (PPIase) assays they can offer.

PfATP4 is an important target for the development of new drugs for malaria. We are providing a dataset of actives and inactives. The challenge is to use the data to develop a model that allows us to (better) design compounds that will be active against that target.

The competition will close on 31st March 2017.

The details of the competition can be found here https://github.com/OpenSourceMalaria/OSMToDo_List/issues/421 and the video below gives more information

There is a Jupyter notebook that can be used to to access the information here http://www.macinchem.org/reviews/osm/osmipython.php or you can access the information in this google document https://docs.google.com/spreadsheets/d/1Rvy6OiM291d1GNcyT6eSwC3lSuJ1jaR7AJa8hgGsc/edit#gid=510297618, but remember the competition is a predictive model for series 4 only.

More details on Open Source Malaria

More details

Programme

09.00 Registration, refreshments and exhibition
Session chair: Adrian Hall, UCB
09.30 Opening remarks
Nicole Hamblin, GlaxoSmithKline
09.35 From phenotypic hit to a validated target for tuberculosis
Robert Bates, GlaxoSmithKline
10.10 Discovery of potent inhibitors of the lysophospholipase autotaxin
Prit Shah, Cancer Research Technology
10.45 Refreshments and exhibition
11.15 Development of Tesirine: a clinical antibody-drug conjugate pyrrolobenzodiazepine payload: medicinal chemistry at the frontier between small molecules and biologics
Arnaud Tiberghien, Spirogen
11.50 NMR conformational analysis in molecular design – case studies and impact
Martin Packer, AstraZeneca
12.25 Highly potent cell-penetrant inhibitors of the KEAP1-NRF2 protein-protein interaction via X-ray fragment screening
Charlotte Griffiths-Jones, Astex Pharmaceuticals
13.00 Lunch and exhibition


Session Chair: Simon Ward, University of Sussex
14:05 Selective on-target chemical probes of protein-protein interactions
Alessio Ciulli, University of Dundee
14.40 Solid state studies of a preclinical candidate in a CRO environment: the importance of de-risking early
Russell Scammell, Charles River
15.15 Refreshments and exhibition
15.45 Drug discovery case study
Tom Miller, Shire
16.20 Optimisation of a series of novel smoothened inhibitors
Matilda Bingham, RedX
16.55 Concluding remarks
17.00 Close

The 2017 Medicinal Chemistry Residential School takes place 11 - 16 June, Loughborough UK, it is always very popular so well worth signing up early.

The 2017 Residential School will take place over 5 days and content is delivered by experts in the field from industry and academia. The programme includes lectures focusing on the fundamental principles of drug discovery, hands-on tutorials allowing delegates to put into practice what they have learnt and case histories from previous drug discovery projects. The programme will also include an evening lecture from a distinguished speaker. Throughout the week course tutors and speakers will be available for informal discussion and there will be plenty of opportunities to network with the broad range of academic and industrial researchers in attendance.

Skin sensitization is an important toxicological endpoint for chemical hazard determination and safety assessment….SkinSensDB has been constructed by curating data from published AOP-related assays. In addition to providing datasets for developing computational models, SkinSensDB is equipped with browsing and search tools which enable the assessment of new compounds for their skin sensitization potentials based on data from structurally similar compounds.

SkinSensDB: a curated database for skin sensitization assays DOI.

6th RSC-BMCS Fragment-based Drug Discovery meeting
Sunday to Tuesday, 5th to 7th March 2017
at Parkhotel Schönbrunn, Vienna, Austria

Full details and registration are online.

Key points are:-

In February 2017 Wellcome will be launching ‘Innovator Awards’ for proposals of up to £500k. One of the aims of this scheme will be to encourage people that do not currently work with us to apply - including translators and innovators from outside of the life and medical science community. We think this is important because new technology has the potential to transform biomedical science, as well as have significant applications to health.

We believe that in order to achieve greater impact on human health - we also need to focus on a smaller number of activities - something that we refer to as Flagships. An example of an existing Flagship is the Hilleman Laboratories – an R&D facility in New Delhi, dedicated to generating new vaccines. This is a joint venture between Wellcome and Merck, USA. We also consider our recently announced Wellcome Centres at Kings College, Dundee University and UCL as Flagships.

We will remain open to great ideas in any area. In our first year much of our support will focus on ideas and solutions involving mental health, neurological disorders and neglected tropical diseases, but these are not exclusive and other areas of particular interest will be announced in the future.

I have to say I delighted to see the focus on mental health and neglected tropical diseases, areas which I've tried to support.

A while back a project was initiated to look at reproducibility in cancer, Science Forum: An open investigation of the reproducibility of cancer biology research DOI.

It is widely believed that research that builds upon previously published findings has reproduced the original work. However, it is rare for researchers to perform or publish direct replications of existing results. The Reproducibility Project: Cancer Biology is an open investigation of reproducibility in preclinical cancer biology research. We have identified 50 high impact cancer biology articles published in the period 2010-2012, and plan to replicate a subset of experimental results from each article. A Registered Report detailing the proposed experimental designs and protocols for each subset of experiments will be peer reviewed and published prior to data collection. The results of these experiments will then be published in a Replication Study. The resulting open methodology and dataset will provide evidence about the reproducibility of high-impact results, and an opportunity to identify predictors of reproducibility.

Well some of the early results are in and they make for pretty sobering if not unexpected reading, of the first 7 papers examined, 2 appear to reproduce the original finding to some extent, three show significant differences from the original studies. The results are published in eLife here and there is an editorial here DOI, and they make an important point.

if all the original studies were reproducible, not all of them would be found to be reproducible, just based on chance. The experiments in the Reproducibility Project are typically powered to have an 80% probability of reproducing something that is true.

The key question is of course, is the failure to reproduce these results due to methodological differences not apparent from the described experimental or whether the fundamental result is invalid. At the moment if you are planning to invest in a drug discovery project based on a single publication then Caveat emptor.

The details of the policy are available online

In particular

• Publications Are Discoverable and Accessible Online. Publications will be deposited in a specified repository(s) with proper tagging of metadata.

• Publication Will Be On “Open Access” Terms. All publications shall be published under the Creative Commons Attribution 4.0 Generic License (CC BY 4.0) or an equivalent license. This will permit all users of the publication to copy and redistribute the material in any medium or format and transform and build upon the material, including for any purpose (including commercial) without further permission or fees being required.

The NIH insists that publications must be made freely available 12 months after publication, Wellcome Trust, also mandates OA publishing, but its policy permits a six-month embargo on making published papers open. CRUK currently encourage, and where an article processing charge is paid, require, license research papers using the Creative Commons Attribution licence (CC-BY). The research councils in the UK have also committed to Open Access publishing as do DNDI.

With charitable funding playing an increasingly important role in drug discovery complying with these Open Access requirements is likely to have a significant impact on the publication landscape.

The SULSA Assay Development Fund: accelerating translation of new biology from academia to pharma DOI describes efforts to support the development of such assays, work carried out in collaboration with the European Lead Factory in Newhouse.

However, many scientifically interesting, novel molecular targets lack associated high-quality, robust assays suitable for hit finding and development. To bridge this gap, the Scottish Universities Life Sciences Alliance (SULSA) established a fund to develop assays to meet quality criteria such as those of the European Lead Factory. A diverse project portfolio was quickly assembled, and a review of the learnings and successful outcomes showed this fund as a new highly cost-effective model for leveraging significant follow-on resources, training early-career scientists and establishing a culture of translational drug discovery in the academic community.

European Lead Factory technical acceptance criteria

• Minimally 384 wells (max 30 μl)
• Homogenous assay (no washing steps)
• Defined endpoint
• Z-prime >0.6
• Readout stability >1 h
• S/B signal >3
• Incubation times <4 h
• DMSO tolerance: minimum 0.5%
• All reagents minimally 8 h stable
• Recombinant proteins(s) >80% pure

Perhaps this quote sums things up very nicely.

‘We only got so far in optimising our assay because in my opinion we do not have either the equipment or the personnel with the skill set required to do this efficiently. So being able to come and work at Newhouse where you are then surrounded by people who can identify quickly where assay improvements should be made and then pass on the knowledge of how to set about applying these changes (as well as gaining experience with various pieces of equipment) was invaluable.’

More details are available here http://www.sulsa.ac.uk/sites/sbsweb2.bio.ed.ac.uk.sulsa/files/downloads/SULSAassaydevelopmentfundguidancenotes4.pdf

The Wellcome Trust also provides Seed/Pathfinder awards that could cover similar projects.

This website continues to increase in popularity with over 108,000 page views, an increase of 16% over the figure for 2015. The pages were visited by over 50,000 viewers and around a quarter of the visitors come back on multiple occasions suggesting they find it useful. The visitors come from 160 different countries with the US and UK topping the list.

The most viewed pages were

• Distribution and Plasma Protein Binding
• Calculating Physicochemical Properties
• Molecular Interactions
• Bioisosteres
• Lipophilicity
• Solvation and desolvation
• Formulation
• Fragment based screening
• Aspartic Acid Protease Inhibitors
• HERG
• CYP Interactions

Interestingly the Books and Grant funding research have seasonal peaks in viewing.

Looking at the operating systems 57% are Windows users, 22% Mac users, 10% iOS and 8% Android, Chrome dominates the browser stats (58%) with Safari second (20%) and Firefox third (15%).

As in previous years all monies saved for not sending greetings cards will be given to the Multiple Sclerosis Society

Dr Mahlapuu’s group, based at the University of Gothenburg, first identified a new target which could be used to reverse metabolic complications in type 2 diabetes. With the help of the European Lead Factory experts, she then screened the Joint European Compound Library of the then 320,000 industry compounds and identified a set of selective and potent small molecules which interfere with this target.

They have now formed a spinout company to develop these leads. ScandiCure has received 1 MSEK from the 2016 SWElife program to continue the development of first-in-class anti-diabetic drug based on small molecule antagonists of a novel key mediator - serine/threonine protein kinase 25 (STK25).

TransportersDB Database of membrane transporters
SureChEMBL Annotated patent database
canSAR Cancer research and drug discovery knowledgebase
iPPI-DB Modulators of protein-protein interactions
Withdrawn Withdrawn drugs
Open Targets platform for therapeutic target identification and validation

Multiple series of compounds were validated through resynthesis, biochemical and biophysical profiling at the European Screening Centre site in Newhouse, complemented with ligand–protein crystallography and antimicrobial evaluation at University of Oxford

Great to see projects like this move forward, demonstrates how important the ELF is in providing hits for academic groups/small companies.

• A platform for Wellcome-funded researchers to rapidly publish any research outputs they wish to share.
• Supports reproducibility and transparency.
• Uses an open research publishing model: immediate publication followed by open invited peer review.
• Includes all supporting data, enabling reanalysis, replication and reuse.

The list of compounds is available here together with brief description of the molecular target and pharmacology, Safety, Tolerability and toxicity information, and any clinical studies that might have been undertaken.

As a result of the screening campaigns >3000 qualified hits have been awarded to private and public target owners. 72 public target programmes have been accepted, 48 high throughput screens finished and 41 hit lists with associated data reports handed over to the target owners. >150 bespoke assays have been developed in order to extract the most interesting hits for public programmes.

There are now 450,000 compounds in the compound library of which 120,000 are novel compound specifically synthesised for the ELF.

You can read more details here https://www.europeanleadfactory.eu/results/

The European Lead Factory is a collaborative public-private partnership aiming to deliver innovative drug discovery starting points. Having established the first European Compound Library and the first European Screening Centre, the EU Lead Factory aims to give free access to up to 500,000 novel compounds, a unique industry-standard uHTS platform, and much more.

We are now starting to see publications describing these endeavours..

https://www.europeanleadfactory.eu/results/publications/scientific-articles/

This version of the database, prepared on 8th August 2016 contains:

• 2,043,051 compound records
• 1,686,695 compounds (of which 1,678,393 have mol files)
• 14,371,219 activities
• 1,246,132 assays
• 11,224 targets
• 65,213 documents

There is more information in the ChEMBL blog post

Imperial War Museum, Duxford, UK Wednesday 12 October 2016

Full details are available here https://www.soci.org/Events/Display-Event?EventCode=FCHEM481

Sounds an excellent meeting and you will have a chance to look around the aircraft at the Duxford Imperial War Museum.

The EU Lead Factory is an IMI-funded project that aims to create new chemistry based on crowd-sourced ideas and boost applicants’ drug discovery programmes at no upfront costs

• A Sweden-based start-up company, ScandiCure AB, has been founded based on the results of an EU Lead Factory target programme. ScandiCure is developed with the support and investment of GU Ventures, which is wholly owned by the Swedish State.
• Patents on EU Lead Factory compounds for treatment of multi-resistant bacteria infections and cancer.
• An EU Lead Factory programme accepted by IMI’s ENABLE for preclinical development.
• In vivo proof-of-concept generated with EU Lead Factory compounds.
• 2 PhD thesis enhanced with EU Lead Factory target programme assay development and screening results.
• >35 scientific, peer-reviewed articles, whereof one is the 4th most downloaded article published in Drug Discovery Today in 2015.
• 450,000 compounds in the Joint European Compound Library (JECL), whereof >120,000 of the prospected 200,000 novel screening compounds have been synthesised. 330,000 compounds were selected and assembled from the EFPIA participants’ proprietary compound collections within 6 months of operation.
• Many testimonials of the high quality of the EU Lead Factory output and the JECL compounds. For example, 17/49 EFPIA partner screens have triggered further work.
• 72 public target programmes accepted, 48 high throughput screens finished and 41 hit lists with associated data reports handed over to the target owners.
• In total, 2925 qualified hits have been granted public and private target owners (1041 and 1884, respectively).
• >1500 bespoke compounds synthesised in hit validation and hit-to-lead phase of public target programmes.
• >10 crystal structures of target–compound complexes have been solved.
• >150 bespoke assays have been developed in order to extract the most interesting hits for public programmes.
• 12/14 of the public target programmes offered to the industry EFPIA participants have been asked to provide a dossier for further assessment.
• >30 academic postdoctoral fellows trained in industry methods and approaches.
• Researchers in 13 countries (BE, DE, DK, ES , FR , IT, IL, HU, NL, PL , PT , SE, UK) involved. Partners spread over 8 countries and target owners over 11.
• 2 Custom-built data management platforms, the Honest Data Broker system developed to enable screening data management and triaging, whilst ensuring confidentiality and patentability; TarosGate2, a chemistry workflow management system with a secure built-in electronic laboratory notebook.

I’ve been involved in a number of screens and we have been very happy with the results, this is a great resource long may it continue.

It is also worth noting that the next submission deadline is 10th October 2016, here is the link for submitting assays for consideration. https://www.europeanleadfactory.eu/how-to-submit/drug-target-assays/

Solubility may also have an impact on preclinical assays, limited solubility in preclinical ADMET assays may give a false impression of the compounds profile in in vitro assays. Many of the false positives seen in Fragment-based screening are thought to be due to poor solubility at the high concentrations used in the screen. Perhaps the most important is the impact poor solubility can have on gastrointestinal absorption it may also preclude other routes of administration (intravenous).

This release brings new web displays and plenty of extra data to assist you in drug discovery and validation:

• 30,591 targets
• 9,425 diseases
• 4.8 million evidence
• 2.4 million target-disease associations

There are also new Web Widgets for both 'RNA baseline expression' and 'Protein Structure' of a target. In the latter, you can now rotate the protein structure, change its colour, zoom in and out, and highlight any amino acid residue:

More information is available on the blog

Imperial War Museum, Duxford, UK Wednesday 12 October 2016

Full details are available here https://www.soci.org/Events/Display-Event?EventCode=FCHEM481

Sounds an excellent meeting and you will have a chance to look around the aircraft at the Duxford Imperial War Museum.

There is also an online database https://opensourcemolecularmodeling.github.io that covers most aspects of computational drug discovery